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Patients who suffer from secondary iron overload, such as β-thalassemia, are heavily iron 
overloaded due to their dependence on frequent blood transfusions. Iron chelation therapy has 
been required for the treatment of the iron overload when the body iron homeostasis has been 
disrupted. CP20/deferiprone, which belongs to the 3-Hydroxypyridin-4-one (3-HPO) family, has 
been used as a clinically useful iron chelator by virtue of its oral activity and good iron 
mobilisation potency. However, it has been associated with some side effects due to the large 
dose administered, which is related to the extensive Phase II glucuronic acid conjugation at one 
of the essential iron chelation sites (3-hydroxyl group) in the liver. So novel iron chelators with 
reduced glucuronide conjugates at the 3-hydroxyl group are sought.  
 
The research questions approached in the thesis are to investigate the in vitro hepatic drug 
metabolism and in vivo iron mobilisation efficacy of 2
nd
 generation 3-hydroxypyridin-4-one 
chelators. The specific aim is to screen their in vitro liver metabolic clearance profiles using liver 
microsomes and to select the candidate compounds with potential potency in iron chelation for 
further in vivo iron mobilisation efficacy study using a Fe
59
-Ferritin loaded rat model.  
 
A rapid, but sensitive and selective bio-analytical method for screening and quantification of the 
hepatic in vitro metabolic clearance of novel 3-hydroxypyridin-4-ones has been developed. This 
new approach is suitable for screening a series of 3-HPOs with high-throughput. A series of 3-
HPO derivatives including two stereoisomers of chiral compounds, deferiprone analogues and 
pegylated 3-HPOs have been screened using the developed method and have represented 
different structure related metabolic profiles, which are of great relevance to investigate the 
structure activity relationships. One of the chiral enantiomers, CN128, was demonstrated to be 
much less susceptible towards the glucuronidation conjugation enzyme in the in vitro 
microsomal model (the percentage of glucuronidation is only 20% less compared to that of 
CP20/deferiprone). Another HPO, the acetamido-alkyl analogue of deferiprone, CM1, was found 
to be extensively conjugated by glucuronic acid (the percentage of glucuronidation is roughly 




value compared with CP20/ deferiprone, consequently, it was predicted to remove intracellular 
iron more efficiently from iron overloaded sites. These two compounds were selected for the in 
vivo iron mobilisation efficacy study in a Fe
59
-Ferritin loaded rat model. CN128 displayed 
significantly higher iron mobilisation from the rat liver at lower doses when compared with 
therapeutic doses of CP20/deferiprone. CM1, although more effective than CP20/ deferiprone, 
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Chapter 1 General introduction 
1.1 The biological role of iron 
Iron is an essential metal for any life form. It participates in a wide variety of biological reactions 
in a range of iron-containing metallo-proteins. These proteins can be divided into three groups: 
(1) Haem proteins: oxygen carriers, such as haemoglobin, myoglobin; oxygen activators, such 
as cytochromes P450, peroxidases and catalases; electron transfer proteins, such as 
cytochromes a, b and c; (2) Iron sulfur proteins, such as dehydratases (4Fe-4S cluster 
containing) and (3) Non-haem, non-iron-sulfur, iron dependent proteins, such as ribonucleotide 
reductase and ferritin (Finkelstein, 2009).  
 
1.2 Cellular iron uptake, storage and export 
The way in which cells import iron from the external environment and export it for functional use 
or store it in temporary storage depots is regulated by a variety of proteins, as illustrated by 
Figure 1.1 (Hentze et al., 2004).  
 
Figure 1.1 Cellular iron metabolism 
modified from Hentze, Muckenthaler et al. (2004) 
TfR: Transferrin Receptor; DMT1: Divalent Metal Transporter 




1.2.1 Celluar iron uptake  
1.2.1.1 Transferrin (Tf) bound iron  
Under normal circumstances, iron circulating in the plasma is tightly bound to serum transferrin 
(Tf), in which manner iron is nonreactive (Mizutani et al., 2012).  Tf is a glycoprotein of 
molecular weight around 80kD. It possesses two iron binding sites, with each binding site 
consisting of two tyrosines, one histidine, one aspartate and a synergistically bound carbonate 




 (Mizutani et al., 2012). Tf, 
synthesised in the liver is secreted into the circulation. The level of Tf circulating in the blood is 
typically 35 µM, with 25% to 35% of the iron binding sites occupied. Tf plays a vital role in iron 
transportation, in brief, Tf bound iron is delivered from the absoption site (the gastrointestinal 
tract) and haem degradation (the reticuloendothelial system) to sites of utilisation (for 
erythropoiesis, and incorporation into iron containing proteins) and storage (in ferritin) (Mizutani 
et al., 2012). Iron uptake from transferrin is mediated by transferrin receptors (TfR), which are 
TfR1 expressed on many cell types and TfR2 limited to hepatocytes and erythrocytes (Cheng et 
al., 2004) (Figure 1.1). The uptake of iron bound Tf via TfR1 follows the receptor mediated 
endocytosis pathway. The complex of iron(III) bound Tf and TfR1 localises to clathrin-coated pit 
and is endocytosed. The release of iron (Fe
3+
) from transferrin-TfR1 complex within the 
endosome requires a pH dependent conformational change, which is provided by the ATP 
dependant proton pump in the endosome (Cheng et al., 2004). The released Fe
3+
 is reduced to 
Fe
2+
 by a ferrireductase on the endosomal membrane and is transported to the cytosol by the 
divalent metal transporter (DMT-1) (Fleming et al., 1998). Alternatively, Steap3 has been 
identified as the endosomal ferrireductase required for efficient Tf dependent iron uptake in 
erythroid cells (Ohgami et al., 2006). Apo-Tf and TfR1 are recycled back to cell membrane, in 
readiness for another cycle of iron binding, transport and release. It has been estimated that Tf 
molecules experience more than 200 cycles during their life span (Cheng et al., 2004). 
Transferrin receptor 2 (TfR2) also mediates transferrin bound iron with the iron binding affinity 
significantly lower than that of TfR1 (Figure 1.1). TfR2 contributes to the susceptibility of the liver 
to iron loading in hereditary haemochromatosis. A truncation mutation in TfR2 is associated with 
a rare form of hereditary haemochromatosis, an iron overload disorder characterised by 
excessive dietary iron absorption and iron deposition in liver and other parenchymal tissues 




(Camaschella et al., 2000). There are three subtypes of transferrin receptors. TfR1 has iron 
response elements in its mRNA and, as a consequence, is down regulated in conditions of iron 
overload. In contrast, TfR2 does not have iron response elements (IREs) and is not reciprocally 
regulated in response to the level of plasma iron (Rouault, 2006). The iron supply for kidney is 
also provided by Tf bound iron but through megalin-dependent, cubilin-mediated endocytosis by 
a third type of TfR located in epithelial kidney cells (Kozyraki et al., 2001) (Figure 1.1).  
 
1.2.1.2 Non-transferrin bound iron (NTBI)  
Under normal circumstance, the Tf iron saturation is 25% to 35%. However, in pathological iron 
overload patients, the Tf iron binding sites are often fully saturated, leading to the appearance of 
circulating “free” iron, namely non transferrin bound iron (NTBI) (Hider, 2002). NTBI is 
characterised by an iron pool whose chemical nature is not well established. Studies on the 
nature of NTBI have suggested that it consists of heterogeneous forms of iron, which may or 
may not be accessible for chelation. The proportion of the iron isoforms varies depending on the 
source and degree of iron overload, involving both non-protein and protein forms (Brissot et al., 
2012). Studies have provided evidence that citrate with a probable involvement of acetate and 
plasma albumin are the possible NTBI ligands (Hider, 2002). A component of NTBI is 
susceptible to iron chelation and is redox active, which is termed labile plasma iron (LPI). Due to 
these attributes, LPI play an essential role in causing pathogenesis of iron toxicity.  There are 
indications that LPI is rapidly cleared from plasma by the liver (Cabantchik et al., 2005). The 
NTBI is taken up by cardiac and endocrine tissues by membrane bound carrier molecules. It 
has been reported that the transportation of NTBI into hepatocytes occurs via DMT-1 (Shindo et 
al., 2006) (Figure 1.1). The Zrt–Irt-like protein 14 (ZIP14) (SLC39A14) is a zinc transporter and 
mediates hepatocellular NTBI uptake (Liuzzi et al., 2006). The uptake of NTBI by cardiac 
myocytes has been reported to be facilitated by L-type voltage-dependent calcium channels 
(Oudit et al., 2003).  
 
1.2.1.3 Dietary Iron  
The uptake of dietary iron is through the intestinal mucosal cell at the upper part of the 
gastrointestinal tract, duodenum (Aisen et al., 1999). Dietary iron, not bound to transferrin, is 




composed of highly bioavailable haem iron and relatively bio-unavailable non-haem iron 
(Carpenter and Mahoney, 1992).  Non-haem iron Fe
3+
 is reduced to Fe
2+
 by a brush-border 
membrane reductase, Dcytb (Duodenal cytochrome-b) (McKie et al., 2001) and transported 
across the apical enterocyte membrane into the cell through a proton coupled process via DMT-
1 (Fleming et al., 1997). Haem iron uptake is via a separate pathway by the transport 
erythrocytes protein haem carrier protein 1 (HCP1), once absorbed, haem is degraded by haem 
oxidase to form Fe(II) (Shayeghi et al., 2005).  
 
1.2.1.4 Haptoglobin and haemopexin iron transporters 
Iron may also be absorbed in the protein bound forms, such as haemoglobin. Intravascular 
haemolysis, associated with senescent erythrocyte degradation by tissue macrophages in 
normal individuals and enhanced under pathological conditions such as haemolytic anaemias, 
thalassaemias etc., lead to the release of haemoglobin into plasma (Garby and Noyes, 1959). 
Haemoglobin turnover releases “free” iron, which is redox-active and can be a source of free 
radical formation (Ascenzi et al., 2005). Haptoglobin, an acute phase protein produced by the 
liver circulates in high concentrations (0.45–3 mg/mL) in plasma and forms a complex with 
haemoglobin (Wada et al., 1970). The haptoglobin-haemoglobin complex can be cleared in the 
reticulo-endothelial (RE) system by receptor-mediated endocytosis. The uptake of this complex 
is via the internalisation by a scavenger receptor CD163 in tissue macrophages (Kristiansen et 
al., 2001) (Figure 1.1). Destruction of the haptoglobin-haemoglobin complex thereby minimises 
haemoglobin toxicity and also contributes to iron recycling (Kristiansen et al., 2001).  
 
Haem arising from the degradation of haemoglobin, myoglobin, and of enzymes with haem 
prosthetic groups could be delivered in plasma (Ascenzi et al., 2005). Haemopexin, a serum 
protein, sequesters free haem as a backup mechanism for haptoglobin and delivers the haem to 
target cells via specific receptors. The haem-haemopexin complex is internalised by CD91 
receptor-mediated endocytosis, and the haem is then released and degraded intracellularly in 
the hepatic parenchymal cells, while haemopexin is recycled back into the circulation (Figure 
1.1). In this way, haem clearance by the haemopexin pathway prevents extracellular damage by 
free haem, and conserves iron by recycling the haem iron (Smith and Morgan, 1981).  




1.2.1.5 Serum ferritin bound iron  
Iron may also be taken up by cells in the plasma ferritin bound form. It has been reported that 
almost all of radio-iron labeled ferritin injected into rats is taken up by the liver in in vivo studies 
(Unger and Hershko, 1974). In vitro studies have demonstrated that rat hepatocytes take up 
ferritin by receptor-mediated endocytosis and the ferritin protein is destroyed by lysosomal 
degradation. The associated iron is re-used for hepatocyte ferritin synthesis (Osterloh and 
Aisen, 1989).  
 
1.2.2 Cellular iron storage  
Once iron enters the cell via different transport mechanisms, the portion that is not needed for 
immediate use is stored in ferritin, located predominantly in the liver, spleen and bone marrow, 
where 25% of total body iron (800-1000 mg) is stored (Laulhere et al., 1989). Ferritin is an 
oligomeric protein composed of an apoprotein shell of 24 subunits, forming a hollow protein 
shell, capable of storing up to 4500 iron atoms. Ferritin sequesters the metal in the water-
soluble, nontoxic, bioavailable ferric oxyhydroxide form and stores iron as the mineral 
ferrihydrite core. The 24 subunits are heteropolymers of light (L) and heavy (H) chain subunits. 
The ratio of H to L subunits varies depending on tissue type and physiologic status. H and L 





 as iron is internalised and packed into the mineral core. This ferroxidase 
activity is an inherent feature of the H subunit, which is characterised by a diiron, ferroxidase 
centre, while L subunits enhance oxidation activity by the increasing the binding affinity of ferric 
iron at the nucleation sites of the iron core. Iron is also stored in haemosiderin, which is derived 
from the intralysosomal aggregation and degradation of ferritin. The storage of iron, whether in 
the form of ferritin or haemosiderin, can be mobilised for cellular utilisation, and released by 










1.2.3 Intracellular iron distribution  
1.2.3.1 Labile iron pool  
Extracellular iron and intracellular iron released from endogenous haem breakdown and ferritin 
degradation enter a transit iron pool, which is a redox-active, labile iron pool (LIP) and can be 
scavenged by iron chelators. This pool was first defined by Jacobs (Jacobs, 1976) (Figure 1.2). 
The nature of LIP has been proposed to be iron(II) bound to a single molecule of glutathione 
and the concentration of this pool falls into a range of 0.5-2 µM. (Hider and Kong, 2013). The 
level of LIP should be under tight control as non-coordinated free iron can generate oxygen 
derived free radicals and render tissue damage (Halliwell and Gutteridge, 1984).   
 
Figure 1.2 Labile iron pool and cellular iron homeostasis 
modified from Hider and Kong (2013) 





1.2.3.2 Intracellular Iron distribution 
LIP is routed to for haem and iron sulfur cluster biosynthesis in mitochondria and for iron 
incorporation into metalloenzymes and ferritin (Ajioka et al., 2006, Lill and Muhlenhoff, 2006). 
The iron uptake by mitochondria is dependent on the membrane potential and facilitated by the 
transport proteins mitoferrin-1 and mitoferrin-2 (Paradkar et al., 2009). The yeast homologue of 
human frataxin, plays a role as an iron chaperone, delivering iron to both the iron sulfur cluster 
and haem biosynthetic pathways. Frataxin gene deletion causes the neurodegenerative 
disorder Friedreich ataxia (Huynen et al., 2001). Erythrocyte precursor cells and hepatocytes 
are the two major sites of haem biosynthesis, where haemoglobin and heam-containing 




enzymes (e.g. cytochrome P450) are synthesised respectively. Iron-sulfur clusters play multiple 
functional roles in electron transport, in catalysis of metabolic reactions and as sensors of 
mitochondrial iron status (Heinemann et al., 2008).  
 
1.2.4 Cellular Iron Export 
The expression of SLC40A1 gene has lead to the identification of an iron exporter ferroportin. It 
plays an essential role in iron export of cells requiring mechanisms to release iron in a 
controlled fashion for different functional use. Ferroportin is specific for iron(II) and is the only 
iron exporter protein identified to date. It is located on the basolateral side of duodenal 
enterocytes and in the cytoplasmic membranes of both macrophages and hepatocytes (McKie 
et al., 2000, Donovan et al., 2000, Abboud and Haile, 2000). Ferroportin functions in concert 
with different ferroxidases, such as hephaestin (Vulpe et al., 1999), ceruloplasmin (Harris et al., 
1999) and glycosylphosphatidylinositol (GPI)-anchored form of ceruloplasmin, to export (Jeong 
and David, 2003) iron from duodenal enterocytes, reticuloendothelial macrophages, 
hepatocytes and cells of CNS respectively.  
 
1.3 Regulation of Iron homeostasis  
1.3.1 Cellular iron homeostasis 
Cellular iron uptake, storage, utilisation and export pathways described above must be 
regulated in a coordinated fashion. Regulation of iron homeostasis is achieved at the level of 
mRNA translation (protein synthesis). The IRE-IRP system constitutes a regulatory mechanism 
for regulating cellular iron homeostasis (Rouault, 2006). Single Iron regulatory elements (IREs) 
are located at the 5’-untranslated regions (UTRs) of ferritin (Leibold and Munro, 1988) and 
multiple IREs are located at the 3’-UTRs of transferrin receptor mRNA respectively (Owen and 
Kühn, 1987). The iron regulatory proteins IRP1 and IRP2, which are iron regulated cytosolic 
RNA binding proteins, bind to the IREs and form IRE/IRP complexes (Rouault, 2006). IRPs 
binding to the single IREs located in the 5’-UTR of ferritin mRNA inhibits mRNA translation, 
whereas binding to the IREs present in the 3’-UTR of transferrin receptor mRNA prevents 
nuclease degradation. This ensures that iron uptake is stimulated in iron deplete cells.  In 




contrast, when iron storage is expanded, the IRPs no longer bind to the IREs, ferritin mRNA is 
translated while transferrin receptor mRNA undergoes endonuclease cleavage. In this case, 
unnecessary iron uptake is suppressed, which avoids potential iron toxicity by up-regulation of 
the storage protein (Wallander et al., 2006). IRP1 and IRP2 both act as iron sensors, essentially 
by existing in two different conformations, regulating either the translation or turnover of the iron 
dependent protein mRNA. The cellular labile iron pool regulates binding of IRP1 and IRP2 to 
IREs through distinct mechanisms. When iron levels are high, IRP1 assembles a [4Fe-4S] 
cluster, which transforms the protein into a functional cytoplasmic aconitase, inhibiting IRE 
binding activity. When cellular iron stores are low, IRP1 was targeted as apoprotein and bound 
to IRE. In contrast, IRP2 does not contain an [4Fe-4S] cluster. It accumulates in iron-deficiency 
and is rapidly degraded by proteasome when iron levels are elevated. The protein FBXL5, 
which targets IRP2 to the proteasome, is also degraded upon iron depletion (Vashisht et al., 
2009) (Figure 1.2). 
 
1.3.2 System iron homeostasis 
1.3.2.1 Body iron distribution 
Around 1 to 2 mg of dietary iron is absorbed by duodenal enterocytes per day. Roughly 1 to 2 
mg of iron is lost from the body per day by means of sloughed mucosal cells, desquamation and 
menstruation. Adult men normally have 35 to 45 mg of iron per kilogram of body weight. More 
than two thirds of the body’s iron content is distributed to the bone marrow, incorporated into 
haemoglobin in contributing to haemoglobin synthesis. Uptake of erythroid iron is facilitated via 
the receptor-mediated endocytosis of diferric transferrin bound to transferrin receptors. Each 
erythrocyte contains a billion atoms of iron; hence, at normal rates of turnover, 2x10
20
 atoms of 
iron are incorporated into haemoglobin per day. Most of the remaining body iron is deposited in 
hepatocytes and reticuloendothelial macrophages, which serves as iron storage depots. The 
liver extracts dietary nutrients by the “first pass effect” and can readily take up an amount of 
circulating iron, which is not bound to transferrin and store iron in ferritin. Reticuloendothelial 
macrophages recycle iron by ingesting senescent red blood cells, catabolising haemoglobin to 
scavenge iron, and loading the iron onto transferrin for reuse. Minor amounts of iron are 
distributed to other tissues: 3.5% is distributed to myoglobin; 0.5% is incorporated into iron 




containing enzymes (cytochromes, dioxygenases, ribonucleotide reductase, lipoxygenases 
etc.); only 0.1% is bound to transferrin at any one time (Andrews, 1999).  
The circulating iron bound to plasma transferrin, although less than 0.1% of total body iron, 
represents a kinetically active iron pool, due to the rapid turnover of plasma transferrin. The 
plasma Tf iron pool turns over more than 20 times per day, iron being recycled for the 
requirement of erythrocyte production (Gkouvatsos et al., 2012).  
 
1.3.2.2 Regulation of body iron status 
As there is no efficient pathway for iron excretion in the human, iron balance requires 
mechanisms for regulating iron entry into and mobilisation from stores. Hepcidin is a small, 
cysteine-rich peptide, which regulates iron export from cells by interacting with an iron efflux 
protein located on cell surface, ferroportin (Section 1.2.4) and inactivates its cellular iron export 
function by the internalisation and degradation of this iron efflux protein. Thus, under high 
hepcidin levels, ferroportin located in the duodenal epithelial cells and macrophages will be 
internalised and as a result, such cells are unable to efflux iron into plasma resulting in low 
transferrin saturation. In contrast, decreased expression of hepcidin leads to increased cell 
surface ferroportin, iron absorption is enhanced and high iron fluxes enter the serum (Nemeth et 
al., 2004). Hepcidin plays a vital role in regulation of iron homeostasis. Dysregulation of 
hepcidin expression results in iron disorders. Overexpression of hepcidin results in the anemia 
of chronic disease, while depression of hepcidin synthesis leads to hereditary hemochromatosis 
(De Domenico et al., 2007)  
 
Plasma hepcidin levels are regulated by different stimuli, including plasma iron, erythropoietic 
signals, cytokines, and hypoxia. Hepcidin expression regulation occurs at the level of 
transcription. Hepcidin antimicrobial peptide (HAMP), which is the gene that encodes hepcidin, 
plays an essential role in the regulation of hepcidin expression. The synthesis of hepcidin is 
regulated by signaling through the bone morphogenetic protein/Smad (BMP/Smad) pathway. 
BMPs bind to cell surface HJV positions and activates BMP receptors on the cell membrane, 
leading to the generation of phosphorylated RSmads, which dimerize with Smad4. The 
RSmad/Smad4 heterodimer translocates into the nucleus and activates transcription of the 




HAMP gene and thereby controls hepcidin synthesis (Casanovas et al., 2009). Inflammatory 
cytokines, predominately IL-6, also stimulate the transcription of HAMP in hepatocytes by 
activation of Stat3, binding a regulatory element in the HAMP (Verga Falzacappa et al., 2007). 
The regulation of hepcidin expression is also modulated by increased erythropoietic activities. A 
candidate erythroid factor, Growth Differentiation Factor 15 (GDF15), was identified, which 
suppresses hepcidin synthesis. It also serves as an oxygen-regulated transcript responding to 
hypoxia, indicating that hypoxia stimulates suppression of hepcidin expression (Lakhal et al., 
2009).  A recently discovered hormone, erythroferrone (ERFE), has also been found to mediate 
the suppression of hepcidin during stress erythropoiesis (such as after hemorrhage) (Kautz et 
al., 2014).  
 
1.4 Disorders of Iron overload 
The accumulation of excessive iron in various tissues causes tissue damage, and ultimately, 
organ failure, which results from iron-generated production of highly reactive free radicals 
(Beutler, 2007). The iron balance in man is predominantly determined by iron absorption, 
because the human body does not have a physiological mechanism to excrete iron (McCance 
and Widdowson, 1937). Inappropriately high duodenal iron absorption in hereditary 
haemochromatosis (HH) and transfusional, parenteral or dietary iron overload (secondary iron 
overload) leads to disorders of systemic iron overload (Andrews, 1999).  
 
1.4.1 Assessment of body iron burden 
The assessment of body iron balance is essential, because it facilitates the diagnosis of 
disorders of iron overload and monitors the iron balance during chelation therapy. The body iron 
burden can be measured by various means. The most common and inexpensive indicator to 
estimate the body iron store is the serum ferritin concentrations. However, the level of serum 
ferritin concentrations can be complicated by various other pathological conditions, such as 
acute infection, chronic inflammation, hepatic damages, and may give inaccurate estimates of 
total body iron (Cavill, 1999). Percentage transferrin saturation with a normal range of 20~30% 
and ~100% for iron overloaded patients can also be used as a combined indicator with the 
serum ferritin level (Wish, 2006). Liver biopsy was used as a gold standard for monitoring body 




iron balance in the past, as the liver is the dominant iron storage organ and its iron 
concentration correlates tightly with the total iron balance. Unfortunately, liver biopsy is invasive, 
expensive and can be unreliable due to the heterogeneity of iron loading in the liver (Crisponi et 
al., 2000). At the present time, Magnetic Resonance Imaging (MRI) has emerged as the 
noninvasive technique of choice for the estimation of liver iron content, due to its sensitivity, 
reproducibility (Wood, 2007). The closely related MRI T2* technique is especially useful for 
monitoring cardiac iron overload (Anderson et al., 2001).   
 
1.4.2 Primary iron overload 
1.4.2.1 Hereditary haemochromatosis (HH)  
HH is a group of genetically distinctive disorders of iron overload. They are hereditary, usually 
transmitted as autosomal recessive. The common clinic-pathology is the inappropriately low 
level of hepatic hepcidin secretion, which renders excessive level of the iron export protein 
ferroportin (FPN1).  This unrestricted activity of FPN1 leads to iron transfer to circulation from 
the duodenum and the macrophages, increasing transferrin saturation (from 30% to fully 
saturation) and serum ferritin levels. The progressive accumulation of iron in parenchymal cells 
can result in severe consequences, such as diabetes, arthritis and cirrhosis of the liver. HH is 
composed of five major types of different genetic disorders (Pietrangelo, 2006). HFE 
haemochromatosis (Type 1 haemochromatosis) is the most widely prevalent form of HH. The 
gene mutated in HH encodes a 348 residue type I transmembrane glycoprotein, HFE.  Most HH 
patients are homozygous for the C282 Y mutation (Feder et al., 1996). HFE is partitioned 
between TfR1 and TfR2. High serum iron concentration renders the formation of the HFE/TfR2 
complex, which signals hepcidin up-regulation, leading to a reduction in both intestinal iron 
absorption and macrophage iron release. While low serum iron concentration favours the 
HFE/TfR1 complex. Upon the mutation of either HFE or TfR2, dysregulation of iron homeostasis 









1.4.2.2 Treatment of Primary Iron overload 
Therapeutic phlebotomy is so far the most effective treatment for haemochromatosis, in which 
one unit (400–500 ml) of blood (containing approximately 200-250mg of iron) is removed weekly 
until serum ferritin drops below 30 μg/l and transferrin saturation is less than 30%. Phlebotomy 
is maintained with the typical removal of 2-4 units per year for the rest of the patient’s life. Once 
organ impairment develops, Phlebotomy should be replaced by other iron removal strategies 
(e.g.chelatIion therapy) (Pietrangelo, 2006).  
 
1.4.3 Secondary iron overload 
Secondary iron overload occurs in haematoglogical diseases (thalassaemia, sickle cell anaemia 
etc.), which are treated with repeated blood transfusion. As there is no mechanism for iron 
excretion, repeated transfusion results in iron overload.  Multiple blood transfusions also 
produce erythroid factors, Growth Differentiation Factor 15 (GDF15), leading to down-regulation 
of hepcidin, which initiates hepatic iron overload (Section 1.3.2.2). In chronic haemolytic 
disorders, excess gastrointestinal absorption of iron is observed prior to transfusion as a 
consequence of ineffective erythropoiesis. In contrast to HH, iron deposition in secondary iron 
overload patients primarily affects cells of the mononuclear phagocytic system (MPS), with 
parenchymal iron loading occurring at larger stages of the disease (Kushner et al., 2001). In 
severely iron-loaded patients, the capacity for transferrin to bind iron is exceeded, and non-
transferrin bound iron (NTBI) is found in serum, which is highly toxic and causes tissue iron 
loading. NTBI occurs in 80% of patients with thalassemia major (Brissot et al., 2012). NTBI is 
avidly taken up by several tissues, such as liver, heart and endocrine, which support the role of 
NTBI as an important source of parenchymal organ iron deposition. In contrast to transferrin 
iron uptake which is down regulated by the IRE/IRP system, in a fashion that a depression of 
transferrin receptor expression responds to an elevated iron store, NTBI uptake is not regulated 
by this system and iron loading from NTBI is apparently rapid and unregulated (Baker et al., 
1998). One component of NTBI, the so-called labile plasma iron (LPI), found when transferrin 
saturation exceed 75%, is iron chelatable, capable of redox cycling and may represent a marker 
of toxicity, due to its potential for generating reactive oxygen radicals in vivo. The direct capture 
of LPI has been suggested as a way to avoid the dangerous accumulation of cellular iron and to 




prevent the resultant adverse consequences (Cabantchik et al., 2005).  
 
1.4.3.1 Sickle cell anemia  
Sickle-cell disease (SCD) refers to a group of genetic haemoglobin disorders that are 
associated with mutations in the HBB gene. A single base pair in the β-globin gene is mutated 
from adenine to thymine generating a corresponding substitution in the sixth position of the β-
subunit from glutamic acid to valine. Under conditions of low oxygen tension, the abnormal 
deoxyhaemoglobin polymerizes and eventually leads to a sickle-shaped red blood cell (Luzzatto 
and Goodfellow, 1989). SCD is characterised by chronic haemolytic anaemia and 
vaso-occlusive events. These events result in acute complications including stroke, acute chest 
syndrome (ACS) and heart failure etc. (Hagar and Vichinsky, 2008). These serious 
complications related to SCD can be prevented by appropriate regular blood transfusions. 
However, regular transfusion leads to iron overload, which should be treated by chelation 
therapy (Lucania et al., 2011).  
 
1.4.3.2 β-Thalassemia 
Thalassemia is a hereditary anemia resulting from haemoglobin production defects. It is 
predominantly classified into α-thalassemia and β-thalassemia, of which β-thalassemia is 
associated with more significant morbidity and mortality. β-thalassemia is clinically 
heterogeneous and can be categorised into (1) β-thalassemia trait (minor); (2) β-thalassemia 
major; and (3) β-thalassemia intermedia. The pathophysiology of the β-thalassemia is well 
outlined. The mutations at the β-globin gene result in an absence or a reduction of the β-globin 
chain production, which lead to an excess of α-globin chain. The unbound α-globin chains 
precipitate in the erythroid precursor cells and cause accelerated apoptosis. The accelerated 
apoptosis is the major reason of ineffective erythropoiesis and hemolysis, which consequently 
cause anemia accompanied with bone marrow expansion and extramedullary haematopoiesis 
in the liver, spleen, and other sites (Schrier, 2002). The life-saving, routine treatment of β-
thalassemia major (associated with the total absence of β-subunits) is by blood transfusion 
thereby maintaining haemoglobin at normal level. This can markedly suppress ineffective 
erythropoiesis and bone marrow expansion (Rund and Rachmilewitz, 2005).  




1.4.3.3 Treatment of secondary iron overload 
Although phlebotomy therapy is applied in patients with thalassaemia intermedia associated 
with ineffective erythropoiesis, iron chelation therapy is the predominant treatment for 
secondary iron overload patients: (i) thalassaemia major patients; (ii) thalassaemia intemediate 
patients who are nontransfusion dependent but become iron loaded because of increased iron 
absorption but are too anaemic to undergo phlebotomy; and (iii) regularly transfused patients 
with sickle cell anaemia and myelodysplasia, aplastic anaemia (Beutler et al., 2003).  
 
Iron chelators are used to alleviate body iron burden in order to prevent damage parenchymal 
organs, such as liver, endocrine and, in particular, heart (Hider et al., 1996).  
 
1.5 Iron chelators  
High-spin iron(III) is a spherically symmetrical tripositive cation with a radius 0.65 Å, which is 
classiﬁed as a hard Lewis acid by virtue of its high charge density. It forms most stable bonds 
with ‘hard’ ligands with oxygen as the donor atoms (Zhou et al., 2012). Based on this 
understanding, efforts to design iron chelators with a high iron scavenging efficacy from 
overloaded sites have been undertaken over the past four decades. Three iron chelators are 
presently in clinical use.  
 
1.5.1 Desferrioxamine  
Desferrioxamine B (DFO, Desferal
®
) is the first clinical effective iron-chelating agent developed 
by Ciba-Geigy in 1960s and has been extensively used for treatment of iron overload for the 
past four decades (Bernhardt, 2007). DFO is derived from a microbial siderophore of 
Streptomyces pilosus. DFO is a hexadentate ligand, of which three bidentate hydroxamate 
moieties are deprotonated and are coordinated with a single ferric iron and form a 1:1 ratio 
complex in a distorted octahedral Fe
III
O6 fashion (Figure 1.3). DFO has exceptionally high 
affinity (pFe
3+
 26.6) and selectivity to iron(III) (Zhou et al., 2012). This highly hydrophilic 
molecule (logD7.4 = -2) can enter the liver via facilitated transport and interacts with both 
hepatocelluar and reticuloendothelial iron stores to promote both biliary and urinary iron 




, is a charged 




compound (1+) with low lipophilicity at pH 7.4 and is kinetically inert and unlikely to redistribute 
iron to other cells (Zhou et al., 2012). However, oral inactivity (molecular weight 560), rapid 
plasma metabolism (plasma half-life of 5-10 min) and fast renal clearance prevent it from being 
an ideal therapeutic agent. In order to alleviate the elevated body iron burden, DFO must be 
given by continuous subcutaneous or intravenous infusion for 8-12h per day, 5-7 days per week 
at a standard dose of 40 mg/kg/day. Consequently, patient compliance with this cumbersome 
and expensive regimen is often poor (Porter et al., 1989a). Moreover, side effects have been 
associated with intensive therapy in young patients with relatively low body iron stores, such as 
neurotoxicity and abnormalities of cartilage formation (Porter et al., 1989b). 
  
                   
Figure 1.3 Desferrioxamine and energy minimised structure of Fe(III) DFO complex  
(Obtained from Avogadro 1.1.1 (Hanwell et al., 2012) and visualised by UCSF Chimera 1.10.1 (Pettersen et al., 2004)) 























, ICL670) is the lead compound of triazole ligands and was 
developed by Novartis and approved by the FDA in 2005 as the first and only iron chelator 
administered orally in the USA and also used worldwide. Deferasirox possessing a pFe
3+
 value 
of 22.5, acts as a tridentate ligand forming a 2:1 iron complex with one triazolyl nitrogen and two 
phenolate oxygens both deprotonated upon coordination  (Figure 1.4). Potentiometric titrations 
of the ligands demonstrated that the ligand is a monoanion at physiological pH 7.4, with the pKa 
of the two phenol groups lying within the range 8.7 to 11 and the pKa of the carboxylic acid 




  is formed 
exclusively and was redox inactive under physiological conditions (Bernhardt, 2007). DFS has 
good oral activity (molecular weight 373) and permeates membranes easily by virtue of its high 
hydrophobicity (logD7.4 = 1.0) (Zhou et al., 2012). It promotes iron excretion four to five times 
more effectively than DFO in hypertransfused rate model. Furthermore, the pattern of iron 
excretion produced by DFS is quite distinct from that of DFO. Whereas with DFO a substantial 
proportion of iron derived from RE cells is excreted in the urine, with DFS all iron excretion is 
limited to the bile regardless of whether it is derived from RE or hepatocellular stores (Hershko 
et al., 2001). By virtue of a high proportion of both the free ligand and the iron complex binding 
to albumin (greater than 98%), the ligand possesses low toxicity despite its strong lipophilic 
character (Weiss et al., 2006). DFS is administered orally in single daily dose owing to its long 
plasma life (~12 h). It has been demonstrated to be efficient at removing liver iron from regularly 
transfused patients (Cappellini et al., 2010) but is apparently less effective at removing cardiac 
iron (Wood et al., 2010). Kidney toxicity is the prevalent side effect of this chelator (Rafat et al., 
2009). 
      
  











Figure 1.4 Deferasirox and energy minimised structure of Fe(III) DFS complex 
(Obtained from Avogadro 1.1.1 (Hanwell et al., 2012) and visualised by UCSF Chimera 1.10.1 (Pettersen et al., 2004) ) 
(Bernhardt, 2007) 
 





CP20/deferiprone (DFP), the 1, 2-dimethyl derivative of 3-hydroxypyridin-4-one family, was 
designed by Hider et al (1982), and demonstrated to be active in man in 1987 (Kontoghiorghes 
et al., 1987) was granted for receiving full marketing authorisation by European Medicines 
Agency in 2002 and was approved by the FDA in 2011 (Figure 1.5). It is marketed by Apotex 
Inc. Toronto, Canada as Ferriprox™ (Zhou et al., 2012). The 3-hydroxypyridin-4-one family 
emerged as the first potentially orally active iron chelator for iron overload chelation therapy. 
HPO compounds possess two pKa values, corresponding to the pKa values of 4-carbonyl group 
(~3.6) and 3-hydroxyl group (~9.9), hence, the ligands are monoprotic acid under physiological 
pH 7.4 (Liu and Hider, 2002). DFP is a small molecule (M.W. 139), which facilitates its good oral 
absorption by the gastrointestinal tract. CP20/deferiprone possesses a pFe
3+
 value of 20.5 and 
forms an 1:3 iron complex [Fe
III
(DFP)3]  in a bidentate fashion (Figure 1.5). It is a quite 
hydrophilic compound with the distribution coefficient (logD7.4 = -0.77). It is able to penetrate 
cells and coordinate with iron, forming a neutral complex, which can also permeate cell 
membranes. Thus, iron can be readily removed from iron-loaded cells including those of cardiac 
tissue. The complex is largely excreted by the urinary route (Glickstein et al., 2006). However, 
CP20/deferiprone rapidly loses its chelating efficacy by undergoing extensive Phase II 
glucuronidation reaction at the 3-hydroxyl group in the liver (Scheme 1.1). Therefore, the dose 
required to achieve body iron homeostasis is relatively large, which is administered at 75 
mg/kg/day fractionated in three doses. Consequently, some side effects are associated with the 
use of CP20/deferiprone, the most significant being agranulocytosis and neutropenia (Hoffbrand 
et al., 2003).                
  

















Figure 1.5 CP20/deferiprone and energy minimised structure of Fe(III) DFP complex  
(Obtained from Avogadro 1.1.1 (Hanwell et al., 2012) and visualised by UCSF Chimera 1.10.1 (Pettersen et al., 2004) ) 




                         
 
Scheme 1.1 Phase II glucuronidation of CP20/deferiprone (CP20) 
  




1.5.4 Chelator Pharmacokinetics  
Desferrioxamine is not orally active and cleared by the kidney very rapidly with a half-life of 20 
min. In contrast, CP20/deferiprone is rapidly absorbed from the gastrointestinal tract (Porter, 
2001). The peak plasma concentration value is typically achieved between 40 and 80 min. Due 
to the extensive glucuronidation of CP20/deferiprone, the concentration of the non-chelating 
metabolite is higher than that of CP20/deferiprone 60min after the oral administration (Al-Refaie 
et al., 1995). Deferasirox is also orally active. The maximum plasma concentration is reached 
after 4 h and the drug remains in the blood stream for much longer periods of time experiencing 
a slow renal clearance, which is a direct result of its tight binding to albumin. In many patients, 
there are appreciable levels of the chelator present after 24 h (Chirnomas et al., 2009). 
 
1.5.5 Combined therapy with Desferrioxamine(DFO) and 
CP20/deferiprone(DFP) 
The plasma half-life is short for both DFO and DFP, 5-10min and 3-4 hrs respectively (Summers 
et al., 1979). The treatment regime cannot provide 24-hour chelation coverage which is 
probably necessary to achieve negative iron balance (Cabantchik et al., 2005). Hence, the 
combination of DFO and DFP has been investigated to treat iron overload and promote urinary 
iron excretion (Giardina and Grady, 2001). Due to the small molecular weight and ability to 
penetrate cells, DFP scavenges intracellular iron efficiently and the formed iron complex can 
also permeate cell membranes and enter the extracellular environment. However, by virtue of 
the bidentate nature of CP20/deferiprone, it is highly concentration dependent in chelating 
Fe(III) and at relatively low concentrations (<5 μM) the iron CP20/deferiprone complex will 
dissociate and redistribute iron. In the case of sequential use of DFO and DFP, the DFP iron 
complex will readily donate iron to the kinetically more inert extracellular DFO sink and DFP 
promotes plasma NTBI clearance in the presence of DFO (Devanur et al., 2008). It has shown 
that treatment of thalassaemic patients with this combination regime reduces myocardial iron 








1.5.6 Second generation hydroxypyridinones.  
In order to further improve chelation efﬁcacy and to avoid agranulocytosis, considerable effort 
has been devoted to the design of novel hydroxypyridinones with enhanced affinity to iron(III) 
(Zbinden, 1997, Hider R. C., 1998). 
 





 is deﬁned as the negative logarithm of the concentration of the free 
iron(III) in solution. Typically pFe
3+
 values are calculated for total [ligand] = 10
−5 
M, total [iron] = 
10
−6
 M at pH 7.4 (Raymond and Carrano, 1979). In general, the pFe
3+ 
value of an ideal iron 
chelator is above 20. However, if the pFe
3+ 
value is too high, the chelator will be toxic because it 
might scavenge iron from essential metallo-enzymes. 
 
A number of iron chelators with high pFe
3+
 have been introduced. Novartis has promoted a 
range of bidentate hydroxypyridinone ligands, which possess an aromatic substituent at the 2-
position. The lead compound CGP65015 (Figure 1.6) was found to be orally active (Lowther et 
al., 1999) and highly effective at scavenging iron from both the iron loaded rat and marmoset 
(Zbinden, 1997). CGP65015 promoted iron excretion in amounts of about 2500-μg iron/kg body 
weight at a dose of 150 μmol/kg in iron overloaded marmosets, which is equivalent to the 
amount promoted by Deferasirox at the same dose (Figure 1.7 a). When comparing the iron 
chelation efficacy with hydroxypyridinones, CGP65015 was 4 times more potent than the most 
effective 1
st




Figure 1.6 High iron(III) afﬁnity hydroxypyridinone, CGP65015 








                
 
 
Figure 1.7 (a) Dose-dependant total iron excretion in iron-overloaded marmosets induced by 
CGP65015 and Exjade. (b) Comparison of total iron excretion in iron-overloaded marmosets (black 
columns) and Cebus monkeys (white columns).  


































































In a similar way, Hider and coworkers demonstrated that the introduction of either a 1’-
hydroxyalkyl group (Figure 1.8 a) or an amido function (Figure 1.8 b) at the 2-position of 3-
hydroxypyridin-4-ones increases the afﬁnity for iron(III) in the pH range 5–8 (Liu et al., 1999b, 
Piyamongkol et al., 2010). This effect results from stabilising the ionised species, due to the 
combined effect of intramolecular hydrogen bonding between the 2-substitutent with the 
adjacent 3-hydroxyl function and electron withdrawal from the pyridinone ring. Although the 
overall iron(III) stability constant is reduced so are the pKa values of the chelating function 
thereby reducing competition from proton, these overall changes lead to an increase in the 
respective pFe
3+
 values. These novel high pFe
3+
 HPOs were found to be promising in their 
ability to remove iron under in vivo conditions. Further dose-response studies imply that 
chelators with high pFe
3+ 
values scavenge iron more effectively at lower doses when compared 
with simple dialkyl substituted hydroxypyridinones. A small number of related compounds were 
selected for preclinical investigation. However, none of these compounds had significantly 
improved therapeutic ratios when compared with CP20/deferiprone and so have not been 















Over the past fifteen years, lysosomotrophic HPOs (Ma et al., 2015), HPO prodrugs (Rai et al., 
1999) have also been thoroughly investigated. However, none of these compounds 
demonstrated superior efficacy/ toxicity ratios to that of CP20/deferiprone.  
 
In this study, a range of novel HPOs has been investigated. Although pegylated HPOs and long 
chain acetamido HPOs (CM1) have been considered, our main effort was directed to 
enantiomeric pairs.  Obviously, chiral compounds share essentially the same physicochemical 
properties, such as partition coefficient, water solubility, pKa values, iron(III) affinity constants 
and pFe
3+
 values. However, due to the three dimensional structures of chiral centers, the 
absorption (A), distribution (D), metabolism (M) and excretion (E) can be in principle different. 
For absorption, the movement of HPOs into cells is predominantly by simple diffusion and thus 
largely dependent on the physical properties of HPOs (i.e. enantiomers will have similar 
properties). For distribution, the binding to plasma proteins (largely albumin) can be 
stereoselective, although differential albumin binding of enantiomeric pairs is minimal. In 
contrast, for metabolism, due to the enantioselectivity of the metabolising enzymes, metabolic 
profiles of enantiomers can be quite different (Lu, 2007). Glomerular filtration, tubular secretion 
and reabsorption of chiral drugs also demonstrate stereoselectivity, leading to different drug 
excretion profiles, although here is no evidence for HPO receptor mediated reabsorption by the 
kidney (Patel and Hutt, 2004). Thus, HPO chirality can serve as a good strategy to modify HPO 
structures in order to influence metabolism and in this way identify the optimal efficacy/toxicity 
ratio for a given structure. In consequence, ten pairs of enantiomers have been investigated, 
many of the pairs demonstrated diverse efficacy in iron mobilisation in the in vivo rat model 
(Brown, 2012) (Figure 1.9). A dominant drawback of CP20/deferiprone is the extensive 
glucuronidation conjugation at one of the essential iron(III) binding sites, 3-hydroxyl moiety, 
which results in loss of the iron chelation ability. By selecting an enantiomer with a low rate of 
metabolism, it was considered likely that we could improve the overall efficacy. Hence, although 
the difference in the iron chelation efficacy of chiral pairs might be attributed to different ADME 
characters and a comprehensive investigation on their ADME profiles is required, their 
metabolic profiles in liver appear to make a dominant contribution to the overall efficacy.  
 

















































































































1.6 Metabolism of 3-hydroxypyridinones 
Drug metabolism by the host organism is one of the crucial determinants of the pharmacokinetic 
profile of a drug. High metabolic lability usually results in poor bioavailability and high clearance. 
In consequence, optimisation of the metabolic liability of the new chemical entities is one of the 
significant steps during the drug discovery process (Kumar and Surapaneni, 2001).  
 
As demonstrated above, CP20 undergoes extensive Phase II conjugation at the 3-hydroxyl 
group, which is crucial for iron scavenging, and forms the 3-O-glucuronide conjugate. One of 
the properties required for an ideal iron-chelating agent is a slow rate of any metabolic route 
leading to inactive chelators. In order to achieve a maximum therapeutic effect, the metabolic 
rate of the chelator to inactive components should be low. This is particularly important if the 
majority of iron scavenging occurs in hepatocelluar iron pool (Porter et al., 1989a).  
Thus structural modifications of the CP20 structure have been made in an attempt to optimise 
the efficacy of this molecule class.  
 
Drug metabolism reactions are broadly divided into two categories: Phase I and Phase II 
reactions (Coleman, 2010). Phase I reactions are functionalisation reactions which introduce a 
polar functional group onto the molecule. Examples of the Phase I reactions are hydrolysis of 
ester or amide groups to their respective acid and alcohol/amines, hydroxylation of aromatic 
and aliphatic carbons, heteroatom dealkylation (secondary/tertiary amines, ethers, thioethers), 
heteroatom oxidation (N-, S- oxidation) and reduction. In some incidences, Phase I metabolites 
are excreted as such or undergo further Phase II metabolism prior to elimination. The most 
important enzymes involved in Phase I metabolism are the cytochrome P450 (CYP) superfamily 
of enzymes, flavin-containing monooxygenases, esterases, and amidases (Pearson and 
Wienkers, 2009). Phase II reactions are usually conjugation reactions, which introduce a polar 
functional group onto either the parent molecule or its Phase I metabolite. The resulting Phase II 
metabolites, termed conjugates, are usually more polar than the parent molecule and in 
consequence are more readily eliminated from the host. The most prevalent Phase II metabolic 
pathways include glucuronidation, sulfation, methylation, acetylation and glutathione 
conjugation. UDP-Glucuronosyltransferases (UGT)-mediated glucuronidation is a predominant 




pathway of Phase II metabolism. Endogenous substrates of UGT include bilirubin, thyroxin and 
steroid hormones. Several xenobiotics metabolised by UGT include morphine, aspirin, 
azidothymidine, ibuprofen, and acetaminophen. β-Glucuronidase, an enzyme produced by gut 
microflora can hydrolyse glucuronide conjugates excreted into the gut via bile to the parent 
drug. The parent drug can then be reabsorbed. The UGT group of enzymes is classified into two 
families based on amino sequence homology. The major subfamilies involved in drug 
metabolism are UGT1A1 (bilirubin, estradiol, EE, and buprenorphine), UGT1A4 (planar phenols 
such as imipramine, doxipen, amitriptyline, and chlorpromazine), UGT1A6 (planar phenols such 
as naphthol and p-nitrophenol), UGT1A9 (bulky phenols such as propofol, propranalol, and 
labetolol), and UGT2B7 (NSAIDs, naproxen and ibuprofen, and valproic acid, clofibric acid, 
benzodiazepines, morphine) (Sies and Packer, 2005).   
 
Microsomes isolated from different organs and species have been widely used for the study of 
xenobiotic metabolism including potential drug materials. Hepatic and extrahepatic cells contain 
a multitude of xenobiotic- and endobiotic- metabolising enzymes that are usually localised to 
intracellular specific organelles. The two major categories of metabolising enzymes, namely 
cytochrome P450 (CYPs) (Phase I) and UDP-glucuronosyltransferases (UGTs) (Phase II), are 
predominantly localised within the endoplasmic reticulum (ER). Thus, microsomes (vesicles of 
endoplasmic reticulum) isolated from multiple organs and species are the most popular 
subcellular fraction for in vitro metabolism studies. The advantages of an in vitro model using 
microsomes include the ease of preparation, commercial availability, flexibility of incubation 
conditions (cofactors, buffer, pH and temperature for optimal catalysis), simple storage protocols 
and the concomitant decrease in the use of animals in drug discovery and development 
(Pearson and Wienkers, 2009) 
 
1.7 Efficacy studies of 3-hydroxypyridinones 
Preclinical efficacy study of iron chelators is essential as it provides preliminary data on the 
efficiency of the compound to scavenge iron and the subsequent routes of iron excretion. 
Combined with information on physicochemical properties and metabolic profiles, a 
comprehensive profile of an iron chelator can be evaluated. In vivo animal models are essential 




in order to establish the disposition and distribution of the chelator, including absorption from the 
gastrointestinal tract. A few models have been developed to investigate the efficacy of iron 
chelators.   
 
In several studies, hypertransfused rat or mice models have been used for screening the 
biological evaluation of potentially useful iron chelators in both small and large-scales. However, 
procedures of iron overloading by hypertransfusion are technically demanding and time-
consuming (Graziano et al., 1974, Grady et al., 1978, Pitt et al., 1979). Hence, iron dextran has 
been introduced for iron loading in the fashion that iron is initially extracted by the 
reticuloendothelial system and then is equilibrated and redistributed to parenchymal tissues, 
which has been used in a mouse model to evaluate a range of N-substituted 3-hydroxypyrid-4-
one chelators (Gyparaki et al., 1987). However, rapid depletion of iron stores occurred after 
cessation of iron dextran supplement, in consequence, using ferrocene-loaded rats has 
demonstrated a more stable iron loading model and a histological similarity in the iron-
overloaded liver to that of primary haemochromatosis (Ward et al., 1991). Although the iron-
overloaded animal models appear ideal and simulate the iron overloading pathological 
conditions in man, the iron loading process is time consuming and not always reproducible in 
providing the equivalent iron mobilisation abilities of iron chelators (Liu et al., 1999c). A rapid 
assay for evaluation of iron-chelators in non-iron-overloaded rats has been developed by 
Pippard and co-workers using 
59
Fe-ferritin to label hepatic parenchymal cells (Pippard et al., 
1981). It has been demonstrated that using a radio-labelled iron probe in the animal model can 
greatly simplify the monitoring of iron excretion by circumventing many of the drawbacks 
associated with faecal contamination and intraluminal chelation observed with cold iron 
measurements. A further advantage is that specific iron pools can be targeted with different 
forms of radio-labelled iron, allowing a more precise investigation of differences in sources and 
routes of excretion of chelatable iron in the presence of various chelators. Thus, it has been 
demonstrated that 
59
Fe-labelled ferritin and haemoglobin–haptoglobin complexes are 
predominantly taken up by hepatocytes in rats, whereas 
59
Fe-labelled heat-damaged red blood 
cells can be used to selectively label reticuloendothelial cells (Hershko et al., 1973, Hershko, 
1978). Since the liver is the major iron storage organ under iron-overloaded conditions, 
59
Fe-




labelled ferritin appeared to be the ideal radio-iron model (Pippard et al., 1981). Two hours after 
radio-iron labeling, a challenge with test chelator was administered at a time when radio-iron 
released by lysosomal degradation of the exogenous ferritin was maximally available. In details, 
the time window of 
59
Fe is accessible for chelation was when in transit within the hepatocyte, 
but that it became relatively unavailable subsequent to incorporation in endogenous ferritin, 
which was shown to occur between the second and sixth hour after 
59
Fe-ferritin injection. With 
the chelators tested, almost all the 
59
Fe was excreted via the bile. In this study, it was concluded 
that animals with normal iron stores could be used for a rapid bioassay of iron chelators 
(Pippard et al., 1981). Subsequently, this in vivo model was elaborated by Liu et al (1999c) in 
screening of some 3-hydroxypyridin-4-ones for the development of an orally active iron chelator. 
The impact of several key parameters in this model has been systematically investigated. 
Different time periods after the injection of 
59
Fe-ferritin and the distribution of injected 
59
Fe were 
monitored. It was demonstrated that the efficient 
59
Fe-ferritin labelling in the liver was conducted 
after 60 min (Figure 1.10) (Liu et al., 1999c). The time intervals between administration of 
59
Fe-
ferritin and chelator were also investigated in order to provide maximal accessibility of the 
59
Fe 
label to the administered chelators. The results revealed a separation of 1 hr between ferritin 
and chelator injections gave higher gut content and faeces counts resulted from biliary 
excretion, which compensate to a corresponding decrease in liver 
59
Fe levels (Liu et al., 1999c). 
This is also in concert with a plasma half-life of 0.5–1.5 hr previous pharmacokinetic studies 
with orally administered HPOs in the rat (Choudhury R., 1995). The bile iron excretion assay 
using the bile duct cannulation model in normal rats confirmed that the peak of iron excretion 
varied with different chelators. Therefore, collections of excreted iron were ideally made over a 
24-hr period (Liu et al., 1999c). In summary, the labelled iron pool was challenged by oral 
administered iron chelators 1 hr after the injection of 
59
Fe-ferritin (Figure 1.11). 24 hr after 
injection of 
59















Figure 1.10 The distribution of injected 
59
Fe-ferritin with time  
(a) Percentage of injected 
59
Fe in liver; (b) Percentage of injected 
59





Liver, gastrointestinal tract contents, urine and faeces were collected separately for gamma 
counting (Scheme 1.2). The Iron mobilisation (%) was used to evaluate the efficiency of 
59
Fe 
scavenged from the hepatocytes by iron chelators, which is termed as the percentage of 
59
Fe 
activity in the gut and faeces compared with the sum of 
59
Fe activity in gut, faeces and liver. 
Efficacy (%) is the Iron mobilisation (%) of drug group minus the Iron mobilisation (%) of control 























































group (animals administered with water). Total recovery (%) was used to assess the efficiency 
of 
59
Fe labeling, which is termed as the percentage of 
59
Fe activity in the gut, faeces and liver 
compared with the total 
59
Fe activity administered by tail vein injection. The reliability and 
reproducibility of this above method has been verified with various ligands. The total recovery of 
59
Fe fell in the range of 76%~ 87% and the mean values together with the standard deviation 
(SD) indicate that the errors associated with this assay were acceptable for comparative 






Figure 1.11 Hepatocellular iron pool labelled by 
59
Fe-ferritin and scavenged by iron chelators 


































































































































































































































































1.8 Aim of project 
Clearly there is still a requirement for improved orally active chelators. Therefore, we have 
undertaken several novel approaches of iron chelator design all based on the 
hydroxypyridinone ring. A range of candidate compounds have been synthesised consisting of 
chiral pairs (Figure 1.12, CN106 and CN108), a ω-acetamido-6-alkyl substituted CP20 analogue 
(Figure 1.12, CM1), a group of closely related CP20 analogues (Figure 1.12, CP679, CP616 
and CP617) and pegylated HPOs (Figure 1.12, K31, C31, K5 and K6). All these compounds 
were predicted to possess similar pFe
3+ 
values to that of CP20/deferiprone. Their hepatic 
metabolic profiles were investigated in order to select compounds with the lowest hepatic 
metabolic clearance. On the basis of this comparison, selected compounds were subjected for 
iron mobilisation efficacy studies. The overall aim of the project is to identify a second-
generation hydroxypyridinone to replace CP20/deferiprone. For this to be a reality, the 
compound should remove iron from the liver more efficiently than CP20/deferiprone, possess a 
lower susceptibility towards metabolism and lack the side effects of agranulocytosis and 
neutropenia. The above work forms the basis of this Ph.D. thesis.    
        
Figure 1.12 Chemical structures of HPOs investigated 
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Chapter 2 Development of in vitro bio-analytical method for 
hepatic metabolism study of hydroxypyridinones 
2.1 Introduction  
2.1.1 Development of the in vitro microsomal incubation model  
As liver is the major metabolising organ and the hepatic metabolic profiles of iron chelators are 
particularly important as the majority of iron scavenging occurs in hepatocellular iron pool, liver 
microsomes isolated from multiple species, containing concentrated Phase I and Phase II 
(UGT-mediated) enzymes are useful subcellular fractions for use in in vitro metabolism studies 
of 3-hydroxypyridinones. In the isolation process of liver microsomes, the cofactors that either 
mediate the oxidation (e.g. nicotinamide adenine dinucleotide phosphate, NADPH) or the 
conjugation (e.g. UDP-glucuronic acid, UDPGA) pathways are lost (Lee and Zhu, 2011). 
Supplementing the microsomal incubations with these cofactors can be used to identify the 
different metabolic pathways and to determine their relative contributions to the 
hydroxypyridinone metabolism. Microsomal incubation conditions can be adjusted to achieve 
the optimum rate of metabolising enzyme catalysis.  
 
2.1.1.1 Disruption of UDP-glucuronosyltransferases (UGT) latency  
Glucuronidation is accomplished by a set of enzymes known as UDP (Uridine Diphosphate) 
glucuronosyl transferases, or UGTs. The UGT protein can be conceptually divided into amino- 
and carboxyl-terminal domains. The C-terminal binds the cofactor UDPGA and the N-terminal 
binds the substrate. The active site of UGT is positioned on the lumenal surface of the 
microsomes (Figure 2.1) (Coleman, 2010). Intact microsomes are mainly composed of 
endoplasmic reticulum (ER) membranes, which are “right side out” closed vesicles and hence 
display enzyme latency. Permeation of microsomal membrane is a rate-limiting step for the 
transport of substrates, cofactors and products. Hence, the full glucuronidation potential of the 
microsomes is not exposed unless the microsomal membranes are disrupted by chemical or 
physical methods. Sonication, cycles of freezing and thawing, pore-forming agents and 
detergents can all be used to enhance the microsomal UGT activity (Meech and Mackenzie, 
1997). We have investigated the ability of a detergent and a pore-forming peptide to disrupt the 
Chapter Two: Development of in vitro bio-analytical method for  




membrane barrier and achieve the optimal enzymatic activity for the glucruonidation of 
hydroxypyridinones. 
 
              
Figure 2.1 Glucuronosyl transferases (UGTs) in endoplasmic reticulum (ER) membranes  
Modified from (Coleman, 2010) 
 
 
2.1.1.2 Endogenous β-glucuronidase 
The enzyme-catalysed hydrolysis of the newly formed glucuronide by the endogenous β-
glucuronidase might also affect the measured UGT activity in microsomal incubations. Human 
endogenous β-glucuronidase has been found in all tissues and body fluids, with the highest 
activity in liver and one third of the β-glucuronidase found in liver cells localised in the 
endoplasmic reticulum (Oleson and Court, 2008). The endogenous β-glucuronidase activity in 
human liver microsomes has been demonstrated to cause 10-20% degradation of both 
estradiol-3-glucuronide and estradiol-17-glucuronide (Oleson and Court, 2008). Thus, 
glucuronidation studies using microsomes can be complicated by the presence of endogenous 
β-glucuronidases, leading to underestimation of glucuronide formation rates. Oleson and Court 
(2008) have also examined the effect of a most frequently used β-glucuronidase inhibitor, D-
Chapter Two: Development of in vitro bio-analytical method for  




saccharic acid 1, 4-lactone (saccharolactone), on eight different UGT activities using pooled 
human liver microsomes (pHLMs) and recombinant UGTs (rUGTs) and found that 
saccharolactone at concentrations ranging from 1 to 20mM did not increase any of the 
glucuronidation activities assessed that could be considered consistent with β-glucuronidase 
inhibition. However they still suggested that if saccharolactione is to be used, concentrations 
should be titrated to achieve activity enhancement. Consequently, saccharolactone was 
included in preliminary HPO microsomal incubation mixtures used in this study and 
concentrations were titrated in order to investigate the impact of the endogenous β-
glucuronidase on the glucuronidation. 
 
2.1.2 LC method development  
2.1.2.1 Reversed Phase separation mode 
The 3-hydroxypyridin-4-one iron chelators display poor chromatographic behavior on 
conventional bonded silica phase, generating non-symmetrical and multiple peaks. This is due 
to the interaction of the compounds with saturable free silanol groups and residual metal 
impurities on the bounded silica phase (Epemolu et al., 1994). Therefore, non-silica-based 
columns with high carbon loading, such as Ultracarb, polymer PLRP and Hypercarb PGC 
columns were adopted. The aqueous mobile phase was adjusted to pH 3.0 and 2 mM of EDTA 
included (Epemolu et al., 1990). However, this system proved to be unsatisfactory when applied 
to more hydrophilic HPOs and their metabolites, their retention times being short and not well 
resolved from the interfering matrix. These problems were largely overcome by using the 
polymer PLRP column with the aqueous mobile phase containing the ion-pair reagent 1-
heptanesulfonic acid and pH adjusted to 2.0 (Liu et al., 1999a). The same polymer PLRP 
column was adopted for the studies reported in this chapter.  
 
2.1.2.2 HILIC separation mode 
Hydrophilic interaction LC (HILIC) phase has been increasingly applied to separate the highly 
polar components in biological samples (Dejaegher et al., 2008). HILIC is characterised by the 
use of a hydrophilic stationary phase and an aqueous-polar organic solvent mobile phase with 
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high organic component (e.g. 90/10 v/v ACN/H2O). The more polar aqueous fraction of the 
mobile phase will preferentially adsorb on the polar HILIC stationary phase creating a semi-
stagnant, water-rich stationary phase and a water-depleted mobile phase. Polar analytes can 
then partition into the aqueous-enriched phase (Buszewski and Noga, 2012). Hydrophilic 
analytes are retained on the HILIC phase by hydrophilic partitioning between the mobile phase 
and the water-enriched aqueous layer, with subsequent interactions with the stationary phase 
functional groups, e.g. dipole–dipole, ion exchange and hydrogen bonding (Goucher et al., 
2010) (Figure 2.2). The retention time increases with increased polarity of the analytes and with 
decreased mobile phase polarity (Dejaegher et al., 2008). Drug metabolism typically produces 
more hydrophilic metabolites, which facilitate drug elimination. This is often a challenge for 
traditional reversed-phase liquid chromatography separation. Because hydrophilic interaction 
liquid chromatography (HILIC) is capable of retaining polar compounds and is compatible with 
mass spectrometry (MS), HILIC has been used as a complementary separation technique to 
RPLC for the analysis of polar drugs and their metabolites (Li et al., 2015b). 
 
Figure 2.2 HILIC retention mechanism on a silica column  
The analyte D partitions into the H2O layer on the silica surface of the packing and further interacts with the stationary 
phase functional groups by dipole–dipole, ion exchange or hydrogen bonding. Modified from (Waters, 2015) 
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Consequently in this study, several different HILIC columns were investigated for their ability to 
resolve HPO compounds. HPO compounds possess two pKa values, corresponding to the pKa 
values of 4-carbonyl group (~3.6) and 3-hydroxyl group (~9.9) (Liu and Hider, 2002). Therefore, 
in extreme acidic and basic environments, they can be protonated or deprotonated, thereby 
possessing ionic properties. Two Waters Acquity
®
 UPLC columns were investigated, which are 
the BEH and BEH Amide columns. Both columns are sub-2 µm columns, which offer 
advantages of increased separation speed with superior resolution and high sensitivity (Swartz, 
2005). The modification of the silica stationary phase by Ethylene Bridged Hybrid (BEH) particle 
introduced by Waters improves the column stability under the ultra-performance LC (UPLC) 
high-pressure conditions over a wide pH range (1–12), in comparison to conventional RP 
columns. This is because nearly one-third of the surface silanol groups are masked by the 
ethylene-bridged groups embedded within the silica matrix (Jian et al., 2010). Another HILIC 
phase, zwitterrionic SP (ZIC HILIC), has also been examined for chromatographing HPOs. ZIC 
HILIC phase carries sulfoalkylbetaine zwitterionic functional groups attached to porous silica, 
which the oppositely charged sulfonic acid and quaternary ammonium groups present in a ratio 
of 1:1, providing a net charge of zero and promoting weak ion exchange interactions 
(Buszewski and Noga, 2012). The bonded phase is highly polar, strongly adsorbing water, 
which facilitates the formation of an aqueous layer. Both neutral and charged compounds can 
be retained on ZIC HILIC phase primarily by hydrophilic partitioning and electrostatic interaction 
(Jian et al., 2010). 
 
2.2 Materials  
Microsomes 
Male Sprague-Dawley (SD) rat liver microsomes (M00001), in VitroCYP
TM 
H-class 25 donor 
male-pooled human liver microsomes (MX008065) were purchased from Celsis in vitro 
technologies (Neuss, Germany). Microsomal protein concentrations were 23.7mg/mL and 
20.3mg/mL, respectively. Microsomes were aliquoted and stored at -80 °C. Frozen microsomes 
were thawed prior to use by placing the vial under cold running water. Once thawed, the vials of 
microsomes were kept in a wet ice bath.  
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CP20 (1,2-dimethyl-3-hydroxypyridin-4-one) was purchased from Sigma Aldwich.  CP94 (1,2-
diethyl-3-hydroxypyridin-4-one, hydrochloride form), CP102  (1-(2’-hydroxyethyl)-2-ethyl-3-
hydroxypyridin-4-one, hydrochloride form), CP95 (1-propyl-2-ethyl-3-hydroxypyridin-4-one, 
hydrochloride form), were synthesised in King’s College London.  CP20, CP94 and CP102 each 
have quite different metabolic profiles, which have been extensively investigated (Singh et al., 
1992, Singh et al., 1996). CP95 was adopted as the internal standard it is a hydroxypyridinone 
analogue, which has the similar but readily distinguishable signal response compared with the 
analytes of interest 
 
Other biological and chemical materials  
Reduced β-nicotinamide adenine dinucleotide 2’-phosphate tetrasodium salt hydrate (NADPH), 
uridine 5’-diphosphoglucuronic acid trisodium salt (UDPGA), triton X-100, alamethicin (from 
Trichoderma viride), D-saccharic acid 1,4-lactone monohydrate, β-glucuronidase type H-3 (from 
Helix pomatia), tris(hydroxymethyl) aminomethane were purchased from Sigma Aldrich (Dorset, 




2.3.1 Microsomal incubation  
Phase I + II (glucuronidation) metabolism reactions were investigated in male SD rats liver 
microsomes and in VitroCYP
TM 
H-class 25 donor male-pooled human liver microsomes for 
CP20, CP94 and CP102 respectively.   
 
2.3.1.1 Stock solution preparation  
NADPH stock solution (10mM), UDPGA stock solution (10mM), MgCl2 stock solution (50mM), 
phosphate buffer (1mM, pH 7.4) and D-saccharic acid 1,4-lactone (100mM) were prepared in 
Milli-Q water. CP20 stock solution (200mM) was prepared in 50% methanol, then further diluted 
to 2mM in Milli-Q water. CP94, CP102 and CP95 stock solutions (20mM) were prepared in in 
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Milli-Q water and further diluted to 2mM in Milli-Q water.  
 
2.3.1.2 Phase I + II (glucuronidation) microsomal incubation 
To investigate phase I metabolism, the following was spiked into an enpendorf tube: 25μL of 
cold liver microsomes (giving a final concentration of 1 mg/mL protein), 50μL of MgCl2 stock 
solution (10mM), 50μL of phosphate buffer (1mM, pH 7.4), 50μL of CP20, CP94 or CP102 stock 
solution (2mM) and 25μL of Milli-Q water. The combined components were then pre-incubated 
at 37 °C for 10 min, after which 100μL of NADPH stock solution (10mM) and 100μL of UDPGA 
stock solution (10mM) were added to initiate metabolic reactions. The mixture was then 
incubated at 37 °C in a thermostat incubator for 24h with gentle shaking to prevent protein 
sedimentation. The reactions were terminated by spiking in 50µL of 10% trichloroacetic acid to 
remove protein, followed by spiking of 50μL of CP95 (2mM) as the internal standard. Samples 
were mixed evenly by the vortex mixer and followed by centrifuge at 14,000 rpm in a 
Spectrafuge™ 16M microcentrifuge (Labnet International Inc., NJ, USA) for 10min. Blank 
samples were prepared by substituting cofactors (NADPH and UDPGA) with water. The 
supernatants were collected for the further analysis. Moreover, in order to disrupt the latency of 
UGT activity and inhibit the endogenous β-glucuronidase, detergent or pore-forming peptide 
and D-saccharic acid 1,4-lactone were added to the microsomes before initiating the reactions 
and their concentrations were optimised as below.   
 
Addition of the detergent to overcome UGT latency 
TritionX-100 was added into 25μL of cold liver microsomes and incubated on ice for 10min 
before adding into the reaction mixture. The detergent/microsomal protein ratios were adjusted 
from 0.1, 0.2, 0.3, 0.5 to 1mg/mg. The optimal detergent activation of liver microsomal UGTs 
was determined as the detergent/microsomal protein ratio, which could induce the maximal 
glucuronidation conversion of the parent drug.  
 
Addition of the pore-forming peptide to overcome UGT latency 
The pore-forming peptide, alamethicin, was incubated with 25μL of cold liver microsomes, with 
an alamethicin/microsomal protein ratio of 5, 10, 25, 50, 100μg/mg on ice for 10min before 
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adding into the reaction mixture. The optimal alamethicin activation of liver microsomal UGTs 
was determined as the alamethicin/microsomal protein ratio, which could induce the maximal 
glucuronidation conversion of the parent drug.  
Addition of D-saccharic acid 1,4-lactone as an endogenous β-glucuronidase inhibitor 
D-saccharic acid 1,4-lactone was included in the reaction mixture in order to investigate whether 
it effectively inhibits the effect of endogenous β-glucuronidase on the glucronidation rate. The 
stock solution of D-saccharic acid 1,4-lactone (100mM) prepared in 1 mM phosphate buffer was 
adjusted to pH 7.4 with potassium hydroxide, and diluted into the reaction mixture before adding 
in the liver microsomes. The final concentrations of D-saccharic acid 1,4-lactone were adjusted 
to 1, 2, 5, 10 and 20mM. The effect of endogenous β-glucuronidase inhibition was confirmed by 
whether an increase of glucuronidation conversion of parent compound was observed 
compared with the D-saccharic acid 1,4-lactone excluded control sample.  
 
Addition of divalent metal ion (Mg
2+
) 
Physiological concentrations of magnesium chloride (5mM) was also added in the microsomal 
incubation mixture (Zakim et al., 1973). Divalent metal ions modify UGTs by direct binding to the 
enzyme to increase their catalytic activities. It has been reported that addition of Mg
2+ 
to the 
alamethicin treated microsomal incubation enhanced the UGTs activity (Fisher et al., 2000). 
Blank samples were prepared by substituting cofactors (NADPH and UDPGA) with water. 
Phase I + II microsomal incubates for each HPO compound were prepared in triplicate.   
 
2.3.2 Development of HPLC conditions using reversed phase (RP) mode 
2.3.2.1 Instrumentation 
A polymer reversed phase (PLRP) column (250mm×4.6mm, 5μm) (Polymer Laboratories Ltd, 
Shropshire, UK) was used on a Hewlett-Packard HPLC 1100 (Agilent Technologies Ltd., 
Shropshire, UK) equipped with UV-Vis detector. 
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2.3.2.2 HPLC conditions 
Supernatants (20µL) of Phase I + II microsomal incubation samples for CP20, CP94 and CP102 
were injected onto the polymer PLRP column. The mobile phases consisted of 1-heptane 
sulfonic acid (5mM, pH 2) and acetonitrile. The flow rate was 1.0 ml/min with the following 
gradient system with 2% to 40% of CH3CN in 20 min and a post-run was followed for 5 min at 
2% of CH3CN.  
 
2.3.2.3 Confirmation of glucuronidation 
Glucuronidation was confirmed by the deconjugation by β-glucuronidase from Helix pomatia. 
Before terminating the reaction, samples were removed from the incubator at 24h. 5000 units of 
β-glucuonidase were added. Samples were returned to the incubator for another 16h before the 
addition of trichloroacetic acid and the internal standard. After 16hr incubation, samples were 
vortexed and followed by centrifugation at 14,000rpm in a Spectrafuge™ 16M microcentrifuge 
(Labnet International Inc., NJ, USA) for 10min. The supernatants from the protein pellet were 
subjected to HPLC analysis. The deconjugation of glucuronidation was confirmed by an 
increase of the parent drug signal.  
 
2.3.2.4 Percentages of hydroxypyridinone metabolic conversion   
CP20, CP94 and CP102 sample solutions at concentrations of 25µM, 50µM, 100µM, 200µM, 
400µM, 800µM were used to construct calibration curves, CP95 added as the internal standard 
(IS) and the concentration of CP95 was constant in each calibration standard, namely 300 µM. 
Calibrations were conducted for each HPO compound (Peak area ratio of HPO/IS vs 
Concentration). The unknown concentrations of the HPO parent drug in the microsomal 
incubates were calculated from the corresponding calibration curve. Percentages of Phase I + II 
reactions were determined by Equation 2.1 
 
% 𝑃𝑎𝑟𝑒𝑛𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑑𝑖𝑠𝑎𝑝𝑝𝑒𝑎𝑟𝑎𝑛𝑐𝑒 = 
 
{1 − [
𝑃𝑎𝑟𝑒𝑛𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝐶𝑜𝑓𝑎𝑐𝑡𝑜𝑟𝑠 𝑖𝑛𝑐𝑙𝑢𝑑𝑒𝑑)
𝑃𝑎𝑟𝑒𝑛𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝐶𝑜𝑓𝑎𝑐𝑡𝑜𝑟𝑠 𝑒𝑥𝑐𝑙𝑢𝑑𝑒𝑑)
]}  ×  100 
                                                                                                                                                     (Equation 2.1) 
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2.3.3 Development of UPLC conditions using HILIC mode 
2.3.3.1 Instrumentation 
HILIC phase columns 
Acquity UPLC BEH column, 130Å, 1.7 µm, 2.1 mm X 50 mm, Waters, Elstree, UK 
Acquity UPLC BEH Amide column, 130Å, 1.7 µm, 2.1 mm X 100 mm, Waters, Elstree, UK 
SeQuant ZIC-HILIC, 100Å, 1.0 x 150 mm; 3.5 um, Merck Millipore, Feltham UK 
 
UPLC-MS 
A Thermo Finnigan MAX LCQ
TM
 3D ion trap mass spectrometer (San Jose, CA) interfaced to 
ESI was coupled to a Jasco X-LC
TM
 system (JASCO UK Ltd, Essex, UK), which was composed 
of two semi-micro pumps (pump A and pump B, 3085 PU), a dynamic mixer, a degasser and an 
auto-sampler. A Thermo Finnigan LCQ
TM
 Deca XP 3D ion trap mass spectrometer (San Jose, 
CA) interfaced to ESI was coupled to a Waters
® 
Acquity UPLC system (Waters Corp., Milford, 




 MS conditions  
The LCQ
TM
 3D ion trap MS was operated in positive ESI mode. Data was acquired in MS full 
scan mode with a mass range of 50 - 300. ESI ion source parameters were as follows, a sheath 
gas (N2) and an auxiliary gas (N2) flow rates were 99.56 L/min and 19.23 L/min respectively. 
The capillary and source voltage were set at 11.42 V and 4.55 kV, respectively. The capillary 
temperature was 199.70 °C. 
 
2.3.3.2 Sample preparation  
A stock solution of 5mg/mL for each HPO, CP20, CP94 and CP102 in 95/5 v/v ACN/H2O was 
prepared separately. 10μL of each HPO stock solution was spiked into 970μL 95/5 v/v ACN/H2O 
in an eppendorf tube tube and mixed evenly on a vortex mixture for 1 min to produce a clear 
solution of 50 μg/mL. 100 μL of the 50μg/mL solution was spiked into 900μL 95/5 v/v ACN/H2O 
solvent in an eppendorf tube and mixed evenly on a vortex mixture for 1 min to produce a clear 
solution of 5 μg/mL in 95/5 v/v ACN/H2O solvent.  
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2.3.3.3 Investigation of HPOs on HILIC phase 
Mobile phase preparation  
 
Acidic mobile phases (pH 3) consisted (A) 95/5 v/v ACN/H2O + 0.125% HCOOH + 10mM 
HCOONH4 and (B) 5/95 v/v ACN/H2O + 0.125% HCOOH + 10mM HCOONH4 
Neutral mobile phases (pH 7) consisted of (A) 95/5 v/v ACN/H2O + 10mM CH3COONH4 and (B) 
5/95 v/v ACN/H2O + 10mM CH3COONH4. 
Basic mobile phases (pH 9) consisted of (A) 95/5 v/v ACN/H2O + 0.04% NH4OH + 10mM 
CH3COONH4 and (B) 5/95 v/v ACN/H2O + 0.04% NH4OH + 10mM CH3COONH4 
Basic mobile phases (pH 8) consisted of (A) 95/5 v/v ACN/H2O + 0.04% NH4OH + 10mM 
CH3COONH4 and (B) 5/95 v/v ACN/H2O + 0.04% NH4OH + 10mM CH3COONH4, acidified with 
CH3COOH to pH 8 
The measurement of pH of the mobile phases was undertaken in the aqueous media before 
mixing with organic phase.  
 
Chromatography 
50μg/mL of HPOs (CP20, CP94 and CP102) solutions were introduced by a loop injection into 
the ESI source at acidic (pH 3), neutral (pH 7), basic (pH 9) conditions in both ESI positive and 
negative ionisation modes. The ESI ion source parameters were optimised automatically to give 
the greatest signal strength of the ionised compounds. 
10μL of CP20, CP94 and CP102 solutions (5μg/mL) were injected onto an Acquity UPLC BEH 
HILIC column and an Acquity UPLC BEH Amide column eluted with acidic (pH 3), neutral (pH 7) 
mobile phases; onto a SeQuant ZIC-HILIC column eluted with acidic mobile phases (pH 3). The 




 ion trap MS system. The same 





 Deca XP Ion Trap MS system. Two BEH columns were run with basic mobile phases at 
pH 9, while ZIC-HILIC column at pH 8. The elution was 0.1% to 99.9% mobile phase B at a flow 
rate of 0.45mL/min for a running time of 10min.  
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2.3.4 Statistical analysis  
Results are expressed as the Mean  S.D.. Bar graphs was plotted using “GraphPad Prism 5.0” 
software and statistical analysis was performed using “Two-Way ANOVA” by “GraphPad Prism 
5.0” software. Chromatographs were plotted using “Origin 8” software.  
 
2.4 Results and Discussion 
2.4.1 Hydroxypyridinones adopted to test various bio-analytical systems 
Three HPOs, CP20/deferiprone, CP94 and CP102, were used as the control groups during the 
development of an in vitro bio-analytical method for hepatic metabolism study of 3-
hydroxypyridinones, due to their metabolic profiles being well established under in vivo 
conditions in both rat and human.  
 
 
                                                                  
 




CP20 CH3 CH3 139 0.17 
CP94 CH2CH3 CH2CH3 167 1.78 
CP102 CH2CH2OH CH2CH3 183 0.22 
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CP20/deferiprone is both extensively conjugated at the 3-hydroxyl group in rat and human. The 
predominant metabolites in urine were 3-O-glucuronides, which accounted for > 44% in rats 
and > 85% in man of the dose administered respectively (Singh et al., 1992). The dominant 
metabolite of CP94 in rat was the 2-(1’-hydroxyethyl) derivative, which accounted for about 40% 
of administered dose recovered in urine (Singh et al., 1992, Lu et al., 2000). In contrast, in 
human, 3-O-glucuronidation accounted for the majority of the biotransformation and more than 
90% of the dose administered was recovered in urine (Porter et al., 1994). CP102 was reported 
not to be metabolised to any considerable extent in rat with the unchanged CP102 as the 
dominant form and minor glucuronide found in urine (Singh et al., 1996, Lu et al., 1998). 
Consequently, the validity of the various methods were assessed by comparing the observed 
metabolic conversions of these three HPOs using the different bio-analytical methods with the 
previously reported in vivo hepatic metabolic conversion results.  
 
2.4.2 Development of HPO chromatography using Reversed Phase mode 
The addition of an ion-paring reagent, 1-heptanesulfonic acid, into the acidified mobile phase 
led to prolonged retention times of both the hydrophilic parent compounds and more hydrophilic 
metabolites. This chromatographic system also led to sharp, symmetrical peaks (Figure 2.3, 2.4 
and 2.5). The percentage of parent CP20 depletion can be calculated by comparing the 
concentration of CP20 in the microsomal incubation sample (NADPH+UDPGA included, Figure 
2.3) and of CP20 in the blank (NADPH+UDPGA excluded, Figure 2.4). The concentrations of 
CP20 in both preparations were extrapolated from the calibration curve of CP20 Concentration 
vs Peak Area Ratio (CP20/CP95), which were 148μM, 198μM, respectively. Recovery of the 
parent HPO was observed when the microsomal incubation mixture (NADPH+UDPGA included) 
was treated with β-glucuronidase from Helix pomatia, when the CP20 level in the β-
glucuronidase treated sample (NADPH+UDPGA included, Figure 2.5) rose to188μM, thereby 
confirming that the parent HPO was conjugated via glucuronidation (Figure 2.5). The 
percentages of parent HPOs depletion for CP94 and CP102 were determined in the same 
fashion (Appendix I).  
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Figure 2.3 Chromatography of CP20 rat liver microsomal incubates 




Figure 2.4 Chromatography of blank rat liver microsomal incubates  
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Figure 2.5 Chromatography of CP20 rat liver microsomal incubates deconjugated by β-
glucuronidase 




2.4.3 Development of Phase I+II microsomal incubation conditions 
Due to the latency of UGTs and possible effects of endogenous β-glucuronidase, incubation 
conditions for glucuronidation by microsomes usually include an agent to disrupt the membrane 
barrier, a divalent metal ion, and the selection of an optimal pH to obtain maximal 
glucuronidation activity (Jia and Liu, 2007).  
 
2.4.3.1 Addition of detergent to overcome UGT latency 
Detergents solubilise UGTs, which are loacated on the lumenal surface of microsomes (Sies 
and Packer, 2005). This permits access of the hydrophilic cofactor UGPDA, which is normally 
synthesised in the cytosol, to the active site of UGTs (Section 2.1.1.1, Figure 2.1). There are 
various types of detergents that can be used to minimise UGT latency, such as the non-ionic 
detergents: triton, digitonin; the ionic detergents: cholate, deoxycholate; the zwitterionic 
detergents: CHAPS (Sies and Packer, 2005). TritonX-100 is commonly added as a detergent in 
order to fully remove UGT latency (Lett et al., 1992) and was adopted in this study. 
Experimental conditions for achieving optimal UGT activation for each HPO substrate incubated 
with both rat and human liver microsomes can be determined by titrating microsomes with 













Chapter Two: Development of in vitro bio-analytical method for  




increasing concentrations of TritonX-100 (0.1 to 1 mg per mg of microsomal proteins) on ice for 
ten minutes before adding into the reaction mixture. The detergent/microsomal protein ratios 
inducing the maximal UGT activity for each HPO in both rat and human liver microsomes were 
determined (Appendix II). However, the optimal detergent/microsomal protein ratio varied for 
each HPO substrate. For instance, at the detergent/microsomal protein ratio of 0.2, UGT activity 
increased to a maximum for CP20 in the rat microsomes. When the detergent/microsomal 
protein ratio was further increased from 0.3 to 1, the activity of UGTs was reduced (Figure 2.6). 
At higher detergent/microsomal protein ratios, the progressive disruption of the microsomal 
membrane organisation probably leads to inactivation of the enzyme (Lett et al., 1992).  
Consequently, the detergent/microsomal protein ratio of 0.2 was applied in CP20 rat microsomal 
































Figure 2.6 Percentage of CP20 metabolism by Phase I+II pathway in rat liver microsomal 
incubations titrated with Triton X-100 
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However, the extent of glucuronidation conversion of HPOs in the detergent-activated 
microsomal incubates did not reflect their in vivo metabolic profiles (outlined in Section 2.4.1). 
CP94 was found to be more resistant to glucuronidation compared with CP20 in the in vivo rat 
models. However, CP94 experienced a higher extent of glucuronidation, when compared with 
CP20, in the TritonX-100 activated rat liver microsomal incubation (Figure 2.7, Table 2.1). 
CP102, which was not metabolised via conjugation reactions to any considerable extent in in 
vivo rat models, was found to be extensively conjugated in TritonX-100 activated rat and human 
liver microsomal incubations ((Figure 2.7, Table 2.1). There are a few possibilities, which might 
contribute to these contradictory results. The detergent not only solubilises the microsomal 
membrane in order to permit the free access of UDPGA to the enzyme active site, but also 
disrupts the integrity of the microsomal membrane, which may affect the activity of the UGTs 
either by altering the microsomal vesicle structure or by solubilising an appreciable amount of 
microsomal proteins (Fulceri et al., 1994). It has also been reported that detergent can render 





Figure 2.7 Percentage of CP20, CP94 and CP102 metabolism by Phase I+II pathway in rat and 
human liver microsomal incubates  
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A disadvantage of this approach is that establishment of conditions for optimal activation will 
vary for each detergent, substrate and microsomal source used and therefore it requires the 
determination of such conditions each time one of these parameters changes (Sies and Packer, 
2005). Consequently, in order to avoid possible non-physiological effects on the native catalytic 
activity of the UGT enzymes and the labor-intensive microsomal incubation procedures, a 
substrate and enzyme source-independent, non-detergent agent is required to disrupt 




Table 2.1 Percentage of CP20, CP94 and CP102 metabolism by Phase I+II pathway in the rat and 
human liver microsomal incubates  
(Triton X-100/microsomal protein ratios varied depending on the substrate and microsomal source) 
 
 
                      HPOs 
 
% Drug metabolised (24 h) 





 9 ± 5 0.2 
CP20/deferiprone HLMs
2
 29 ± 6 0.2 
CP94 RLMs
1
 19 ± 7 0.1 
CP94 HLMs
2
 35 ± 10 0.2 
CP102 RLMs
1
 46 ± 4 0.3 
CP102 HLMs
2
 45 ± 9 0.2 
1
RLMs Rat Liver microsomes; 
2





2.4.3.2 Addition of alamethicin to overcome UGT latency  
The antibiotic fungal peptide, alamethicin, is known to insert into membranes and form well 
defined pores, facilitating entry of substrate and UDPGA into, and the diffusion of conjugate and 
UDP out of the lumen of the microsomes. In addition, alamethicin enhances UGT activity in a 
substrate-independent fashion, without affecting the intrinsic enzyme catalytic activity. Thus, in 
principle, it is a more effective activator of UGTs as compared with conventional detergents 
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(Fisher et al., 2000). Alamethicin was used in HPO microsomal incubations. 
Alamethicin/microsomal protein ratios of 5, 10, 25, 50, 100μg/mg were investigated. The 
maximal UGT activity, illustrated as the most extensive glucuronidation of CP20 incubated in rat 































Figure 2.8 Percentage of CP20 metabolism by Phase I+II pathway in rat liver microsomal incubates 




Similar alamethicin titration studies were performed for each HPO substrate incubated in both 
rat and human liver microsomes (Appendix III). The optimal alamethicin/microsomal protein 
ratios was found to be 25μg/mg for all three HPOs in two microsomal sources, which further 
implied that alamethicin removed the microsomal UGTs latency regardless of substrates and 
enzyme sources.  Consequently, all HPO microsomal mixtures were all incubated in the 
presence of 25μg alamethicin per mg microsomal protein. The depletion of parent HPOs by 
glucuronidation is illustrated in Figure 2.9 and Table 2.2. CP20 experienced relatively extensive 
glucuronidation in both rat and human microsomes. CP94 was conservatively glucuronidated in 
rat, but appreciable metabolism was observed in human microsomes. Very low levels of 
glucuronidation of CP102 occurred in rat and human microsomes. These results are 
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comparable with the in vivo metabolic profiles of these HPO compounds reported previously 




Figure 2.9 Percentage of CP20, CP94 and CP102 metabolism by Phase I+II pathway in rat and 
human liver microsomal incubates  









Table 2.2 Percentage of CP20, CP94 and CP102 metabolism by Phase I+II pathway in rat and human 
liver microsomal incubates  
(alamethicin/microsomal protein ratio: 25 μg/mg) 
 
HPOs % Drug metabolised (24 h) 
(Mean ± SD, n=3) 
CP20/deferiprone RLMs
1 25 ± 1 
CP20/deferiprone HLMs
2 35 ± 5 
CP94 RLMs
1 6 ± 2 
CP94 HLMs
2 37 ± 4 
CP102 RLMs
1 1 ± 4 
CP102 HLMs
2 1 ± 4 
1
RLMs Rat Liver microsomes; 
2
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2.4.3.3 Addition of saccharolactone as an endogenous β-glucuronidase inhibitor 
A range of saccharolactone (D-saccharic acid 1, 4-lactone) concentrations was titrated to HPOs 
rat and human liver microsomal incubates in order to observe the degree of inhibition of 
endogenous β-glucuronidase (Appendix IV). A saccharolactone concentration-dependent 
increase in glucuronidation activity was expected. However, percentage glucuronidation of 
parent HPOs in human liver microsomes showed no increase when saccharolactone was 
included (p>0.05) (Figure 2.10).  Oleson and Court (2008) have investigated the effect of 
different enzyme sources and estradiol glucuronide substrates on the amount of glucuronide 
degraded by endogenous β-glucuronidase in relation to glucuronide formation. The degradation 
as a percentage of glucuronide formed for different estradiol glucuronides fell in a range of 9 to 
19%, which indicated that although human liver microsomes exhibit β-glucuronidase activity, 
different types of glucuronides might differ in susceptibility to hydrolysis by β-glucuronidase. 
Since the addition of saccharolactone did not shown any enhancement of glucuronidation 
formation, implied that HPO glucuronides were not labile to endogenous β-glucuronidase 





























Figure 2.10 Percentage of CP20 metabolism by Phase I+II pathway in rat liver microsomal 
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2.4.4 Development of HPO chromatography using HILIC mode 
Since the introduction of the electrospray ionisation (ESI), which is a relatively gentle ionisation 
technique, suitable for labile conjugation metabolites, LC-MS has become a preferred 
metabolite detection tool owing to its superior specificity, sensitivity and efficiency. Therefore, in 
order to further confirm the Phase I+II results of HPOs using the HPLC-UV analytical method 
developed in Section 2.4.2 and Section 2.4.3.2, an UPLC-ESI-MS system was also 
investigated.  However, the LC conditions developed with the non-volatile ion-paring reagent (1-
heptanesulfonic acid) are not compatible with MS systems. The use of volatile solvents and 
additives in chromatographic separation is essential for mass spectrometry, because 
undesirable build-up from non-volatile buffer deposits interfere with ESI ionization (Naegele, 
2011). HILIC mobile phases tend to contain a higher organic solvent fraction (Section 2.1.2.2), 
which are more compatible with MS detection, leading to higher detector signals. Consequently, 
HILIC mode was investigated for HPO chromatography. A mixture of three HPO compounds 
was used to develop the HILIC method. These three HPO compounds ionised nicely in the ESI 
source as [M + H]
+
 ions in positive ion mode for CP20 (140), CP94 (168) and CP102 (184) 
respectively in acidic (pH 3) and neutral (pH 7) conditions (Figure 2.11). Surprisingly, the three 
HPOs also ionised even more effectively under basic (pH 9) conditions in positive ion mode 
(Figure 2.12). In negative ion mode, the HPO mixtures did not readily ionise. Hence, ESI 
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Figure 2.11 Mass spectrum of 50 μg/mL of three HPOs (CP20, CP94 and CP102) mixture solution 




     
Figure 2.12 Mass spectrum of 50 μg/mL of three HPOs (CP20, CP94 and CP102) mixture solution 
introduced by loop injection at basic (pH 9) condition. 
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However, chromatography of HPOs on HILIC columns with BEH HILIC (un-bonded), Amide 
(bonded) and zwitterionic ZIC-HILIC phases at acidic, neutral and basic conditions did not show 
any promising retention and separation, see for example (Figure 2.13 to 2.16). Problems 
associated with HPO chromatography on HILIC phases might result from solute-metal 




, originating from the corrosion of stainless 
steel frits in the presence of acidic mobile phases, can complex with HPO iron chelators (Ma 
and Carr, 2007). Addition of iron chelating agents in the mobile phase, such as EDTA, has been 
reported to improve HPO chromatography when using LC-UV as the analytical tool (Epemolu et 
al., 1990). However, EDTA is a non-volatile buffer, not compatible with mass spectrometry, in 
addition, the solubility of EDTA is poor when ACN concentration is more than 85% and therefore 
has limited use in HILIC (Heaton and McCalley, 2016). Furthermore, because the HILIC 
retention mechanism is a combination of mixed modes (Section 2.1.2.2), HPO compounds, 
containing more than one ionisable group, might interact with the HILIC phase in a combination 
of complex modes, which could lead to undesirable secondary interactions and result in 
deterioration of chromatographic peaks.  
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Figure 2.13 UPLC-MS chromatography of 5 μg/mL of CP20, CP94 and CP102 mixture solution in 
95/5 v/v ACN/H2O injected onto Acquity UPLC BEH HILIC column eluted with acidic (pH 3) MPs. 
MPs at acidic condition (pH 3) consisted (A) 95/5 v/v ACN/H2O + 0.125% HCOOH + 10mM HCOONH4 and (B) 5/95 v/v 









Figure 2.14 UPLC-MS chromatography of 5 μg/mL of CP20, CP94 and CP102 mixture solution in 
95/5 v/v ACN/H2O injected onto Acquity UPLC BEH Amide column eluted with acidic (pH 3) MPs. 
MPs at acidic condition (pH 3) consisted (A) 95/5 v/v ACN/H2O + 0.125% HCOOH + 10mM HCOONH4 and (B) 5/95 v/v 
ACN/H2O + 0.125% HCOOH + 10mM HCOONH4 
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Figure 2.15 UPLC-MS chromatography of 5 g/mL of CP20, CP94 and CP102 mixture solution in 95/5 
v/v ACN/H2O injected onto Acquity UPLC BEH Amide column eluted with neutral (pH 7) MPs. 









Figure 2.16 UPLC-MS chromatography of 5 μg/mL of CP20, CP94 and CP102 mixture solution in 
95/5 v/v ACN/H2O injected onto SeQuant ZIC- HILIC column eluted with acidic (pH 3) MPs. 
MPs at acidic condition (pH 3) consisted (A) 95/5 v/v ACN/H2O + 0.125% HCOOH + 10mM HCOONH4 and (B) 5/95 v/v 
ACN/H2O + 0.125% HCOOH + 10mM HCOONH4 
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In order to investigate the in vitro metabolic profiles of HPO compounds, a microsomal 
incubation protocol of Phase I+II metabolic reactions has been developed. The conditions of 
some essential elements in the incubation mixtures were investigated to achieve the optimal 
catalysing activity of microsomal enzymes. In order to disrupt the concealed UGTs activity due 
to the enzyme latency, both Triton-X 100 and the pore-forming peptide alamethicin were titrated 
into the microsomal incubation mixture to overcome UGT latency. Consequently, alamethicin 
was adopted as an ideal agent at an optimal concentration of 25μg/mg because of its ability to 
enhance UGT activity in a substrate and enzyme source independent manner. In addition, the 
resulting in vitro metabolic profiles of the corresponding HPOs were comparable with those of 
previous in vivo studies. Taking into account that there might be deconjugation of newly formed 
glucuronide by endogenous β-glucuronidase hydrolysis, a commonly used inhibitor, D-saccharic 
acid 1,4-lactone, was also added the reaction mixture. In this work, it did not show any effect on 
enhancing the glucuronidation conversion. Hence, D-saccharic acid 1,4-lactone was not 
included in the protocol.  
After examining the ideal concentrations of the above reagents to generate the optimal 
conditions for HPO microsomal incubation, we decided to substitute these tedious incubation 
procedures with more efficient in vitro drug metabolism commercial kit. The kit is manufactured 
by Corning Ltd-Life Sciences and contains the same concentrations of key elements as our 
optional incubation protocol. The results obtained with this kit are described in Chapter 3.  
In order to analyse HPO microsomal incubation samples, HPLC-UV using a polymer reversed 
phase column eluted with mobile phases containing an ion-paring additive was initially applied. 
This system successfully resolved HPO compounds from the microsomal matrix, characterised 
by symmetrical and sharp chromatographic peaks. Further quantitative analysis of the parent 
HPO depletion over the time of microsomal incubation demonstrated a comparable in vitro 
metabolic profile with the previously obtained in vivo data. In order to further verify the above 
results, mass spectrometry offered as a sensitive and specific tool. Since the non-volatile 
buffers used in the above HPLC-UV method cannot be interfaced with ESI-MS, HILIC analytical 
columns with ESI-MS-compatible mobile phases were investigated as alternatives. 
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Unfortunately, none of the HILIC phases investigated in the study serves as a reliable method to 
establish well resolved good chromatography of HPOs. As a consequence, a reliable analytical 
method based on UPLC-ESI-MS was sought to further investigate the in vitro microsomal 
metabolism of HPOs and this is described in Chapter 3.  
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Chapter 3 Development of a high throughput bio-analytical 
method for the in vitro hepatic metabolism study of novel 
hydroxypyridinones  
3.1 Introduction 
A series of novel 3-hydroxypyridin-4-one analogues have been designed based on the structural 
modification of the lead iron chelator CP20/deferiprone, in order to optimise the physiochemical 
properties and stereochemical orientations, which might improve the iron chelation efficacy. The 
investigation on their in vitro metabolic profile using human liver microsomal incubation 
approach has provided the hepatic metabolism information and has facilitated the selection of 
candidate compound which might possess the better oral availability and improved 
pharmacokinetic characters leading to an enhanced iron chelation efficacy. A high throughput 
bio-analytical method was sought to screen the metabolic profiles of the investigated 
compounds 
3.2 Materials  
Hydroxypyridinones 
CP20, CP94, CP102, CP365, CP364, CP21 were synthesised in King’s College London. CN128 
(Batch No. 20121228) and CN126 were synthesised in Zhe Jiang University, China. The purity 
of CN128 was certificated as 98.77%. CP20 analogues (CP669, CP69, CP616, CP28, CP679, 
CP617) and pegylated HPOs (C11, C21, 6d, C31, K31 K8, K5, K7, K6) were synthesised by 
Y.Y.Xie and J.P.Li in King’s College London. CM1 was synthesised in Chiang Mai University, 
Thailand. 
Chemicals 
All solvents and reagents were purchased from Fisher Scientific Ltd 
(Loughborough,Leicestershire,UK). Pentadecafluorooctanoic acid (PFOA, analytical grade) was 
purchased from Fluorochem LTD (Hadfield, UK).  
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Male rat liver microsomes (20 mg/mL in 0.5mL), UltraPool™ human Liver microsomes, 150 
mixed gender pooled (20 mg/mL in 0.5mL) were purchased from Corning Ltd-Life Sciences 
(Ewole, UK). NADPH-regenerating system A (consisting of 31 mM NADP+, 66 mM glucose-6-
phosphate and 66 mM MgCl2 in water), NADPH-regenerating system B (consisting of 40 U/mL 
glucose-6-phosphate dehydrogenase in 5mM sodium citrate), UDP reaction mix solution A 
(consisting of 25 mM UDP-glucuronic acid in water) and UDP-regenerating system B (consisting 
of 250 mM Tris–HCl, 40 mM MgCl2 and 0.125 mg/mL alamethicin in water) were also purchased 
from Corning Ltd-Life Sciences (Ewole, UK). Rabbit serum (Cat No. R4505-100mL) was 





 Xevo TQ tandem quadrupole mass spectrometer (Waters, Elstree, UK) equipped 
with an ESI interface, corporate with an Ultra Performance LC system (Waters, Elstree, UK), 
equipped with a binary solvent delivery system, an Acquity auto-sampler was used throughout 
this study.  
 
3.4 LC-MS method development 
3.4.1 Liquid Chromatography 
The LC analysis was performed on a Waters
®
 Acquity Ultra Performance LC system (Waters, 
Elstree, UK), equipped with a binary solvent delivery system, an auto-sampler. The 
chromatography was performed on an Agilent Poroshell 120 EC-C18 column, 2.1 x 50mm, 
2.7μm (Agilent, Lakeside, UK). The mobile phases were composed of (A) 1g 





 ACN and (B) 1g PFOA in 0.1% formic acid, 95% Optima
®
 ACN, 5% Optima
®
 H2O. 
The UPLC eluting conditions were optimised as follows: linear gradient from 30% to 90% B (0–4 
min), isocratic at 90% B (4–5.5 min), linear gradient from 90% to 30% B (5.5–5.6 min), isocratic 
at 30% B (5.6–9 min). The flow rates of 0.2, 0.5, 0.7 mL/min for a total run time of 9 min were 
attempted for optimising the chromatographic separation.  0.5 mL/min was found to be the 
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optimal flow rate. The column and the auto-sampler were maintained at 45 °C and 15 °C, 
respectively. Three cycles of seal wash were performed including a strong wash, a weak wash 
and a sample syringe wash. Each wash cycle consisted of 50% of strong solvent (50/50 v/v 
ACN/MeOH) and 50% of weak solvent (95/5 v/v H2O/ACN). The injection volume of the 
standards and sample was 5μL. Samples were introduced from HPLC vials placed in the ANSI-
48 vial 2mL holder sample bed layout or a Waters
®
 Acquity UPLC 700μL round 96- well sample 
plates (Waters, Elstree, UK) in the ANSI-96 well 1mL bed layout of the autosampler.  
 
3.4.2 Mass spectrometry 
Mass spectrometry was operated on a Waters
®
 Xevo TQ tandem quadrupole mass 
spectrometer using an ESI operated in positive ion mode. The desolvation gas (N2) was set to 
650 L/hr at temperature of 400 °C. The cone gas flow was 5 L/hr. The capillary voltage was set 
to 2.00 kV. Argon was used as the collision gas, the collision gas flow was set at 0.15 mL/min. 
LM/HM resolution 1 and 2 were both 3/15, ion energy 1 and 2 were both 0.5. Data acquisition 
was carried out in the MS/MS, Multiple Reaction Monitoring (MRM) mode. Data were processed 




3.4.3 MS/MS (MRM) method development 
3.4.3.1 Optimisation of MS and MS/MS parameters  
Manual optimisation was performed to preliminarily optimise the MS parameters and to select 
the appropriate diagnostic ions. 1μg/mL of pure standard solution of the HPO compound in a 
mixture of 0.1% formic acid in 50/50 v/v ACN/water was directly infused with a flow rate of 
200μL/min from the integrated fluidics. The precursor ion spectrum was monitored in the “Mass 
Tune” of MassLynx
TM
 by setting a mass span of 150 centered on the mass of the infused 
compound. The cone voltage, capillary voltage, desolvation temperature were adjusted to 
achieve the highest signal intensity of the HPO compound. The collision energy was increased 
until the HPO precursor ion was fragmented to several product ions and the fragmented product 
ion with the most abundance was observed. The product ion spectrum of the precursor HPO ion 
fragmentation showed the most intense fragmented product ion at the optimised collision 
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3.4.3.2 MRM method development 
The IntelliStart
TM
 system was used to tune the standard HPO sample and develop the MRM 
method for the investigated compounds. The standard solution of individual HPO (1μg/mL) was 
introduced by the direct infusion with a flow rate of 200μL/min from the integrated fluidics. The 
“sample tuning and develop method” process has optimised cone voltage and collision energy. 
The cone voltage was adjusted over a range of 2-100 V, and the collision energy was optimised 
over a range of 2-80 V. The procedure has also searched for precursors and fragmented ions. 
The MS1 and MS2 resolutions were 1.0 and 0.75. Multiple MRM transitions were generated to 
provide qualitative and confirmatory information for the targeted compound in the HPO 
biological samples. The dwell time of the MRM transitions was 35 ms with the pause time of 5 
ms. 
 
3.4.3.3 Selection of the MRM transition for quantification  
In addition to the manual optimisation and the IntelliStart
TM
 “sample tune and method 
development”, the CS ChemDraw Ultra (Cambridge Soft Co.) was used to further analyse the 
fragmentation pathways. The MRM transition used for quantification was selected and applied 
for the quantification of metabolic conversion of the HPO biological samples.  
 
3.4.3.4 Quantification method.  
The TargetLynx
TM
 software was used for the quantification. In the chromatographic peaks of the 
investigated compounds, a TargetLynx
TM
 quantification method was created by defining the 
compound and calibration properties, including the compound name and the retention time etc. 
In a TargetLynx
TM 
method editor, the parameters were stored and applied to all samples of the 
same compound. The integration of the peak was accomplished by ApexTrack
TM
. A calibration 
curve was developed with the calibration curve standards. The concentrations of unknown 
samples were calculated from the fitted calibration curve.  
 
Chapter Three: Development of a high throughput bio-analytical method for the in vitro 




3.5 In vitro metabolic stability incubation method using liver 
microsomes 
To investigate phase I metabolism, the following was spiked into an enpendorf tube: 50μL of 
0.1mM HPO compound (prepared in HPLC H2O), 250μL of 0.2 M phosphate buffer (pH 7.4), 
25μL of NADPH regenerating system A, 5μL of NADPH regenerating system B and 145μL of 
H2O. The combined components were then pre-incubated at 37 °C for 10 min, after which 25μL 
of cold human liver microsomes were added to initiate metabolism, giving a final concentration 
of 1mg/mL protein. The mixture was then incubated at 37 °C in a thermostat incubator for 24 h 
with gentle shaking to prevent protein sedimentation. The reactions were terminated by spiking 
in 400μL 4% phosphoric acid to remove protein, followed by spiking in 100μL of 100μM internal 
standard. Samples were mixed evenly by the vortex mixer and followed by centrifuge at 
14,000rpm in a Spectrafuge™ 16M microcentrifuge (Labnet International Inc., NJ, USA) for 
10min. The supernatants were collected for the further solid phase extraction.  
Phase I+II metabolism was performed alongside Phase I using the same experimental 
procedure as described above, with the exception of 145μL water, with 40μL of UDP reaction 
mix solution A and 100μL of UDP reaction mix solution B and 5μL of water.  
Blank sample was prepared by substituting microsomal protein with water. Phase I and Phase 
I+II microsomal incubates for each HPO compound were prepared in triplicate.   
 
3.6 The development of a sample clean-up method using the Solid 




 MAX (Mixed-mode Anion-eXchange, 1 cc Flangeless Vac syringe cartridge, 10 mg 
sorbent per cartridge, 30 µm particle size, Waters, Elstree, UK) with an exchange capacity of 
0.25 mol/kg and the Oasis
®
 MCX (Mixed-mode Cation-eXchange, 1 cc Flangeless Vac syringe 
cartridge, 10 mg sorbent per cartridge, 30 µm particle size, Waters, Elstree, UK) with an 
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exchange capacity of 1 mol/kg were applied on a Visiprep solid phase extraction vacuum 
manifold (Sigma-Aldrich, UK). An Oasis
® 
96-well MCX µElution plate (2 mg sorbent per well, 30 
µm Particle Size, Waters, Elstree, UK) with an exchange capacity of 1 mol/kg was applied on a 
high throughput Supelco
®
 SPE PlatePrep vacuum manifold (Sigma-Aldrich, Poole, UK). 
 
3.6.2 SPE sorbent selection  
3.6.2.1 Sample preparation  
The Phase I+II metabolism of CP20 was investigated in rat liver microsomes following the 
procedure, which was described in the Section 3.5. A series of CP20 standard solutions were 
prepared in the rabbit serum in a total volume of 500μL. Serial dilutions of the standard solution 
CP20 (10μg/mL) in the rabbit serum were performed to provide a set of stock standard solutions 
with the following concentrations 1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.80, 3.90, 1.95ng/mL. A 
stock solution of CP21 (IS, 4200ng/mL) in the rabbit serum was also prepared.  
 
3.6.2.2 Sample pre-treatment 
The sample was pre-treated by a 1:1 dilution with acidified water diluent for the MCX sorbent 
and with basified water diluent for the MAX sorbent. The acidified water diluent was 4% 
phosphoric acid prepared by diluting 47 mL 85% phosphoric acid to 1 L final volume with water. 
The basified water diluent was 5% ammonium hydroxide prepared by diluting 142mL 35% 
ammonium hydroxide to 1 L final volume with water. 500μL sample microsomal incubates and 
500μL acidified or basified water diluent were spiked into an eppendorf tube. 500 μL CP20 
standards in the rabbit serum solutions, 10μL CP21 (IS, 4200ng/mL) and 450μL acidified or 
basified water diluent were spiked into an eppendorf tube. Samples were subjected to the SPE 
using the Oasis
®
 syringe cartridge with different sorbents.  
 
3.6.2.3 SPE elution procedure 
An Oasis
®
 MCX cartridge or an Oasis
®
 MAX cartridge was placed on the Supelco
®
 24 port 
Visiprep vacuum manifold. The cartridge was conditioned with MeOH, equilibrated with water. 
The diluted acidified or basified sample was loaded on the cartridge. The vacuum valve was 
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switched on slowly and gradually increased to provide a pressure of 5 mmHg in order to load 
the entire sample onto the sorbent bed. Then the vacuum pump was disconnected. Formic acid 
(2%, 1mL), prepared by diluting formic acid (≥ 95%) 20mL to 1L final volume with water, or 
ammonium hydroxide (5%, 1mL), prepared by diluting ammonium hydroxide (35%) 142 mL to 
1L final volume with water, was applied as the initial wash solvent. The vacuum was switched 
on, set to 10 mm Hg and pulled for another half a minute to eliminate the residual wash solvent; 
the vacuum line was then disconnected. 100% MeOH (1mL) was applied to elute most of the 
proteins and phospholipids from the matrix. The vacuum was switched on, set to 10 mm Hg and 
pulled for another half a minute to eliminate the residual wash solvent, then the vacuum 
released and the waste fluid discarded. An eppendorf tube was placed under the cartridge. 
Ammonium hydroxide in methanol (5%, 1mL), prepared by diluting ammonium hydroxide (35%, 
142mL) to 1 L final volume with methanol, or formic acid in methanol (2%, 1mL), prepared by 
diluting formic acid (≥ 95%, 20mL) to 1 L final volume with methanol, was applied as the elution 
solvent. The vacuum valve was switched on slowly, gradually increased to 5 mm Hg and pulled 
for another 30 sec to collect all elution solvent. This step was repeated a second time. The 
sample was evaporated to dryness in a Genevac EZ-2 series evaporator (Genevac Ltd, Suffolk, 
UK) and reconstituted in 100μL mobile phase. The sample was stored at -80 °C deep freezer 
before the analysis by LC-MS. 
 
3.7 Validation of the bio-analytical method 
3.7.1 Sample preparation  
Calibration curve standards 
Serial dilutions of the standard solution CN128 (100ng/mL) in rabbit serum were conducted to 
give a set of stock standard solutions with the concentrations over the range 100, 50, 25, 12.5, 
6.25, 3.125, 1.5625, 0.7813, 0.3906, 0.1953ng/mL. A stock solution of CP21 (IS, 420ng/mL) in 
rabbit serum was also prepared. 50μL CN128 stock standard solution, 10μL CP21 stock 
solution (both in rabbit serum) and 40μL 4% phosphoric acid were spiked into one single well of 
the 96 well plate and transferred onto the 96-well MCX µElution plate for the SPE. The SPE 
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elution steps and post-sample treatments were the same as those using the Oasis
® 
MCX 
cartridge, apart from that 200μL was used instead of 1mL for the elution solvents at each elution 
step and a Waters
®
 Acquity UPLC 700μL round 96- well sample collection plate (Waters, 
Elstree, UK) was used to collect the final eluents (Refer to Section 3.6.2.3).  
Sample sets 1,2,3 
Three sets of standard samples were prepared to evaluate the assay accuracy, precision, 
recovery, and matrix effect. The first sample set (set 1) was prepared to evaluate the MS/MS 
response for the neat standards of CN128 and CP21 (IS) spiked in the LC-MS mobile phase. 
The second set (set 2) was prepared in the rabbit serum extracts and CN128 and CP21 (IS) 
spiked after extraction. The third set (set 3) was prepared in the rabbit serum, but CN128 and 
CP21 (IS) were spiked before extraction. The SPE elution steps and post-sample treatments 
were the same as those for the CN128 calibration curve standards in rabbit serum. 
 
Set 1. The solutions were prepared using neat solutions of CN128 and CP21 in the LC-MS 
mobile phase. A set of stock standard solutions with concentrations 75, 40, 1.5625, 0.7813, 
0.3906, 0.1953ng/mL were prepared by diluting from the 100ng/mL CN128 standard solution in 
the mobile phase. A stock solution of CP21 (IS, 420ng/mL) was also prepared in the mobile 
phase. 50μL of CN128 stock standard solution, 10μL of CP21 stock solution (both in the LC-MS 
mobile phase) and 40μL of 4% phosphoric acid were spiked into one single well of the 96 well 
plate.  
 
Set 2. Rabbit serum (60μL) was acidified by 40μL of 4% phosphoric acid. After the MCX SPE 
extraction and evaporation to dryness in a Genevac EZ-2 series evaporator (Genevac Ltd, 
Suffolk, UK). The samples were reconstituted by spiking 50μL of CN128 stock standard solution 
and 10μL of CP21 stock solution (both in mobile phase and the concentrations same as in Set 
1) and 40μL mobile phase into the dried well.  
 
Set 3. The solutions were prepared by using CN128 and CP21 in the rabbit serum with 
concentrations the same as those in Set 1. 50μL of CN128 stock standard solution, 10μL of 
CP21 stock solution (both in rabbit serum) and 40μL of 4% phosphoric acid were spiked into 
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one single well of the 96 well plate. 
 
QC samples 
A set of QC samples using the pure standard compounds CN128 and CP21 were prepared in 
the rabbit serum. The sample preparation procedure and SPE were the same as that in sample 
Set 3. The QCL concentrations were set as 1.5625, 0.7813, 0.3906, 0.1953 ng/mL; the QCM 
concentration was 40 ng/mL; the QCH was 75 ng/mL.  
 
Calibration curve standards, samples from sets 1-3 and QC samples were analysed in a 
Waters
®
 Acquity UPLC-Xevo MS system in ESI+ mode. The order of injection was as follows: 
calibration curve standards were injected first (from a low to a high concentrations), followed by 
QC samples, then samples from Set 1, Sets 2 and Set 3 injected from low to high 
concentrations. Samples were analysed within inner-days (n=3) and intra-days (n=3). The 
matrix effect during the LC-MS analysis of CN128 and CP21 was assessed. In addition, 
precision, accuracy, linearity, limit of detection, limit of quantification of the method and recovery 
of analytes were also determined. Due to the batch difference of the 96-well MCX µElution 
plate, a fluorescent HPO compound with the same binding mechanism to the SPE sorbent was 
used to monitor the efficiency of the sample clean-up of the investigated HPOs.  
 
3.7.2 Method validation 
The assay was validated in accordance with the guidance of the International Conference on 
Harmonisation (ICH) (ICH). 
 
Assessment of recovery (RE), matrix effect (ME) and progress efficiency (PE) 
The recovery (RE) was determined by comparing the mean peak areas of CN128 and CP21 
obtained in Set 3 to those in Set 2 (Equation 3.2); The matrix effect (ME) was evaluated by 
comparing the mean peak areas of CN128 and CP21 obtained in Set 2 to those in Set 1 
(Equation 3.1); The progress efficiency (PE) was assessed by comparing the mean peak areas 
of CN128 and CP21 obtained in Set 3 to those in Set 1 (Equation 3.3)  
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ME (%) = Set 2 / Set 1 × 100        (Equation 3.1) 
RE (%) = Set 3 / Set 2 × 100         (Equation 3.2)  
PE (%) = Set 3 / Set 1 × 100         (Equation 3.3) 
 
Precision and Accuracy 
The precision of the method was determined by the replicate analyses (n= 9, each sample was 
analysed in triplicate over three consecutive days) of Set 1, 2, 3 samples containing CN128 and 
CP21, which was indicated by CV % of mean peak areas of CN128, CP21 and mean peak area 
ratio of CN128/CP21. The inner-day and intra-day precision was assessed for the CN128 
calibration curve standards in rabbit serum by the triplicate analysis of each standard 
concentration over three consecutive days. CV % of peak areas of CN128, CP21 and peak area 
ratio of CN128/CP21 was used to evaluate the inner-day and intra-day precision. The accuracy 
of the method was evaluated by replicate analysis (n=9) of QC samples (CN128 and CP21), 
which was expressed by   
[(Mean observed concentration) / (Nominal concentration)]× 100.  
 
Linearity  
The calibration curve was plotted as concentrations versus the response (the concentration 
ratio vs the peak area ratio of CN128/CP21). The goodness to fit was evaluated by its 
correlation coefficient and intercept value calculated in the statistical study, which was 
represented by linear regression equation. The slope and y-intercept values were obtained from 
the regression equations. The correlation coefficient (r
2
) was calculated by the method of least 
square to confirm linearity of the regression line. In addition, an analysis of the deviation of the 
slopes of the regression lines was also used to evaluate the reproducibility of the method.  
 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
The detection limit was set as the dilution showing a signal-to-noise ratio of more than 3. The 
limit of quantification was not determined based on a signal-to-noise ratio (although this ratio 
exceeded 10), but was set as the lowest standard on the calibration curve that exhibits 
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acceptable accuracy and precision (a precision of 20% and an accuracy of 80-120%)  
3.8 Screening for metabolism conversion of novel 
hydroxypyridinones  
Serial dilutions of the standard solution of each HPO (100ng/mL) in the rabbit serum were 
conducted to give a set of stock standard solutions with the concentrations falling in the range 
1000, 500, 250, 125, 62.5, 31.25, 15.625, 7.813, 3.906, 1.953ng/mL. A stock solution of CP21 
(IS, 4200ng/mL) in the rabbit serum was also prepared. 50μL of CN128 stock standard solution, 
10μL of CP21 stock solution (both in the rabbit serum) and 40μL of phosphoric acid (4%) were 
spiked into one single well of the 96 well plate and transferred onto the 96-well MCX µElution 
plate for the SPE. The SPE elution steps and post-sample treatments were the same as those 
using the Oasis
®
 MCX cartridge, apart from 200μL was used instead of 1mL for the wash 
solvents and a Waters
®
 Acquity UPLC 700μL round 96- well sample collection plate (Waters, 
Elstree, UK) was used to collect the final eluents (Refer to Section 3.6.2.3). Eighteen HPO 
compounds were screened for their metabolic stability using the human liver microsomes 
(HLMs) model. The metabolic stability results of CP20, CP94 and CP102 using the rat live 
microsomes (RLMs) and the HLMs were used as the control groups. The incubation procedure 
was detailed in the Section 3.5. The incubates were subjected to the SPE sample clean-up 
method developed in the Section 3.6, then introduced to the LC-MS system optimised in the 
Section 3.4. The results of metabolic stability were expressed as percentage of parent HPO 




 % 𝑃𝑎𝑟𝑒𝑛𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑑𝑖𝑠𝑎𝑝𝑝𝑒𝑎𝑟𝑎𝑛𝑐𝑒 = 
{1 − [
𝑃𝑎𝑟𝑒𝑛𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑆𝑎𝑚𝑝𝑙𝑒 𝑤𝑖𝑡ℎ 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠)
𝑃𝑎𝑟𝑒𝑛𝑡 𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝐵𝑙𝑎𝑛𝑘 𝑤𝑖𝑡ℎ𝑜𝑢𝑡 𝑚𝑖𝑐𝑟𝑜𝑠𝑜𝑚𝑒𝑠)
]} ×  100 
                                                                                                                         Equation 3.4  
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3.9 Results and Discussion  
3.9.1 Hydroxypyridinones (HPOs) investigated in the metabolism study 
CP20, CP94 and CP102 were used as control groups as their metabolic profiles were well 
established in vivo (Section 2.4.1). Two chiral HPOs (CN128 and CN126), which are 
enantiomers, and CM1 (Pangjit et al., 2015) have been identified as new lead compounds. A 
group of closely related CP20 analogues (CP669, CP69, CP616, CP28, CP679, CP617) was 
synthesised in order to investigate whether it is possible to reduce the tendency to be 
extensively metabolised (Xie et al., 2016). Pegylation of iron chelators has been reported in 
recent years and one such chelator, deferitazole (Hider et al., 2015), has recently been 
successfully investigated in Phase 2 clinical trials (Neufeld et al., 2012). The advantage of 
polyethylene glycol (PEG) is that PEG provides favorable biological properties, good solubility in 
both aqueous and organic milieu, good flexibility and high hydration that increases its 
hydrodynamic volume(Veronese and Mero, 2008). A series of 1-, 2-, 6- substituted pegylated 
HPOs were sythesised and their susceptibility towards metabolism has also been investigated 
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HPOs R1 R2 R5 R6 
CP20/Deferiprone −CH3 −CH3 −H −H 
CP94 −CH2CH3 −CH2CH3 −H −H 
CP102 −CH2CH2OH −CH2CH3 −H −H 
CP364 −CH3 −CH2OH −H −H 
CP365 −CH2CH3 −CH2OHCH3 −H −H 
CP21 −CH2CH3 −CH3 −H −H 
 
CN128 −CH(C6H5)CH2OH −CH3 −H −H 
CN126 −CH(C6H5)CH2OH −CH3 −H −H 
CM1 −(CH2)6NHCOCH3 −CH3 −H −H 
 
CP28 −H −CH3 −H −H 
CP679 −H −H −CH3 −H  
CP669 −CH3 −H −CH3 −H 
CP69 −CH3 −H −H −CH3 
CP616 −H −CH3 −CH3 −H 
CP617 −CH3 −CH3 −CH3 −H 
 
C11 −CH2(CH2OCH2)2CH2NHCOCH3 −CH3 −H −H 
C21 −(CH2)2(CH2OCH2)3(CH2)2NHCOCH3 −CH3 −H −H 
6d −CH2(CH2OCH2)2CH2NHCOCH2CH3 −CH2CH3 −H −H 
C31 −(CH2)2O(CH2)2OCH3 −CH3 −H −H 
K31 −(CH2)2O(CH2)2OH −CH3 −H −H 
K8 −CH3 −CH2OCH2O(CH2)2OCH3 −H −CH3 
K5 −CH3 −CH2O(CH2)2O(CH2)2OCH3 −H −CH3 
K7 −CH3 −H −H −CH2OCH2O(CH2)2OCH3 
K6 −CH3 −H −H −CH2O(CH2)2O(CH2)2OCH3 
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3.9.2 LC-MS/MS (MRM) method development 
As the quantitative analysis of the parent drug metabolic stability was the major information 
sought, the analytical strategy selected for this analysis is to produce high throughput and 
therefore the analytical method should be as efficient and fast as possible. The quantitative 
determination of HPO compounds in the complex matrix (microsomal metabolism incubates and 
serum samples) requires a method with very high selectivity and sensitivity for the substance. 
Therefore, triple quadrupole (QqQ) was used in the Multiple Reaction Monitoring (MRM) mode 
with great sensitivity, selectivity and efficiency, where the precursor ion was isolated in the first 
quadrupole (Q1) and after fragmentation in the collision cell (Q2) a specific fragment ion is 
isolated in the last quadrupole (Q3), was adopted for the metabolites analysis of the HPO 
compounds investigated. This transition from precursor to fragment ion gives sufficient 
specificity and sensitivity for quantification (Kostiainen et al., 2003).  
 
In order to obtain the optimum performance, a standard solution of the individual HPO at a 
concentration of 1μg/mL was introduced by direction infusion into the ESI source before the 
mass spectrometry. The positive ionisation mode was also selected for both HPO compounds 
and their metabolites, as the conjugate metabolites (glucuronides included) are usually ionised 
in positive ionisation with electrospray (+ESI) (Keski-Hynnila et al., 2002). The MS parameters 
of the instrument, such as the cone voltage, capillary voltage, desolvation temperature etc, were 
adjusted for the highest signal intensity of the precursor ion in the precursor ion spectrum. The 
subsequent optimisation of the collision energy provided the highest intensity for the main 
fragment product ion in the product ion spectrum.  
 
The setting of the MRM transition channels for the monitoring of target analytes is generally 
selected with the consideration of the signal intensities and structure specificities of the product 
ions (Konstantinou, 2006). The IntelliStart
TM
 “sample tune and method development” 
determined the optimum cone voltage over the range of 2-100 V for the HPO. For instance, the 
optimum cone voltage to generate the most intense signal intensity (Figure 3.1 a) for the 
precursor ion of CN128 ([M + H]
+
= 260.28) was 28 V (Figure 3.1 b). With this optimised cone  
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Compound Name: CN128 
Transition 1: ES+, m/z 260.28 > 125.92  
 
 
                                                          (a) 
 
 
                                                          (b) 
 
Figure 3.1 Optimisation of the cone voltage by IntelliStart
TM
 “sample tune and method 
development” 
(a) The plot of signal intensity of the precursor ion vs cone voltage (2-100 V) 
(b) The optimised precursor ion spectrum of signal intensity vs m/z (259.02 - 262.00) at the optimum cone voltage of 28 
V 
2.0 21.6 41.2 60.8 80.4 100.0








Optimised MS Spectrum (at Cone Voltage 28V)
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voltage, the application of collision energy over the range of 2-80 induced the fragmentation of 
the precursor ion [M + H]+ 260.28 (Figure 3.2 a). The emerging most intense fragmented ion 
selected for the product ion was the ion with the m/z of 125.92 in the product ion spectrum when 
increasing collision energy with an optimum intensity at 18 V (Figure 3.2 b).  
 
With the optimised MS conditions for cone and collision energy voltages, a MRM transition was 
generated with two characteristic ions as the precursor and the product ions. In the case of 
CN128 (Figure 3.1 and 3.2), the MRM transition selected was m/z 260.28 > 125.92.  
The MRM transitions for each HPO compound were generated using the aforementioned 
method and were summarised in Table 3.2.  
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Compound Name: CN128 
 






                                                          (b) 
 
Figure 3.2 Optimisation of the collision energy voltage by IntelliStart
TM
 “sample tune and method 
development” 
(a) The plot of signal intensity of the product ion vs collision energy voltage (2-80 V) 
(b) The optimised product ion spectrum of signal intensity vs m/z (100 - 2000) at the optimum collision energy of 18 V 
 
2.0 17.6 33.2 48.8 64.4 80.0













Optimised Daughter Spectrum (at Collision Energy 18eV)
3.709e+006
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CP20 140.00 18 52.97 22 
 140.00 18 94.01 20 
CP94 168.03 4 139.92 18 
 168.03 4 152.95 18 
CP102 184.09 32 124.94 22 
 184.09 32 111.91 22 
CP364 155.90 6 41.89 24 
 155.90 6 81.89 22 
CP365 183.90 6 109.91 26 
 183.90 6 124.10 22 
CP21 154.10 32 125.95 18 
 154.10 32 138.89 18 
     
CN128 260.28 28 125.92 18 
 260.28 28 117.00 20 
CN126 260.21 28 125.98 20 
 260.21 28 116.99 18 
CM1 267.01 6 125.91 26 
 267.01 6 99.99 24 
 267.01 6 54.97 28 
 267.01 6 71.91 22 
     
CP28 126.00 30 79.92 18 
 126.00 30 52.95 22 
 126.00 30 66.89 22 
CP679 125.94 14 52.95 22 
 125.94 14 72.92 16 
 125.94 14 52.96 16 
CP669 139.84 6 140.63 18 
 139.84 6 110.03 22 
 139.84 6 124.75 28 
 139.84 6 106.18 26 
CP69 140.03 4 66.57 22 
 140.03 4 93.93 20 
 140.03 4 66.96 22 
 140.03 4 52.95 22 
CP616 140.03 26 52.95 22 
 140.03 26 93.99 18 
 140.03 26 66.96 22 
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CP669 139.97 4 66.57 18 
 139.97 4 66.96 22 
 139.97 4 93.93 28 
 139.97 4 52.95 26 
CP617 153.90 4 66.89 22 
 153.90 4 108.00 20 
 153.90 4 92.89 24 
     
     
C11 298.97 8 125.92 32 
 298.97 8 239.84 22 
 298.97 8 214.00 24 
 298.97 8 151.97 26 
C21 370.99 8 272.05 24 
 370.99 8 311.99 26 
 370.99 8 125.92 40 
 370.99 8 204.05 30 
6d 327.35 30 271.05 22 
 327.35 30 99.92 28 
 327.35 30 139.84 32 
C31 227.87 4 125.98 20 
 227.87 4 102.93 16 
 227.87 4 151.96 20 
 227.87 4 200.00 16 
K31 213.98 6 125.92 18 
 213.98 6 151.90 18 
 213.98 6 185.95 16 
 213.98 6 107.94 30 
K8 258.22 16 151.89 14 
 258.22 16 123.95 28 
 258.22 16 58.95 24 
K5 271.90 4 151.90 16 
 271.90 4 123.97 28 
 271.90 4 108.73 46 
K7 244.22 22 155.92 26 
 244.22 22 137.95 18 
 244.22 22 109.95 24 
K6 257.89 4 109.96 24 
 257.89 4 137.96 20 
 257.89 4 155.87 30 
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Multiple MRM transitions per analyte were applied in order to confirm the presence of the 
desired HPO compound (Table 3.2). To quantify the analyte in the biological samples, one 
transition was selected based on the comparisons between the signal intensities of the 
integrated peaks (Table 3.3). Therefore, other MRM transitions were just used to obtain 
confirmatory or qualitative information in addition to the quantitative data. The MRM transitions 
selected for quantification were also analysed by the ChemDraw software. The fragment 
pathways for each MRM transition could be analysed to determine whether the fragmentated 
ion was stable and specific to the precursor ion.  
 
 
Table 3.3 The MRM transition selected for quantification 






     
CP20 140.00 18 52.97 22 
CP94 168.03 4 139.92 18 
CP102 184.09 32 124.94 22 
CP364 155.90 6 41.89 24 
CP365 183.90 6 109.91 26 
CP21 154.10 32 125.95 18 
     
CN128 260.28 28 125.92 18 
CN126 260.21 28 125.98 20 
CM1 267.01 6 54.97 28 
     
CP28 126.00 30 52.95 18 
CP679 125.94 14 52.95 22 
CP669 139.97 4 52.95 26 
CP69 140.03 4 52.95 22 
CP616 140.03 26 52.95 22 
CP617 153.90 4 66.89 22 
     
C11 298.97 8 125.92 32 
C21 370.99 8 125.92 40 
6d 327.35 30 271.05 22 
C31 227.87 4 125.98 20 
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K31 213.98 6 125.92 18 
K8 258.22 16 123.95 28 
K5 271.90 4 151.90 16 
K7 244.22 22 109.95 24 





Two examples of fragmentation pathways analysed by the ChemDraw software are illustrated in 
Figure 3.3 and 3.4, the collision energy applied in the ESI-MS/MS (MRM) induced the cleavage 
of the heteroatom-carbon bond. The charge was stabilised on the heteroatom cleaved moiety, 
fragmented ion mass was the m/z of precursor ion [M + H]
+
 minus the leaving group plus two 
mass unite (two protons), which obeyed the “+2” rule of ESI-MS-MS fragmentation 
pattern(Weissberg and Dagan, 2011). The cleavage occurred possibly at the C-N bond of 
CN128 precursor ion with a m/z of 260.31 and produce a fragmented ion with a m/z of 126.13, 
which correspond to the MRM transition 260.28 > 125.92 generated by IntelliStart
TM
 (Table 3.3). 
The same fragmentation pattern was also observed on the pegylated HPO (K31), which 
followed the pathway of 214.24 > 126.13 and corresponded to the MRM transition 213.98 > 
125.92 developed by IntelliStart
TM
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Figure 3.3 The fragmentation pathway of CN128 
Precursor ion > Product ion: 260.31 > 126.13 
 
                       
Figure 3.4 The fragmentation pathway of K31 
Precursor ion > Product ion: 214.24 > 126.13 
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By monitoring the specific MRM transition in Table 3.3, each HPO compound investigated was 
identified and integrated (Appendix V), the metabolic conversion of the parent HPO compound 
was evaluated by quantifying the percentage of parent drug elimination over the time-course of 
the in vitro microsomal incubation (Section 3.8).  The accurate quantitative determination of the 
HPO compound using LC/ESI/MRM in the biological sample is essential for studying their 
metabolic profile. However, it could be hampered by interferences from the in-source 
fragmentation or the fragmentation occurred in the collision cell of their biotransformation 
metabolites (Korfmacher, 2005). Glucuronides are the metabolite class that is most commonly 
labile to the in-source fragmentation in the ESI source (Yan et al., 2003). In addition, in the 
MS/MS (MRM mode), Q1 and Q3 are set at the selected m/z values for glucuronide and its 
parent molecule respectively to detect the glucuronide (Trontelj, 2012). Thereby, an increase in 
the signal of the parent ion will occur, which causes the over-estimation of the parent drug. In 
consequence, an adequate chromatographic separation of the glucuronic conjugate from its 
parent drug is essential (Jemal and Xia, 1999). Because most of the investigated HPO parent 
compounds are hydrophilic (Table 3.4, milogP values), they are prone to co-elute with their 
metabolites at the beginning of the chromatography. Consequently, a volatile ion-paring agent, 
which is compatible with the MS conditions, was added in the mobile phases. A perfluorinated 
carboxylic acid, pentadecafluorooctanoic acid (PFOA) was selected (Gao et al., 2006), in order 
to increase the retention time of the analytes and thereby achieve a good separation.  
 
Table 3.4 The pKa and milogP values of HPO 
 
 
 pKa1 pKa2 miLogP  pKa1 pKa2 miLogP   pKa1 pKa2 miLogP 
CP20 3.65 9.76 -0.60 CP28 3.64 9.73 -0.56 C11 3.39 9.74 -1.67 
CP94 3.81 9.93 0.35 CP679 3.31 9.49 0.33 C31 3.42 
 
9.80 -0.82 
CP102 3.37 9.80 -0.66 CP669 3.31 9.34 0.56 K31 3.43 9.75 -1.34 
CP364 3.06 9.19 -1.25 CP69 3.64 9.13 -0.28 K5 3.26 9.33 -0.49 
CP365 3.15 8.93 -0.64 CP616 3.43 10.27 0.55 K7 3.20 8.63 -0.54 
CP21 3.65 9.88 -0.23 CP617 3.37 10.32 0.78 K6 3.19 8.67 -0.71 
CN128 3.26 9.90 0.56     C31 3.42 
 
9.80 -0.82 
CN126 3.26 9.90 0.56         
CM1 3.52 9.80 0.10         
pKa1
  
carbonyl group,  pKa2
 
hydroxyl group (Chen, 2013),   milogP (Molinspiration, 2015) 
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In positive ESI mode, an abundant fragment [M + H − 176]+ was detected in most cases after 
glucuronide fragmentation. The neutral loss of 176 Da corresponds to a monodehydrated 
glucuronic acid. Therefore, the MRM transitions set for HPO-glucuronides were [M + H − 176]
+
 
> [M + H]
+
 for the conjugate which the glucuronide acid moiety directly bound to the nucleophilic 
site on the HPO aglycon. Since both Phase I and Phase II substrates were incubated in the 
microsomes. The conjugation could also occur at the functional group introduced from Phase I 
reaction, such as oxidation. Hence, another MRM transition was set as [M + H + 16 − 176]
+
 > [M 
+ H]
+
 to identify the glucuronides of the mono-hydroxylated HPO (Figure 3.5).  
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3.9.3 Sample clean-up method (SPE) development 
The biological matrix components in rabbit serum (mainly phospholipids) and microsomal 
incubation matrix (microsomal proteins), co-elute with the target analytes and impact the MS 
response, particularly affecting the efficiency and reproducibility of the electrospray ionisation 
process (Chambers et al., 2007). In addition, the microsomal incubation media is a chemical 
complex, in which buffer is also suspected as the main cause for ionisation suppression due to 
its high concentration and high ionic strength (Zheng et al., 2002).  
 
The main goal to develop a sample clean-up method is to achieve the elimination of matrix 
components in order to reduce ion suppression during LC-MS analysis, to decrease method 
variability, to increase sample detection sensitivity and to improve the reproducibility of the 
further LC-MS analytical system performance (Waters, 2015). The analytes of interest, such as 
HPO parent compounds and their possible metabolites in sample solutions can bind to the solid 
phase sorbent with a greater affinity than the matrix components. Thus, the matrix components 
are washed away. A stronger elution solvent is then used to elute the analytes from the sorbent 
and collect them for further LC- MS analysis (Trontelj, 2012).  
 
The retention of the possible metabolites on a solid phase sorbent can be facilitated by a 
number of mechanisms, from reverse phase to ion exchange, depending on the ionisation and 
lipophilic properties of the parent compounds(Roškar and Lušin, 2012).  
 
The predicted log partition coefficient values (milogP) of HPOs are presented in Table 3.4, and 
indicate the lipophilicity of the investigated HPOs (Molinspiration, 2015). Negative milogP values 
of the pegylated HPOs and most of the CP20 analogues indicate that they are all relatively 
hydrophilic. Consequently, the ion exchange sorbent is preferred over the reversed phase as 
the mechanism of retention for the sample clean-up by the SPE.  The ionisable functional 
groups of HPO parent compounds and their possible metabolites can interact with the ion 
exchange sorbent at controlled pH conditions. The elution procedure during SPE using an ion 
exchange sorbent includes a rigorous washing step with a strong solvent (such as 100% 
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methanol, Section 3.6.2.3) in order to elute the phospholipids in the serum sample and proteins 
in the microsomal incubates, without any detrimental effect on the recovery of analytes of 
interest. Buffer in the microsomal media, which is soluble in water, is also washed away from 
the SPE sorbent by aqueous solutions. Thus, minimal matrix effects can be achieved by such 
stepwise elution.  
 
The investigated HPOs contain two ionisable functional groups, the 3-hydroxyl and 4-carbonyl 
group, with two pKa values (Table 3.4, Figure 3.6). The pKa values of 4-carbonyl falls between 
3.06 ~ 3.81(pKa1), while the pKa values of the 3-hydroxyl group falls in the range 8.67~10.32 
(pKa2). The presence of the acidic carboxylic group on glucuronic moiety has a pKa value 
(pKa3) around 3 (Farrell et al., 2011). Therefore, at the pH value ≤ 1 or ≥ 12, the HPO 
compounds and their metabolites will be completely ionised (protonated or deprotonated 





Figure 3.6 The protonation equilibria for HPOs 
 pKa1 carbonyl group (3.06~3.81), pKa2 hydroxyl group (8.67~10.32), pKa3 carboxylic group (~3) 
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Four kinds of ion exchange sorbents are available from the Waters Oasis
® 
SPE products 
(Waters, 2015). The Mixed-mode Weak Cation-eXchange (WCX) sorbent with a carboxylic acid 
ion-exchange functional group (pKa = 5), which is deprotonated at pH ≥ 7 and possess a 
negative charge (Figure 3.7 a). However, the net charge of most HPOs is neutral over the pH 
range 7 to10 and partially negatively charged over the pH range 10 to12 (Figure 3.6 b and c). 
The glucuronide possesses a negative net charge at pH ≥ 7 (Figure 3.6 f). Therefore the WCX 
is not applicable for the retention of the analytes of interest.  
 
The Mixed-mode Weak Anion-eXchange (WAX) sorbent with a piperazine ion exchange 
functional group (pKa = 6) is be protonated at pH ≤ 4 and contain one positive charge (Figure 
3.7 b). The HPO compounds and their glucuronides are partially positively charged when pH ≤ 4 
and completely protonated at pH ≤ 1 (Figure 3.6 a and d). Hence, the WAX sorbent is also not 
feasible for the extraction of the investigated compounds.  
 
At pH 1, the carbonyl group of the parent HPOs is protonated (Figure 3.6 a). The carboxylic 
group on glucuronic moiety and the carbonyl group of the HPO-glucuronide are also protonated 
(Figure 3.6 d). Consequently, The Mixed-mode Cation-eXchange (MCX) sorbent with the 
negatively charged sulfonic acid functional group (pKa<1) (Figure 3.7 c) will provide a strong 
cation-exchange interaction with the positively charged nitrogen atom of the parent HPOs and 
their glucuronide conjugates. 
 
At pH 12, the hydroxyl group of the parent HPOs is deprotonated (Figure 3.6 c). The carboxylic 
group on glucuronic moiety of the HPO glucuronide is also deprotonated (Figure 3.6 f). Hence, 
the positively charged quaternary-amine functional group on the Mixed-mode Anion-eXchange 
(MAX) sorbent (Figure 3.7 d) can offer strong anion-exchange interaction with the negatively 
charged deprotonated functional groups of the parent HPOs and their glucuronide conjugates. 
 
Based on the above analysis, the MAX and MCX sorbents were selected for investigating the 
extraction efficiency of the microsomal incubates containing the HPOs and their metabolites.  
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Figure 3.7 Four Oasis
® 
ion-exchange SPE sorbents 
Modified from Waters Oasis
® 
sample extraction products brochure(Waters, 2015) 
(a) WCX (b) WAX (c) MCX (d) MAX 
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The SPE procedures of the MCX and the MAX sorbents were detailed in in Section 3.6.2. Prior 
to SPE, the biological samples (the rabbit serum solutions and microsomal incubates) were pre-
treated with acidified or basified diluent for two purposes. Firstly, it is used to ionise the 
functional groups of the analytes, which interact with the ion exchange sorbents. Secondly, at 
those pH conditions, the ionisation states of amino acid side chains were altered, thereby 
changing protein charge distributions and hydrogen-bonding requirements, causing protein 
precipitation and aggregation (Voet et al., 2013). The pre-treated samples were then subjected 
to the SPE elution steps. The initial washing step using 2% formic acid (MCX) or 5% ammonium 
hydroxide (MAX) was used to ionise the functional group on the sorbent so as to enable the ion-
exchange interaction between the ionised analytes and the sorbent. The following rigorous 
washing step with 100% methanol was an essential step to eliminate the endogenous 
phospholipids in the rabbit serum and microsomal proteins, which could cause ion suppression 
when subjected to the LC-MS analysis. The final washing step with 5% ammonium hydroxide 
(MCX) or 2% formic acid (MAX) in methanol was used to convert the electrical polarity of the 
analytes bound to the sorbents by changing the pH, thus the analytes of interest were no longer 
bound by the sorbents. The final eluent, containing the clean-uped analytes, was collected, 
evaporated and reconstituted in the relevant mobile phase before being subjected to the LC-MS 
analysis  
 
The efficiency of the SPE sample clean-up by the MAX and MCX sorbents was assessed by 
comparing the signal response of the targeted compounds and the cleanliness of the matrix 
background of the SPE eluents of CP20 Phase I+II microsomal incubates, when subjected to 
the LC-MS analysis. A UPLC system with a reverse phase analytical column was employed to 
separate the possible metabolites from the parent compound CP20 in the SPE eluents by 
employing a linear gradient elution with the ion pairing agent in the mobile phases (Section 
3.4.1). The triple quadruple (QqQ) MS system using the MRM scanning mode was employed for 
the parent drug CP20 and its metabolite detection in the SPE eluents (Section 3.4.3, 3.9.2). The 
MRM chromatographs (ion signal intensity vs time) with specific MRM transitions demonstrated 
that the targeted compounds were present in the SPE eluents of CP20 Phase I+II microsomal 
incubates. The identification of the parent compound CP20 and the 2-methyl hydroxylated 
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metabolite of CP20 was facilitated by applying the specific MS fragmentation pathway (MRM) 
established by the direct infusion of the authentic chemical synthesised standards CP20 and 
CP364 (Section 3.4.3, 3.9.2). Although the authentic standards of HPO glucuronides could not 
be obtained, the abundant fragmentation [M + H − 176]+ of a glucuronide in the ESI positive 
mode in most cases offered evidence to set the MRM transition for the CP20 glucuronide 
metabolite as a loss of mass 176 (Section 3.9.2). Hence, the MRM transition was set as m/z 
316>140.  
 
The MRM chromatographs of the CP20 Phase I+II microsomal incubate MAX SPE eluent in 
Figure 3.8 illustrated that the glucuronide conjugate of CP20 eluted at 0.96 min at the MRM 
trace 316>140 (a); the 2-methyl hydroxylated CP20 (CP364) was not extracted efficiently at the 
MRM transition 155.90 > 41.89 (b), while the parent compound CP20 eluted at 2.20 min at the 
MRM trace 139.996>52.969 (c). 
 
 




















                            min
MRM 316>140 (CP20-GLU)





Figure 3.8 The MRM chromatographs of the MAX SPE eluent of CP20 Phase I+II microsomal 
incubation  
(ion signal intensity vs time (min)) 
(a) The MRM trace 316>140 (CP20-GLU) 
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Figure 3.8 The MRM chromatographs of the MAX SPE eluent of CP20 Phase I+II microsomal 
incubation  
(ion signal intensity vs time (min)) 






The MRM chromatographs of the CP20 Phase I+II microsomal incubate MCX SPE eluent in 
Figure 3.9 demonstrated that the glucuronide conjugate of CP20 was found to elute at 0.99 min 
at the MRM trace 316>140 (a); the 2-methyl hydroxylated CP20 was also extracted and eluted 
at 1.63 min (b). The parent compound CP20 eluted at 2.25 min at the MRM trace 
139.996>52.969 (c). 
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Figure 3.9 The MRM chromatographs of the MCX SPE eluent of CP20 Phase I+II microsomal 
incubation  
(ion signal intensity vs time (min)) 
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The MRM chromatographs (Figure 3.8, 3.9) demonstrated good chromatographic separation of 
the 2-methyl hydroxylated metabolites and glucuronide from the parent molecule CP20. In 
addition, a clean background was achieved after sample clean-up using both the MAX and the 
MCX SPE procedures, which indicated that most of the matrix components have been washed 
away during the SPE procedures. By comparison of the signal response of investigated 
compounds after the MAX and MCX SPE clean-up. The signal intensity of the CP20 
glucuronide after the MCX clean-up was three magnitudes higher than that after the MAX clean-
up; 1.37x10
7
 compared with 2.21x10
4
. The signal intensity of the CP20 after the MCX clean-up 
was one magnitude higher than that after the MAX clean-up; 2.30x10
6
 compared with 1.34x10
5
. 
The MCX SPE also extracted the 2-methyl hydroxylated CP20 efficiently, while the MAX SPE 
failed to retain it. Thus, the MCX SPE has a higher recovery of CP20 and its glucuronide and 
hydroxylated metabolites compared to the MAX SPE, and is therefore a more suitable sample 
clean-up mechanism for the HPO microsomal incubates. Based on the results of the sorbent 
comparison study above, the MCX SPE was selected as the optimal ion exchange sorbent to 
develop the clean-up procedure of the Phase I+II microsomal incubates of CP20.  
 
The percentage of the HPO parent compound elimination after microsomal incubation was used 
to assess the metabolic stability of the parent compound and the concentrations of the parent 
compound before and after microsomal incubation was obtained from a calibration curve 
conducted with a series of same HPO standards in rabbit serum (Section 3.8). Thus, a suitable 
sample clean-up method was also required for calibration standard samples in the rabbit serum. 
A calibration of with CP20 standards (1.95 to 1000 ng/mL) in the rabbit serum was assessed to 
develop the calibration standard sample clean-up method (Section 3.6.2.1, Figure 3.10). The 
MCX SPE elution was applied for the sample clean-up and subjected to the LC/MS (Figure 
3.11).  
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Figure 3.10 The calibration curve of the MCX SPE eluents of standards CP20 in rabbit serum  










Figure 3.11 The MRM chromatographs of the MCX SPE eluents of standards CP20 and IS (CP21, 
210 ng/mL) in the rabbit serum 
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A structural analogue of the investigated HPOs, CP21, was used as the internal standard (IS) in 
the calibration curve standard rabbit serum samples and was also included in the microsomal 
incubates in the metabolic stability screen of the investigated HPOs. It was added to the 
biological matrix prior to the extraction procedure to correct for any variations occurring during 
the SPE extraction, chromatography separation and the mass spectrometric detection 
(Rosenfeld, 2009). The concentration of the CP21 was 210 ng/mL, which was between 1/3 and 
1/2 of the ULOQ of the analyte, at which concentration, the MS sensitivity could achieve a high 
S/N with the high sensitivity (Xu and Madden, 2012). On the other hand, the IS concentration 
was not so high that the peak area ratios of CP20/CP21 for the lower concentrations standards 
were too low (Figure 3.11 a). A good chromatographic separation of CP20 from CP21 was 
achieved at the MRM transitions 139.996 > 52.969 and 153.968 > 125.954, illustrated in the 
MRM chromatographs (Figure 3.11). In addition, The MCX SPE offered an efficient sample 
clean-up as a neat background was obtained.  
 
In summary, the MCX was selected as the sorbent chemistry for the sample clean-up of the 
CP20 microsomal incubates and the CP20 calibration curve standards in the rabbit serum 
samples. The other investigated HPOs and their metabolites have the similar chemical 
physiological properties (Table 3.4, Figure 3.6), which share the same ionisation pattern at 
acidic pH when interacting with the ion-exchange MCX sorbent, therefore, the MCX sorbent was 
also selected as the clean-up method for the microsomal incubates and the calibration curve 
standards in the rabbit serum samples of other HPOs in this study. Furthermore, in order to 
enhance the throughput in the labor-intensive screening of the HPOs metabolic stability, the 
MCX µElution SPE plate format was adopted instead of the SPE cartridge format.   
 
3.9.4 Validation of the bio-analytical method  
The established LC-MS/MS (MRM) assay (Section 3.4) with the SPE sample clean-up 
treatment (Section 3.6) has been proposed to be an efficient quantitative bio-analysis with a 
high throughput, due to the high sensitivity and selectivity of MRM mode and the elimination of 
matrix effect impact by the sample clean-up procedures. Hence, the matrix effect, recovery, 
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precision, accuracy, linearity, limit of detection and limit of quantification were assessed for this 
bio-analytical method. One of the investigated HPO compounds CN128 and the internal 
standard CP21 was selected for the method validation (Section 3.9.1, Table 3.1). Rabbit serum 
was chosen as the biological matrix instead of human liver microsomes for the cost-
effectiveness. The assay was validated in accordance with the guidance of the International 
Conference on Harmonisation (ICH) (ICH). 
 
Matrix effect, Recovery and Process efficiency 
The co-eluting matrix components may reduce or enhance the ion intensities of the analytes 
and affect the reproducibility and accuracy of the assay (Matuszewski et al., 2003). Thus three 
sets of samples were investigated to determine the matrix effect, recovery of the sample from 
SPE extraction, process efficiency of the assay, with reference to Section 3.7.1 (Sample sets 
1,2,3) and Section 3.7.2 (Equation 3.1, 3.2, 3.3) respectively, in the triplicate analysis over three 
successive days.  
The matrix effect was examined by comparing the MS/MS (MRM) response  (mean peak area) 
of CN128 or CP21 at the given concentrations spiked post-extraction into the serum extract (Set 
2) to the MS/MS (MRM) response of the same analyte prepared in the LC-MS mobile phase 
(Set 1) multiplied by 100. An example of the MRM chromatograph of sample Set 1 is illustrated 
in Figure 3.12 a, b; CN128 or CP21 eluted at identical retention times with different ion 
intensities among the three sets of samples examined. The mean values of the matrix effect 
were 97% and 94% for CN128 and CP21 respectively (Table 3.5, Columns G and H). A value of 
100% indicates that the response in the plasma extracts (Set 2) and the neat mobile phase (Set 
1) is the same and no potential matrix effect is observed. Thus, a value of > 100% indicates 
ionisation enhancement, and a value of < 100% indicates ionisation suppression. Hence the 
mean values of matrix effect of CN128 and CP21 have indicated that very small ion suppression 
was observed under the SPE and LC-MS/MS conditions.  
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Figure 3.12 The MRM chromatographs of the MCX SPE elutent of Set 1 
(ion signal intensity vs time (min)) 
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Set 1 Set 2 Set 3 Set 1 Set 2 Set 3 CN128 CP21 CN128 CP21 CN128 CP21 
0.0977 0.7 0.7 0.7 16.4 15.4 14.5 94 94 94 94 94 89 
0.1953 1.2 1.1 1.1 16.2 16.0 13.8 99 86 94 86 94 85 
0.3906 2.1 2.0 1.9 14.2 14.1 13.6 99 96 90 96 90 96 
0.7815 3.9 3.7 3.8 14.8 14.5 13.9 98 96 98 96 98 94 
20 104.7 103.1 98.8 15.5 14.5 13.6 93 93 94 94 94 88 
37.5 168.0 166.9 154.4 15.7 15.6 15.1 99 97 92 97 92 96 
Mean       97 94 94 94 94 89 
%RSD       2.8 4.3 2.8 4.3 2.8 5.1 
Column A B C D E F G H I J K L 
 
a 
Matrix effect: The ratio of the MS/MS (MRM) response (mean peak area) of CN128 or CP21 at the given 
concentrations spiked post-extraction into the serum extract (Set 2) to the MS/MS (MRM) response (mean 
peak area) of the same analyte prepared in the LC-MS mobile phase (Set 1) multiplied by 100.  
b
 Recovery: The ratio of the MS/MS (MRM) response (mean peak area) of CN128 or CP21 at the given 
concentrations spiked pre-extraction into the serum extract (Set 3) to the MS/MS (MRM) response (mean 
peak area) of the same analyte spiked post-extraction into the serum extract (Set 2) multiplied by 100.  
c
 Process efficiency: The ratio of the MS/MS (MRM) response (mean peak area) of CN128 or CP21 at the 
given concentrations spiked pre-extraction into the serum extract (Set 3) to the MS/MS (MRM) response 
(mean peak area) of the same analyte prepared in the LC-MS mobile phase (Set 1) multiplied by 100.  
 
 
The recovery of CN128 and CP21 extracted from the rabbit serum using the developed SPE 
method (Section 3.6) was assessed by determining the ratio of the MS/MS (MRM) response  
(mean peak area) of CN128 or CP21 at the given concentrations spiked pre-extraction into the 
serum extract (Set 3) to the MS/MS (MRM) response (mean peak area) of the same analyte 
spiked post-extraction into the serum extract (Set 2) multiplied by 100. The recovery values for 
CN128 and CP21 were both 94% (Table 3.5, Columns I and J), which have represented good 
recovery of the SPE method used for sample extraction.  
The progress efficiency was also included to evaluate the efficiency of the SPE extraction for 
CN128 and CP21 in rabbit serum. By comparing the MS/MS (MRM) response (mean peak 
area) of CN128 or CP21 spiked into the rabbit serum, followed by extraction, reconstitution in 
the LC-MS mobile phase, and LC-MS analysis with the corresponding peak areas of the same 
compound analysed directly in the mobile phase, the efficiency of the SPE extraction procedure 
can be determined. Owing to the observed small ionisation suppression for both CN128 and 
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CP21 due to the matrix effect (97% and 94%, respectively, Table 3.5, columns G and H), the 
process efficiency values (Set 3 / Set 1 × 100) were ≤ 100 (94% and 89%, respectively, Table 
3.5, columns K and L). The value of the process efficiency has indicated a reliable and efficient 
extraction method developed for sample clean-up.  
The low % RSD values (Table 3.5, Columns G to L), which are typically less than about 5%, 
have demonstrated only small variations among the matrix effect, recovery and progress 
efficiency assessed at the investigated concentrations for both CN128 and CP21, which 
indicates the reproducibility and robust of the method.  
 
Precision and accuracy 
Precision of the bio-analysis of Sample Set 1, Set 2 and Set 3 was evaluated in the triplicate 
analysis over three successive days, which was expressed as the coefficient of variation (%) in 
determining peak areas of CN128, peak areas of CP21 and peak area ratios (CN128/CP21) for 
each sample set. The precision values (CV, %) obtained for peak areas of CN128, peak areas 
of CP21 and peak area ratios of CN128/CP21 for Sample set 1 were ranging from 2.5-5.5%, 
4.2-5.4% and 3.5-5.1% respectively (Table 3.6, Columns A, D, G); for Sample set 2 fell in the 
range 4.6-12.4%, 6.7-13.5% and 6.7-11.8% respectively (Table 3.6, Columns B, E, H); for 
Sample set 3 were within the range of 5.8-10.7%, 5.9-10.4% and 5.6-11.3% respectively (Table 
3.6, Columns C, F, I). The precision value determined for these sample sets at each 
concentration was less than 15%, and consequently achieved the precision acceptance criteria 
based on the ICH guideline and indicates the reliability of the established bio-analysis method. 
The accuracy of the method was assessed by the quality control sample (QCs) from triplicate 
analysis over three successive days. The high QC concentration (QCH) should be in the upper 
quartile of the calibration curve. The mid QC concentration (QCM) is near the middle (~ 50%) of 
the calibration range (Li et al., 2013). Hence, the QCH was set at the concentration of 75 ng/mL 
and the QCM concentration was selected at 40 ng/mL, according to the calibration curve 
standard concentration range investigated 0.1953 ~ 100 ng/mL. Four low concentrations 
(1.5625, 0.7813, 0.3906, 0.1953 ng/mL) at the low concentration range of the calibration curve 
were selected as the QCL sample. The accuracy values were expressed as [(mean observed 
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concentration)/ (nominal concentration)] × 100. The accuracy values (%) of the QC samples 
ranging from 90-107% (Table 3.6, column J) were less than 15% variation of their corresponding 




Table 3.6 Precision (CV, %) of determining peak areas of CN128, peak areas of CP21 and peak area 
ratios (CN128/CP21) in Sample Set 1, Set 2 and Set 3 and Accuracy (%) determined from QC 
samples. 
 




























0.0977 5.5 7.9 9.5 4.5 6.9 10.4 3.5 7.5 10.6 95 
0.1953 5.3 7.9 10.7 5.4 6.7 9.9 5.1 7.6 7.1 90 
0.3906 4.9 6.3 8.7 4.8 7.2 8.5 4.5 6.8 6.5 97 
0.7815 4.5 12.4 5.9 4.2 9.7 6.7 4.0 10.5 11.3 105 
20 3.8 4.9 6.7 4.6 8.4 5.9 3.5 6.7 5.6 107 
37.5 2.5 4.6 5.8 4.5 13.5 6.5 3.7 11.8 10.6 101 
0.0977 5.5 7.9 9.5 4.5 6.9 10.4 3.5 7.5 10.6 95 
Column A B C D E F G H I J 
 
a 
in neat LC-MS mobile phases. 
b
 CN128 and CP21 spiked post-extraction into the serum extract. 
c 
CN128 and CP21 
spiked pre-extraction into the serum extract. 
d
 Determined from QC samples, expressed as [(mean observed 
concentration)/ (nominal concentration)] × 100, observed concentrations were calculated from the calibration curves 
 
 
The inter-day and the intra-day precision were determined as the coefficient of variation of the 
triplicate analysis of calibration curve standards (Section 3.7.1, Calibration curve standards). 
The precision values (CV, %) obtained for peak areas of CN128, peak areas of CP21 and peak 
area ratios of CN128/CP21 at each concentration of the inter-day analysis fell in the range 1.2-
11.1%, 2.0-15.0% and 1.2-14.2% respectively (Table 3.7, Columns A, B, C); of the intra-day 
analysis was within the range of 1.5-11.7%, 1.7-9.3% and 1.4-14.4% respectively (Table 3.7, 
Columns D, E, F). According to the ICH guideline, the acceptance criteria for method precision 
is ≤15%. Thus, the precision values determined for the triplicate analysis of calibration curve 
standards over three days validation demonstrate the robustness and reproducibility of the 
developed method.  
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Good linearity was obtained for the calibration curves plotted within inter-day (n=3) and intra-
day (n=3) validation, which was assessed by the correlation coefficient r
2
 values of 0.991377, 
0.980759 and 0. 988663 (Table 3.8, Column C, Figure 3.13). The % RSD of the mean slope 
values of the calibration curves was 4.5% (Table 3.8, column A). The %RSD values 
demonstrated only small variations during the inner-day and intra-day validation and implied 
that the overall system performance was robust, reproducible and reliable. 
 
 
Table 3.8 Linearity of the calibration curve 
 




















0.0977 1.7 2.0 2.9 3.2 1.7 3.6 
0.1953 3.9 8.0 14.2 11.1 4.2 1.9 
0.3906 6.0 15.0 9.7 9.4 8.5 11.1 
0.7813 9.5 11.7 5.7 11.7 8.3 14.4 
1.5625 6.4 12.8 6.4 4.1 7.9 4.6 
3.125 11.1 14.5 5.5 8.5 9.2 3.2 
6.25 10.4 10.0 2.2 8.0 7.4 1.4 
12.5 1.2 8.5 7.5 1.5 9.3 7.8 
25 10.3 10.0 1.2 8.3 8.3 4.2 
50 2.7 7.6 5.0 2.9 6.5 4.6 
Columns A B C D E F 
Day Slope (Mean, n=3) Intercept (Mean, n=3) Regression Coefficient (r
2
) 
1 0.357586 0.0136156 0.991377 
2 0.327511 0.0180073 0.980759 
3 0.337598 0.0165789 0.988663 
Mean 0.340898   
%RSD 4.5   
column A B C 
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(a) Day 1 validation: Calibration curve Y = 0.357586 X + 0.01361; Curve type: Linear; Weighting 1/x 
           
 
  (b) Day 2 validation: Calibration curve Y = 0.327511 X + 0.0180073; Curve type: Linear; Weighting 1/x 
           
 
   (c) Day 3 validation: Calibration curve Y = 0.337598 X + 0.0165789; Curve type: Linear; Weighting 1/x 
 
Figure 3.13: Calibration curve of the MRM response  
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Limit of Detection (LOD) and Limit of Quantification (LOQ) 
As defined in Section 3.7.2, LOD is set as the concentration showing a signal-to-noise ratio of 
more than 3, which was 0.02931 ng/mL for the developed method. LOQ was set as the lowest 
standard concentration on the calibration curve that exhibits acceptable precision and accuracy 
(a precision of 20% and an accuracy of 80-120%). The precision determined for the triplicate 
analysis of calibration curve standards over three days validation at the concentrations of 
calibration standards were all less than 15% and with the accuracy ranging between 90-107% 
as discussed before. Thus the LOQ is the lowest standard concentration of CN128, which is 
0.0977 ng/mL.  
 
3.9.5 Screening for metabolic conversion of novel HPO compounds 
3.9.5.1 Metabolic conversion of CP20/deferiprone, CP94 and CP102 
As previously discussed, the extensive glucuronidation pathway of CP20/deferiprone and CP94 
observed in humans result in limited iron chelation efficacy. Particularly the formation of 
glucuronide at the 3-hydroxyl group will inactivate the pharmacological activity. Therefore, a 
series of 3-hydroxypyridin-4-one compounds with modifications on the ring substitution has 
been screened for their metabolic profiles in the liver microsomal incubations in order to select 
the alternative candidate compound for CP20/deferiprone.  
 
The percentages of Phase I and Phase I+II metabolism biotransformation have been evaluated 
for 18 novel HPO compounds (Section 3.9.1, Table 3.1). The reactions were incubated in the 
presence of human liver microsomes together with the cofactors: NADPH (the cofactor for 
CYPs-dependent metabolism) and UDPGA (the cofactor for UGTs-dependent glucuronidation) 
(Section 3.5). The sample clean-up and LC-MS analysis utilised the methods discussed in the 
previous sections (Section 3.9.2 and 3.9.3). The percentages of metabolism biotransformation 
for CP20/deferiprone, CP94 and CP102 have been assessed in both rat and human liver 
microsomes, which were used as control groups, as their metabolism profiles have been 
previously subjected to extensive investigation (For chemical structures, refer to Section 3.9.1, 
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Table 3.1). CP20/deferiprone is substantially metabolised by both rat and human liver 
microsomes, fortified with both NADPH and UDPGA. The percentages of CP20/deferiprone 
metabolised after Phase I+II microsomal incubation were found to be 46% and 90% 
respectively, suggesting extensive loss of the parent compound by glucuronidation conjugation 
(Figure 3.14, Table 3.9 Row A and B). In contrast, CP20/deferiprone was moderately 
metabolised by both rat and human microsomes in the presence of NADPH (Phase I cofactor). 
The percentages of CP20/deferiprone metabolised under these conditions were 19% and 25% 
respectively (Figure 3.14, Table 3.9 Row A and B). The metabolic pathway of CP20 is illustrated 
in Scheme 3.1.  
 
Figure 3.14 Metabolic conversions of CP20, CP94, and CP102 in human and rat liver microsomes 
Black: Phase I; Grey: Phase I+II 
 
Table 3.9 Metabolic conversions of CP20, CP94, CP102 in human and rat liver microsomes 
 
 % Drug metabolised (24 hr) (Mean ± SD, n=3) 
HPOs Phase I Phase I+II Row 
CP20/deferiprone RLMs 19 ± 9 46 ± 5 A 
CP20/deferiprone HLMs 25 ± 4 90 ± 1 B 
CP94 RLMs 30 ± 5 11 ± 3 C 
CP94 HLMs 67 ± 5 88 ± 1 D 
CP102 RLMs 8 ± 4 12 ± 2 E 
CP102 HLMs 9 ± 1 8 ± 3 F 
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Scheme 3.1 Metabolic pathways of CP20 
(a) CP20;  
(b) 3-O- glucuronide conjugate of CP20;  
(c) CP20-2-hydroxymethyl metabolite;  
(d) Glucuronide conjugate of CP20-2-hydroxymethyl metabolite. 
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The Phase I metabolism pathway represents the major route of metabolism for CP94, when the 
incubation was performed in rat liver microsomes (Scheme 3.2). The percentage of CP94 
elimination in the Phase I reaction was 30% compared with 11% in the Phase I+II reaction 
(Figure 3.14, Table 3.9 Row C). CP94 was found to undergo extensive glucuronidation 
conjugation in human liver microsomes; only 12% of the parent compound remained intact after 
Phase I+II incubation reaction (Figure 3.14, Table 3.9 Row D). The Phase I metabolic pathway 
of CP94 has led to considerable conversion of the parent compound (67%, Table 3.9 Row D), 
which indicates that the extensive glucuronidation occurs on the hydrophilic site introduced by 
Phase I metabolic pathway. This metabolic pathway is shown in Scheme 3.2. CP102 has 
previously been demonstrated to be resistant to both Phase I and Phase II (glucuronidation) 
(Singh et al., 1996). This was confirmed in this study where the percentages of parent 
compound conversion in both Phase I and Phase I+II were minor, 8% and 12% respectively in 
rat liver microsomes and 9% and 8% respectively in human liver microsomes (Figure 3.14, 
Table 3.9 Row E and F). In summary, the metabolic profiles for CP20/deferiprone, CP94 and 
CP102 reported in this work were in a good agreement with the previous studies (Section 
2.4.1). These findings further suggest that the system developed in this work to screen the 
metabolic conversion of a series of novel HPO compounds is both reliable and robust.  
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Scheme 3.2 Metabolic pathways of CP94 
(a) CP94;  
(b) 3-O- glucuronide conjugate of CP94 (the major metabolite in man); 
(c) CP94-2-(1’-hydroxyethyl) metabolite (the major metabolite in rat) 
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3.9.5.2 Metabolic conversion of CN128 and CN126 
CN128 and CN126 are two enantiomers of a chiral HPO compound, (R) and (S)-3-hydroxy-1-(1-
hydroxy-3-phenylpropanyl)-2-methylpyridin-4(1H)-one (For chemical structures, refer to Section 
3.9.1, Table 3.1, p74). It has been reviewed that metabolising enzymes often display a 
preference for one enantiomer of a chiral drug over the other, resulting in enantioselectivity (Lu, 
2007). The enantioselective metabolism has been reported with both the CYP-mediated and 
UGT-mediated Phase I and II metabolism respectively (Sten et al., 2006, Kaminsky and Zhang, 
1997). Consequently, although these two enantiomers share essentially the same 
physicochemical properties, their interaction with metabolising enzymes could be different at the 
binding step and/or at the catalytic step, resulting in different affinities and/or reactivities, which 
could produce metabolites distinguished in nature and/or extent (Lu, 2007). Indeed, CN128 and 
CN126 were found to display enantioselective metabolism profiles (Figure 3.15 and Table 3.10). 
The two enantiomers are eliminated to different degrees, when mediated by CYPs and UGTs 
enzymes, in both Phase I and Phase II reactions. CN126 was substantially metabolised to a 
higher extent compared with CN128, 89 % and 38 % (Figure 3.15, Table 3.10, Rows E and D). 
The extent of parent drug glucuronidation of CN126 in human liver microsomes was almost 
identical to that of CP20/deferiprone and CP94, 90% and 88% respectively (Table 3.10, Rows A 
and B). Glucuronidation of CN128 indicates that it is much more resistant to UGTs when 
compared with its enantiomer CN126, CP20/deferiprone and CP94, implying better chelation 
efficacy. With respect to the CYP-mediated Phase I reaction, the metabolism has also displayed 
a preference for one enantiomer over the other; where CN128 was found to be metabolised by 
18% as compared to 31% for CN126 (Figure 3.15, Table 3.10, Rows D and E). The possible 
pathway of metabolic biotransformation is presented in Scheme 3.3. The metabolic pathway of 
CN126 is listed in Appendix VI-I. In consequence, the (R)-enantiomer HPO, CN128, has 
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Figure 3.15 Metabolic conversions of CN128, CN126 in human liver microsomes  
Metabolic conversions of CP20/deferiprone, CP94, CP102 in human liver microsomes were taken from Figure 3.14 






Table 3.10 Metabolic conversions of CN128, CN126 in human liver microsomes 
Metabolic conversions of CP20/deferiprone, CP94, CP102 in human liver microsomes were taken from Table 3.9 
 
 
 % Drug metabolised (24 hr) (Mean ± SD, n=3) in HLMs 
HPOs Phase I Phase I+II Row 
CP20/deferiprone 25 ± 4 90 ± 1 A 
CP94 67 ± 5 88 ± 1 B 
CP102 9 ± 1 8 ± 3 C 
CN128 18 ± 2 38 ± 1 D 
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Scheme 3.3 Metabolic pathways of CN128 
 
(a) CN128; 
(b) 3-O-glucuronide conjugate of CN128; 
(c) CN128-1-(1-O-glucuronide) conjugate; 
(d) N-dealkylated metabolite of CN128; 
(e) 3-O-glucuronide conjugate of N-dealkylated metabolite of CN128 
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3.9.5.3 Metabolic conversion of CM1 
Another novel HPO compound, CM1, with the ω-acetamido-6-alkyl substituent at the position-1 
of the hydroxypyridinone ring has also been investigated for its in vitro metabolic clearance 
during human liver microsomal incubation (For chemical structures, refer to Section 3.9.1, Table 
3.1, p74). The percentage of parent compound elimination by UGTs metabolising enzyme was 
less than those of CP20/deferiprone and CP94, 69% compared with 90% and 88% (Figure 3.16, 
Table 3.11, Rows D, A and B). The extent of Phase I metabolism reaction was minor, only 4% of 
the parent drug was converted by the CYP enzymes (Figure 3.16, Table 3.11 Row D). The 
probable metabolic pathway is illustrated in Scheme 3.4.  
 
 
Figure 3.16 Metabolic conversion of CM1 in human liver microsomes 
Metabolic conversions of CP20/deferiprone, CP94, CP102 in human liver microsomes were taken from Figure 3.14 
Black: Phase I; Grey: Phase I+II 
 
Table 3.11 Metabolic conversion of CM1 in human liver microsomes 
Metabolic conversions of CP20/deferiprone, CP94, CP102 in human liver microsomes were taken from Table 3.9 
 
 % Drug metabolised (24 hr) (Mean ± SD, n=3) in HLMs 
HPOs Phase I Phase I+II Row 
CP20/deferiprone 25 ± 4 90 ± 1 A 
CP94 67 ± 5 88 ± 1 B 
CP102 9 ± 1 8 ± 3 C 
CM1 4 ± 1 69 ± 4 D 
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Scheme 3.4 Possible metabolic pathways of CM1 
 
(a) CM1; 
(b) 3-O-glucuronide conjugate of CM1; 
(c) CM1-2-hydroxymethyl metabolite; 
(d) Glucuronide of 2-hydroxymethyl conjugate of CM1; 
(e) 3-O-glucuronide conjugate of CM1-2-hydroxymethyl metabolite  
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3.9.5.4 Metabolic conversion of close analogues of CP20 
A series of mono-, di- and tri- methyl substituted analogues at ortho-, meta- and para-positions 
with respect to the phenolic group of 3-hydroxypyridin-4-one ring have been investigated for the 
effect of the substitution patterns on the drug metabolism profiles in the human liver 
microsomes (For chemical structures, refer to Section 3.9.1, Table 3.1, p74). Regioselectivity in 
drug metabolism has been reported previously. For instance, a regioselective oxidation by 
CYPs-dependent monooxygenase was observed with preferential insertion of oxygen at meta-
para unsubstituted carbon atoms rather than the ortho-meta unsubstituted position, by altering 
the chloride substitution patterns of the polychlorinated biphenyls (Borlakoglu et al., 1990). The 
conjugation reaction mediated by the UGT enzymes also demonstrated regioselectivity, where 
glucuronides were formed to different extents depending on the isomers of ortho-, meta- and 
para-xylene (Corn, 1993). Hence, it was of great interest to investigate the impact of varying the 
methyl substitution patterns on the 3-hydroxypyridin-4-one ring on the metabolic profiles. Similar 
to both CP20/deferiprone and CP94, the major route of metabolism of this series of methyl-
substituted analogues was found to be glucuronidation. The parent drug elimination percentage 
incubated in the human liver microsomes with UDPGA cofactor fell in the range from 73% to 
98% (Table 3.12, Rows D to I, Figure 3.17) in comparison to 90% and 88% for 
CP20/deferiprone and CP94 (Table 3.12, Rows A and B, Figure 3.17). This regioselective attack 
by the UGT enzymes was not apparent for this series of analogues. The 2,5- and 1,6- dimethyl 
HPOs (CP616 and CP69) displayed a slightly reduced of glucuronidation conjugation (73% and 
79%, Table 3.12, Rows E and D). Concerning the biotransformation of parent compounds by the 
Phase I pathway, the 1, 6- dimethyl and 1, 2, 5- tri-methyl, CP69 and CP617, demonstrated 
similar extents of oxidative metabolism (28% and 29% respectively, Table 3.12, Rows D and F, 
Figure 3.17) compared with that of CP20/deferiprone (25%, Table 3.12, Row A, Figure 3.17), 
while CP669, the 1, 5- dimethyl substituted HPO, displayed a slightly higher degree of Phase I 
biotransformation (39%, Table 3.12, Row G, Figure 3.17). The degree of Phase I metabolism of 
another 2, 5- di-methyl substituted HPO, CP616, demonstrated a slightly reduced extent (16%, 
Table 3.12, Row E) compared with that of CP20/deferiprone. The two mono-methyl substituted 
HPO analogues, 2- methyl and 5- methyl HPOs, CP28 and CP679 experience the lowest 
degree of Phase I metabolic conversion (11% and 10%, Table 3.12, Rows H and I, Figure 3.17) 
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and the extent was comparable with that of CP102 (9%, Table 3.12, Row C, Figure 3.17). The 
likely metabolic pathway of one compound of this series of analogues, CP28, is presented in 
Scheme 3.5. For other compounds of this series, their metabolic pathways are listed in 
Appendix VI-II. 
 
Figure 3.17 Metabolic conversions of CP69, CP616, CP617, CP669, CP28 and CP679 in human liver 
microsomes 
Metabolic conversions of CP20/deferiprone, CP94, CP102 in human liver microsomes were taken from Figure 3.14 
Black: Phase I; Grey: Phase I+II 
Chemical structures are given in Section 3.9.1, Table 3.1 
 
 
Table 3.12 Metabolic conversions of CP69, CP616, CP617, CP669, CP28 and CP679 in human liver 
microsomes 
Metabolic conversions of CP20/deferiprone, CP94, CP102 in human liver microsomes were taken from Table 3.9 
 
 % Drug metabolised (24 hr) (Mean ± SD, n=3) in HLMs 
HPOs Phase I Phase I+II Row 
CP20/deferiprone 25 ± 4 90 ± 1 A 
CP94 67 ± 5 88 ± 1 B 
CP102 9 ± 1 8 ± 3 C 
CP69 28 ± 5 79 ± 4 D 
CP616 16 ± 3 73 ± 7 E 
CP617 29 ± 8 91 ± 1 F 
CP669 39 ± 3 97 ± 1 G 
CP28 11 ± 1 93 ± 7 H 
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Scheme 3.5 Metabolic pathways of CP28 
 
(a) CP28; 
(b) 3-O-glucuronide conjugate of CP28; 
(c) CP28-2-hydroxymethyl metabolite; 
(d) Glucuronide of 2-hydroxymethylconjugate of CP28; 
                                             (e) 3-O-glucuronide conjugate of CP28-2-hydroxymethyl metabolite 
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3.9.5.5 Metabolic conversion of pegylated hydroxypyridinones 
As previously discussed, pegylation has provided advantageous biological properties, improving 
the pharmacokinetic character and efficacy of iron chelators (Veronese and Mero, 2008). The 
series of 1-, 2-, 6- substituted pegylated HPOs (Section 3.9.1, Table 3.1) were incubated in the 
human liver microsomes in order to study the influence of the presence of pegylated groups on 
the metabolic profiles (For chemical structures, refer to Section 3.9.1, Table 3.1, p74). 
Comparable with the CP20/deferiprone and CP94, K8 and K5, where the pegylated function is 
ortho with respect to the phenolic group, demonstrated marked glucuronidation with 80% and 
97% parent drug disappearance (Figure 3.18, Table 3.13 Rows H and I).  In contrast there is a 
reduction of glucuronidation in both K7 and K6 with 40% and 26% parent drug conjugated by 
glucuronidation (Figure 3.18, Table 3.13 Rows J and K), where the pegylated group is para with 
respect to the phenolic group. The rate of glucuronidation is further reduced ranging from 20 % 
to 38% (Table 3.13 Rows D to G), when the pegylated function is placed on the N-atom of the 
ring (C11, C21, C31, K31).  
 
 
                      
 
Figure 3.18 Metabolic conversions of pegylated HPOs in human liver microsomes 
Metabolic conversions of CP20/deferiprone, CP94, CP102 in human liver microsomes were taken from Figure 3.14 
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With regard to Phase I metabolic pathway, K8, K7 and K6, where the pegylated group is on the 
ortho-, para- position with respect to phenolic group, were transformed by CYPs to a similar 
extent (18%, 18% and 22%, Table 3.13, Row H, J and K, Figure 3.18) to that of 
CP20/deferiprone (25%, Table 3.13, Row A, Figure 3.18). In contrast, C11, C21, C31, K31, 
where the pegylated function is at the position-1 of the ring, and K5, where the pegylated group 
is ortho- to the phenolic group were metabolised to a reduced extent, with C31 experiencing no 
detectable phase I metabolic pathway (Table 3.13, Row D to G and I, Figure 3.18).  
 
Table 3.13 Metabolic conversions of pegylated HPOs in human liver microsomes 
Metabolic conversions of CP20/deferiprone, CP94, CP102 in human liver microsomes were taken from Table 3.9 
 
 % Drug metabolised (24 hr) (Mean ± SD, n=3) in HLMs 
HPOs Phase I Phase I+II Row 
CP20/deferiprone 25 ± 4 90 ± 1 A 
CP94 67 ± 5 88 ± 1 B 
CP102 9 ± 1 8 ± 3 C 
C11 9 ± 3 20 ± 3 D 
C21 7 ± 4 29 ± 4 E 
C31 0 ± 4 38 ± 2 F 
K31 8 ± 2 23 ± 1 G 
K8 18 ± 5 80 ± 5 H 
K5 6 ± 7 97 ± 1 I 
K7 18 ± 1 40 ± 2 J 
K6 22 ± 3 26 ± 7 K 
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As both Phase I and Phase II metabolic conversions were both markedly reduced for C11, this 
chelator was selected for further investigation, whereby C11 was incubated in the presence of 
human liver microsomes fortified only with UDPGA in the absence of NADPH. Under these 
conditions, direct Phase II glucuronidation can be observed without any prior Phase I oxidative 
metabolism. There was virtually no direct glucuronidation on the parent compound observed 
(Figure 3.19, Table 3.14), indicating that the glucuronidation of C11 occurs after some degree of 
oxidative metabolic modification (Scheme 3.6). Metabolic pathways of other compounds from 
this series are listed in Appendix VI-III. 
 
 
                            
  
Figure 3.19 Phase I+II and Phase I metabolic conversion of C11 in human liver microsomes 





Table 3.14 Phase I+II and Phase I metabolic conversion of C11 in human liver microsomes 
 
 % Drug metabolised (24 hr) (Mean ± SD, n=3) in HLMs 
HPOs Phase I+II Phase II 
C11 20 ± 3 1 ± 1 
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Scheme 3.6 Metabolic pathways of C11 
  
(a) C11; 
(b) C11-2-hydroxymethyl metabolite; 
(c) Glucuronide of 2-hydroxymethyl conjugate of C11; 
(d) 3-O-Glucuronide conjugate of C11-2-hydroxymethyl metabolite; 
(e) N-dealkylated metabolite of C11; 
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As the loss of C11 by both Phase I and II metabolising enzymes was found to be much less 
substantial than that of CP20/deferiprone, the study has been extended to its less hydrophilic 
analogue (6d, Table 3.1). Unfortunately both Phase I and phase II metabolic conversions were 
found to be more substantial compared with those of C11. (Figure 3.20, Table 3.15). 
Consequently, the substitution with pegylated groups at different positions on the HPO ring has 
introduced regioselective metabolic profiles, with some of the candidates displaying reduced 
degree of metabolism.  
 
 
Figure 3.20 Metabolic conversion of C11 and 6d in human liver microsomes 
Metabolic conversion of CP20/deferiprone in human liver microsomes were taken from Figure 3.14 





Table 3.15 Metabolic conversion of C11 and 6d in human liver microsomes 
Metabolic conversion of CP20/deferiprone in human liver microsomes were taken from Table 3.9 
 
 
 % Drug metabolised (24 hr) (Mean ± SD, n=3) in HLMs 
HPOs Phase I Phase I+II Row 
CP20/deferiprone 25 ± 4 90 ± 1 A 
C11 9 ± 3 20 ± 3 B 
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3.10 Summary  
A rapid, sensitive and selective bio-analytical method for simultaneous screening and 
quantification of novel 3-hydroxypyridin-4-one analogues has been developed and validated. 
The method is useful for the investigation of metabolic profiles of hydroxypyridinones. The high 
throughput sample clean-up pre-treatment of biological samples using a mixed-mode cation 
exchange (MCX) solid phase extraction to concentrate and purify parent compounds and their 
metabolites is coupled to a quantitative method using ultra performance liquid-chromatography 
(UPLC) coupled with a tandem quadrupole mass spectrometer (TQ-MS) operated in the 
multiple reaction monitoring (MRM) acquisition mode. The UPLC and MS/MS (MRM) conditions 
have been optimised and established. This new approach is suitable for high sample throughput 
and has been applied to the screening and quantification of Phase I and Phase II metabolic 
biotransformations and clearance of a range of novel 3-hydroxypyridin-4-one compounds.  
 
The modification of methyl substitution patterns does not further optimise deferiprone/CP20 
properties regarding to glucuronidation. Another HPO, CM1, suffered a slightly lesser extent of 
glucuronidation compared with CP20 in HLMs. Large decreases of the extent of glucuronidation 
were observed in most of the pegylated HPOs and one of the chiral enantiomers CN128. The 
reduced metabolic elimination of these parent HPOs by the liver metabolism enzymes will 
enhance the iron chelation efficacy of the compounds. However, the pegylated side chain 
increases the hydrophilicity of the hydroxypyridinones, when compared with CP20/deferiprone, 
the milogP values all being negative (Section 3.9.2, Table 3.4). The lipid solubility of the free 
ligand HPOs is desirable for access to intracellular iron by permeating the membranes by non-
facilitated diffusion. The reduced lipophilicity of the pegylated HPOs is likely to reduce the rate 
of penetration of the cell membranes. Consequently, CN128, with ideal physicochemical 
properties and metabolic profiles, was subjected to a further detailed efficacy study. Although 
the glucuronidation rate of CM1 was not reduced to a large extent, this HPO was also 
investigated in the efficacy study due to its ideal physicochemical properties. 
























Chapter 4 Efficacy study of 3-hydroxypyridin-4-ones 
4.1 Introduction 
An in vivo animal model is essential in order to establish the iron chelation activity of iron 
chelators, including absorption from the gastrointestinal tract in the intact organism. We have 
adopted the in vivo 
59
Fe-ferritin-labelled non-iron overloaded rat model to evaluate the oral 
availability and iron mobilisation from the major iron overload site, the liver (Liu et al., 1999c). 
We have compared two lead chelators, CN128 and CM1 (Figure 4.1) with CP20/deferiprone. 
CN128 was selected for the efficacy study due to its slow rate of metabolism in the liver 
(Chapter 3, Section 3.9.5.2). CM1 possessed suitable physicochemical characteristics to act as 
a candidate of an ideal iron chelator, which possesses high affinity and selectivity for iron(III) 
and a suitable partition coefficient  for both the ligand and iron complex  to permeate cell 
membranes (Pangjit et al., 2015). All the animal work in this project has been conducted under 
the animal license PPL 70/6954, and carried out under the regulations of Animals (Scientific 
Procedures) Act 1986. The efficacy study of CN128 involved collaboration with the Medicinal 
Chemistry Research Group of the Institute of Pharmacy, Zhejiang University, China in order to 
provide preclinical efficacy data of CN128 for Phase I clinical trial. The efficacy study of CM1 




                                    HPO                   R1 
                                    CN128   −CH(C6H5)CH2OH 
                                              CM1      −(CH2)6NHCOCH3 
                                        
 









4.2 Materials and apparatus  
Hydroxypyridinones  
CN128,(R)-3-hydroxy-1-(1-hydroxy-3-phenylpropanyl)-2-methylpyridin-4(1H)-one (hydrochloride 
form)  and CP20/deferiprone, 1,2-dimethyl-3-hydroxypyridin-4-one (hydrochloride form) were 
designed and synthesised by the Medicinal Chemistry Research Group of Institutie of 
Pharmacy, Zhejiang University, China. Ferriprox
TM
 (film coated CP20/deferiprone tablets, 
500mg) was purchased Apotex Inc. Canada; CM1, 1-(N-acetyl-6-aminohexyl)-3-hydroxypyridin-
4-one  (free base form) was synthesised in Chiang Mai University, Thailand. 
 
Animal experiments 
Male (230 to 300g) and female (210 to 220g) young adult (7 weeks) Sprague-Dawley rats 
(Harlan UK Ltd., Oxon, UK); Buprenorphine (Archimedes Pharma Ltd Reading, UK); Liquid 
isoflurane (Aesica Queenborough Ltd, Kent, UK); Euthatal (Merial S.A.S, Toulouse, France); 
Rodent vascular access port with pre-attached silastic catheter, 3 Fr; Huber needle (Harvard 
Apparatus, Kent, UK); Plastipack
TM
 syringes (BD, NJ, US); Neolus
®
 hypodermic needles 
(Terumo, Leuven, Belgium); Feeding needles, FNC-12-4, curved, 12 gauge, 3.9 inches (Kent 
Scientific Corporation, Torrington, US); Most of the surgical tools and facilities were kindly 




Fe radionuclide (Perkin Elmer, Cambridge, UK); Sephadex
®
 G-25 disposable PD-10 desalting 
columns (Sigma-Aldrich, Dorset, UK); T25 digital Ultra-Turrax homogenizer (IKA, Staufen, 
Germany); Sorvall RT7 centrifuge (GMI, Inc., Minnesota, US); Compugamma CS gamma 
counter (LKB Wallac, Victoria, Australia); Optima
TM
 L-90K ultra centrifuge (Beckman Coulter 
Inc., UK); Sodium acetate anhydrous, sodium phosphate，sodium ammonium sulphate, sodium 
carboxymethyl cellulose (NaCMC)  (Sigma-Aldrich Company Ltd, Dorset, England).  
 
 




4.3 Methods  
4.3.1 59Fe labeled ferritin rat model 
Three batches of 
59
Fe labeled ferritin were prepared in order to accomplish the project.  
 
 
4.3.1.1 Implantation of catheter into the right jugular vein of rats (Day 1) 
Five adult male SD rats were anaesthetised with 2-3% inhaled isofluoran and placed on a 
heated mat. 20µg/kg buprenorphine was administered by intramuscular (i.m.) injection in order 
to provide postoperative analgesia. The body weights and doses of analgesia are listed in Table 
4.1 
 
Table 4.1: Animals body weight and analgesia administration record 
 
Batch No. 










263.9 5.3 280.2 5.6 285.0 5.7 
259.8 5.2 278.3 5.6 287.5 5.8 
276.4 5.5 293.8 5.9 275.5 5.5 
254.6 5.1 282.2 5.6 280.2 5.6 
252.0 5.0 281.2 5.6 290.3 5.8 
 
The dorsal and ventral neck regions were shaved and a 1.5 cm incision is made at both sides. 
The dorsal incision was 1 cm left to the midline of the body, the ventral incision was on the 
midline. A skin-tunneling needle passed subcutaneously over the right shoulder from the ventral 
to the dorsal incision site. A vascular access port catheter was threaded subcutaneously to the 
ventral neck region, leaving the saline filled port at the right side of the dorsal incision site. The 
catheter was cut to the appropriate length and flushed with 50 IU/ml heparin in clinical grade 
saline (0.9%). The right jugular vein was carefully isolated with two suture threads, and the 
anterior portion completely occluded. A small incision was made with a 23-gauge needle and 
the catheter insert posteriorly for approximately 1 cm past the suture and secured in place. The 
ventral neck region was sutured and the region sterilised. The port portion of the catheter was 
placed subcutaneously at the dorsal incision site and the incision site sutured and sterilised. 
The jugular veins of five male 230 to 240g male adult SD rats were cannulated and implanted 
with catheters. Animals were recovered in a heated chamber (30°C for 1-2 hours) before placed 




in the holding room. 
 
4.3.1.2 Packed red blood cell preparation and administration into animals (Day 2) 
Packed red blood cells (RBCs) were prepared from adult male SD rats (250 to 300g) 
anaesthetised as in Section 4.3.1.1. Approximately 10ml of blood was removed from each rat 
and added to 80ml of 20mM phosphate buffered saline (PBS) at pH 7.4, containing 2mM citrate 
at 4°C. The diluted blood was centrifuged in Sorvall RT7 centrifuge (2500 rpm) for 5 min at 4°C.  
The supernatant was carefully decanted; the RBCs were washed with PBS several times. The 
combined packed red blood cells were approximately 10 to 20 mL and kept in the incubator at 
37°C. 24 hours post vascular access port catheters implantation, no animals displayed any 
visual clinical signs of distress or infection. Animals were re-anaesthetised with inhaled 
isofluorane 2-3% and the catheter line was flushed with heparinised saline followed by 3ml of 
warmed packed red blood cells (0.5ml/min) using a Huber needle followed by a further 
heparinised saline flush. Animals were recovered in a heated chamber (30°C for 1-2 hours) and 
returned to the holding room.  
 
4.3.1.3 59Fe labeling (Day 3) 
24 hours post red blood cell infusion; animals did not display any visual clinical signs of distress 
or infection. Animals were re-anaesthetised with inhaled isofluorane 2-3% and the catheter line 
flushed with heparinised saline. 200 µCi of 
59
Fe in 0.25ml of sodium citrate (50mM, pH7.0), 
prepared by diluting the stock solution (1mCi 
59
Fe 50µl in sodium citrate, 50mM, pH7.0) five 
times, was administered via the access port and flushed through with heparinised saline. 
Animals recovered were placed in a designated holding room for further 24 hours.  










4.3.1.4 Purification of 59Fe ferritin (Day 4) 
Animals were sacrificed and the livers were removed. The weights of livers were recorded 
(Table 4.2).  The combined livers were homogenised in 4vol (w/v) of sodium acetate (0.25M pH 
4.8), the volumes of sodium acetate used were listed in Table 4.2.  
 
 
Table 4.2: Animal liver weight and volume of sodium acetate (NaAc) 
 
Batch No. 
1 2 3 
Liver weight (g) Liver weight (g) Liver weight (g) 
10.60 9.41 13.63 
10.20 11.48 12.80 
10.80 8.30 12.40 
11.20 9.30 14.10 
12.00 10.24 NA 
Total Liver weight(g) Total Liver weight(g) Total Liver weight(g) 
54.8 48.7 52.9 
Volume of NaAc(mL) Volume of NaAc(mL) Volume of NaAc(mL) 
219.2 194.8 211.6 
 
 
The homogenate was heated from 20°C to 70°C for 20 min and maintained 70 to 75°C for 10 
min on a heated magnetic plate. After cooling to 10°C, the coagulated proteins were removed 
by centrifugation at 2500 g for 15min at 4°C (Sorvall RT7 centrifuge). The supernatant 
containing tissue ferritin was precipitated by half saturated sodium ammonium sulphate (every 
325ml was treated with 95g sodium ammonium sulphate to obtain a 50% saturated solution), 
and left to stand for 30min at 4°C in an ice-bath. The resulting precipitate was separated by 
centrifugation at 3500 g for 15min at 4°C (Sorvall RT7 centrifuge). The precipitate was dissolved 
in 15ml sodium acetate (0.25M, pH 4.8) (sample solution). Undissolved precipitate was 
removed by passing through PD-10 columns (Sephadex G25). The process using PD-10 
columns was described as follows: a PD-10 column was firstly conditioned with 2 mL sodium 
acetate (0.25M, pH 4.8); 1mL sample solution was loaded on the PD-10 column; followed by a 
wash step with 3 mL sodium acetate (0.25M, pH 4.8) to wash out the undissolved precipitate. 
The tissue ferritin was collected by eluting the column with 4ml sodium acetate (0.25M, pH 4.8). 
The combined eluent from all the PD-10 columns was 70ml in total. The combined eluent was 
super-centrifuged at 4°C for 2h at 100,000g (Optima
TM 
L-90K ultra centrifuge). The resulting 
precipitate was dissolved in 10ml sodium phosphate solution (50mM, pH 7.4) and stored at 4°C. 




10μL of the solution was subjected to a Compugamma CS gamma counter to measure the 
initial radioactivity (Table 4.3). The purified 
59
Fe ferritin solution was used for the following HPO 
efficacy study.  
 
 
Table 4.3: Initial radioactivity of 
59





1 2 3 
Counts per Min/10µL 17268 47562 12345 
µCi/mL 75 206 54 
 
 
4.3.1.5 HPO preparation  
Two milliliters of stock solution of CN128 hydrochloride form (M.W. 296) at five dosages were 
prepared in water, which were 75µmol/kg b.w., 150µmol/kg b.w., 300µmol/kg b.w., 600µmol/kg 
b.w., 1200µmol/kg b.w.. The sample amount weighed in each stock solution (2mL) 
corresponded to the dose administered to a 300g b.w. animal. The oral gavage volumes to each 
animal were calculated by the equation: (Animal b.w. ⁄ 300g) x 2mL. The stock solutions of CM1 
free base form (M.W. 266), at three doses of 75µmol/kg b.w., 150µmol/kg b.w., 300µmol/kg b.w., 
were prepared in 50% propanediol and oral administered to rats in the same manner as CN128. 
Ferriprox
TM
, film coated CP20/deferiprone tablets, was initially used as the positive control. 
Twenty tablets were weighed together and the average weight of tablets was calculated, which 
was 822g. According to the “QC analysis report” provided from China, the purity of the active 
ingredient in a tablet (500g CP20/deferiprone in one tablet) is 98.8%. Thus the percentage of 
CP20/deferiprone in each tablet was obtained from (Amount of CP20/deferiprone in the tablet ⁄ 
Mean weight of the tablet)×100%, which was [(500g×98.8%) ⁄ 822g]×100% equal to 60%. The 
amount of ferriprox
TM
 tablet administered to achieve the equivalent dose investigated for CN128 
was converted by (Dose investigated ⁄ Percentage of CP20/deferiprone in the tablet). Tablets 
were crushed to fine powder and each dose was prepared in 5% sodium carboxymethyl 
cellulose (NaCMC). A fine suspension was formed after sonication for 30min. The supernatant 
after centrifugation for 5min was used for administration. CP20/deferiprone (free base form, 
M.W. 139) stock solutions were later used as positive control and prepared at doses equivalent 




to CN128, which were suspended in 50% propanediol and sonicated until totally dissolved. Due 
to the insolubility of high doses (600µmol/kg b.w. and 1200µmol/kg b.w.), the suspensions were 
titrated with concentrated hydrochloric acid until a clear solution was achieved. Water was used 
as negative control throughout the study. 
 
4.3.1.6 Procedures for the efficacy study  
Rats were fasted overnight. 1µCi of 
59
Fe-ferritin was injected intravenously through the rat tail 
vein. One hour later, rats were administered with CN128 by oral gavage at five doses. Positive 
control rats were administered with ferriprox
TM
 or CP20 crude drug at the same doses as 
CN128. Negative control rats were administered with an equivalent volume of water. Rats were 
placed in separate metabolic cages with urine and faeces collected separately and were 
allowed free access to food 1 hr after oral gavage. There was no restriction of water throughout 
the study period. The investigation was terminated 24 hrs after the 
59
Fe-ferritin administration; 
the rats were killed by intraperitoneal (i.p.) injection of 1ml euthatal. The liver and 
gastrointestinal tract (including its contents and the faeces) were removed. Urine and faeces 
were collected from metabolic cages. Samples were subjected to gamma counting. The 
calculations of “Iron mobilisation,” “Efficacy” and “Total recovery” are represented by equations 
4.1, 4.2 and 4.3. 
 
Iron mobilisation(%) =
Activity  (gut and faeces)
Activity  (gut and faeces)+ Activity  (liver)
× 100             Equation 4.1 
 
Efficacy (%)=Iron mobilisation(%) – Control(%)                         Equation 4.2                         
 
Total recovery(%) =
Activity  (gut and faeces)+ Activity  (liver)
Activity  (total)
× 100                                   Equation 4.3 
 
Activity(total)  was obtained from the initial radioactivity of the purified 
59
Fe-ferritin (Section 4.3.1.4, 
Table 4.3) multiplied by the decay factors demonstrated in “
59
Fe decay table “(PerkinElmer). 
 
Each study group included five animals administered with five doses of CN128 (one animal per 
each dose), five animals administered with corresponding doses of ferriprox
TM
 or 




CP20/deferiprone crude drug as a positive control (one animal per each dose) and one animal 
administered with water as a negative control. Ten groups of SD rats (half male and half female) 
were investigated for the whole project. Injection dose of 
59
Fe-ferritin was adjusted daily 
according to the “
59
Fe decay table “(half life 44.51 days) throughout the study.  
 
4.3.1.7 Statistical analysis 
The statistical significance of difference was determined for the “iron mobilization” and “efficacy” 
among different iron chelators, using “GraphPad Prism 5.0” software (LaJolla, CA, USA).  
 
4.3.2 Recovery of deferiprone/CP20 in the ferriproxTM suspension  
Known amounts of CP20/deferiprone standard compound were suspended in 5% NaCMC and 
appeared as clear solutions. Solutions were further diluted 100 folds before subjecting to HPLC-
UV analysis. A Hewlett-Packard HPLC (Agilent Technologies Ltd., Shropshire, UK) equipped 
with UV-Vis detector was used and coupled with a polymer PLRP column (250mm×4.6mm, 
5μm) (Polymer Laboratories Ltd, Shropshire, UK). Mobile phase was consisted of 1-heptane 
sulfonic acid (5mM, pH 2) and acetonitrile. The elution flow rate was 1.0 ml/min with a gradient 
of 2%–40% CH3CN in 20 min and post-run was followed for 5 min at 2% CH3CN. A calibration 
curve (Concentration vs Peak area) of the CP20/deferiprone standard solutions was conducted 
by Origin 8 (OriginLab Corporation, Northampton, USA). The supernatant of a ferriprox
TM
 
suspension, in which the theoretical CP20/deferiprone content is equivalent to a 
CP20/deferiprone dose of 75µmol/kg b.w. administered to a 300g rat, was diluted 100 folds and 
injected into HPLC-UV. The peak area of the effective component CP20/deferiprone in this 
supernatant of ferriprox
TM
 suspension was integrated and the concentration of 
CP20/deferiprone in the suspension was obtained by back calculation from the calibration curve 
of deferirpone standards. The recovery of CP20/deferiprone in the fine sonicated ferriprox
TM
 








4.4 Results and discussion 
4.4.1 Efficacy study of CN128 
As iron overload develops, proportionally more iron is found in parenchymal cells, 
predominantly in hepatocytes; the most important source of rapidly chelatable intracellular iron 
is a transient low molecular weight iron pool, namely labile iron pool (Porter et al., 1989a). 
Hence, in the established in vivo model, mobilisation of iron from liver parenchymal cells by the 
investigated chelating agents is to be measured. Consequently, this specific labile iron pool is 
targeted allowing the study of the site of action of new candidate iron chelators. Using a radio 
iron probe allows the precise labeling of the iron pool to study the site of action and route of 
excretion; 
59
Fe labeled ferritin taken up by hepatocytes was used to label this iron pool (Hershko 
et al., 1973). Thus, optimal 
59
Fe-ferritin labeling of the labile iron pool in the hepatocytes is 
crucial. 
59
Fe-ferritin when injected via the rat tail vein is rapidly removed to the hepatocyte (Liu 
et al., 1999c). It is then broken down by lysosomal degradation to constituent amino acids and 
59
Fe, the latter entering the labile iron pool (LIP). Over a period of 1 to 2 h, the labeled iron pool 
is removed to endogenous ferritin. Hence, there is a time window, about 1h after the 
administration of 
59
Fe-ferritin, that the LIP in hepatocytes contain a high content of 
59
Fe in transit 
before storage in endogenous ferritin, where oral active iron chelators can mobilise and 
scavenge 
59
Fe (Liu et al., 1999c). Efficient liver clearance of 
59
Fe-ferritin can be achieved 1h 
after injection with the majority of radiolabel being located in the liver representing as a 
significantly enhanced gamma radiation counts values of the liver above the detection limit. 
Thus, test HPO compounds were administered 1 h after the administration of 
59
Fe-ferritin. The 
increase in gut content and faeces radiation counts, which resulted from biliary excretion, was 
reflected by a commensurate decrease in liver counts. Different ligands have different 
pharmacokinetic profiles, which in turn lead to different iron excretion time profiles. The peak of 
iron excretion varies with different ligands in the previous investigation within 24 hrs (Liu et al., 
1999c). Therefore, collections of excreted iron were made over a 24 h period. There was no 
appreciable iron excretion by the urinary route induced by the investigated compounds.  Three 
parameters were examined to evaluate the oral availability, iron mobilisation capacity of an iron 
chelator and system reliability, which are “Iron mobilisation,” “Efficacy” and “Total recovery” 
(Section 4.3.1.6).  




Water was used as the vehicle solvent for CN128 hydrochloride form, which is the simplest 
vehicle for drug administration. Ferriprox
TM  
tablets contain a number of inert materials, known 
as additives or excipients including diluent, adhesive, disintegrents and lubricants. Hence, given 
that sodium carboxymethyl cellulose (NaCMC) has been widely used as drug vehicle, crushed 
ferriprox
TM 
tablets were suspended in 5% NaCMC and sonicated to a fine suspension. However, 
when administering the suspension to rats, blockage of oral gavage needle often occurred and 
hindered the effective oral administration, which was mainly due to the sediment of tablet 
additives leading to uneven suspension. Thus, the supernatants of the above suspensions were 
used instead. Consequently, the recovery of CP20/deferiprone in the supernatant of a 
ferriprox
TM
 suspension, in which the theoretical CP20/deferiprone content is equivalent to a 
CP20/deferiprone dose of 75µmol/kg b.w. administered to a 300g rat, was back-calculated from 
the CP20/deferiprone standards calibration curve (Figure 4.2) using the method described in 
Section 4.3.2.  
 









Conc. of CP20 (uM)
Equation y = a + b*
Adj. R-Squar 0.98627
Value Standard Erro
B Intercept 0 --
B Slope 779.03525 41.05168
 
                 
Figure 4.2 Calibration curve of CP20/deferiprone standards 
 
  




The concentration of the CP20/deferiprone in the above suspension was 51.9 µM/L, while the 
theoretical CP20/deferiprone concentration is 215.6 µM/L. Therefore, the recovery of 
CP20/deferiprone in the supernatant of the above ferriprox
TM
 suspension was determined as 
only 24%. Hence, using the supernatant of the tablet suspension in 5% NaCMC led to under-
evaluation of CP20/deferiprone efficacy. Consequently, we decided to use CP20/deferiprone 
crude drug (free base form) as the positive control. It has been reported that 50% 1,2-
propanediol can be used in man for oral administration of drugs (Liu, 1997). Thus it was 
adopted as the vehicle for the CP20/deferiprone crude drug and concentrated hydrochloric acid 
was used to assist dissolution at the high doses. These sample solutions all appeared as clear 
solutions. It is this preparation of CP20/deferiprone crude drug that was used as the positive 
control during the efficacy studies.  
 
A preliminary experiment was designed to examine the effectiveness of the 
59
Fe ferritin animal 
model. The dose of 300µmol/kg b.w. was selected. The iron mobilisation of CN128 was found to 
be 30.7 %, which was nearly 4.5 fold more than that of CP20 (7.2 %) (Figure 4.3, Table 4.4).  
The efficacy of CN128 (28.1 %) was almost 6 fold more than that of CP20 (4.5 %) (Figure 4.4, 
Table 4.4). Hence, CN128 at dose of 300µmol/kg presented significantly improved oral 
availability and iron scavenging efficacy compared with CP20/deferiprone at the equivalent 
dose.  
 
The standard deviations (SD) of the values of “Iron mobilisation,” “Efficacy” and “Total recovery” 
for eight groups of rats assessed in the above preliminary study were low, which fell in a range 
of 2.8% to 5.2% (Table 4.4).  Thus the method was considered to be consistent and reliable. 
The total recovery of 
59
Fe in the liver, gut contents and faeces were 80.3 % and 75.4 % for 
CP20 and CN128 groups respectively (Table 4.4), indicating the success of radio-iron labeling in 







































Figure 4.4 Efficacy of CN128 and controls at dose 300 µmol/kg (N=8) in preliminary experiment 
 





Iron mobilisation % 
Mean ± SD 
Efficacy % 
Mean ± SD 
Total recovery % 
Mean ± SD 
No. 
CP20/deferiprone 300 7.2 ± 2.8 4.5 ± 3.7 80.3  ± 4.5 8 













































A dose response study of CN128 in rats was further investigated to establish the magnitude of 
the iron chelation effect of CN128 as a function of the dose, which would provide valuable 
information for identification of optimal dosage regimens (Appendix VI). From the dose 
response study, increasing iron mobilisation efficacy has been observed when the administered 
doses of CN128 increased from 75µmol/kg b.w, to 1200µmol/kg b.w. Compared with 
CP20/deferiprone, the iron mobilisation capacity has been significantly improved at equivalent 
doses (Figure 4.5).  
 
 





























Figure 4.5 Iron mobilisation of CN128 in a dose response study 
  




Efficient iron mobilisation from the liver was observed in CP20 groups when administered dose 
increased to 600 µmol/kg (18.9%), which has resulted in comparable iron scavenge capacity 
with CN128 administered at a dose of 300 µmol/kg (18.3%) (Figure 4.6; Table 4.5). At the dose 
of 150µmol/kg b.w., CP20 had an extremely low efficacy (0.6%) in contrast to CN128, which 
was 15 times more efficacious (8.7%) (Figure 4.6; Table 4.5). The results have demonstrated 
that the dose used for inducing the efficient iron mobilisation could be reduced when CN128 
used as a chelating agent. The total recovery values demonstrated the reliability of the assay 



























Figure 4.6 Efficacy of CN128 in a dose response study 
 
 






Iron mobilisation % 
Mean ± SD 
Efficacy % 
Mean ± SD 
Total recovery % 
Mean ± SD 
No. 
CN128 75 22 6.4 ± 1.7 3.6 ± 1.7 73.1 ± 6.7 10 
CP20 75 10 1.8 ± 0.7 −0.7 ± 0.8 64.0 ± 14.2 10 
CN128 150 44 11.4 ± 3.6 8.7 ± 3.9 71.5 ± 18.2 10 
CP20 150 21 3.0 ± 1.3 0.6 ± 1.2 68.8 ± 12.7 10 
CN128 300 89 21.0 ± 5.3 18.3 ± 5.7 70.6 ± 22.0 10 
CP20 300 42 6.7 ± 2.7 4.4 ± 2.8 72.6 ± 14.2 10 
CN128 600 177 36.7 ± 9.2 33.9±10.2 69.4 ± 19.6 10 
CP20 600 83 21.3 ± 6.5 18.9 ± 7.0 64.6 ± 11.3 10 
CN128 1200 354 51.2 ± 8.1 48.5 ± 9.1 72.8 ± 17.9 10 
CP20 1200 167 31.7 ± 4.3 29.2 ± 5.0 66.0 ± 12.8 10 




The impact of sex difference of animals on the efficacy of iron mobilisation has also been 
investigated. There was no substantial variation between the male and female groups at all five 
doses administered (Figure 4.7).     
 


















Figure 4.7 Sex differences in efficacy of CN128  
 
4.4.2 Efficacy study of CM1 
 
CM1 was selected as another candidate iron chelator and its iron-scavenging efficacy was 
evaluated in the same in vivo model. A dose response study has also been investigated for 
CM1.  At a dose of 450 μmol/kg, CM1 was demonstrated to be 2.5 times more efficacious than 
deferiprone/CP20 (18.6% compared with 7.5%, Table 4.6) in iron mobilisation from the liver, 
when administered to rats via the oral gavage (Figure 4.8 and 4.9). Although there was a 
decrease in efficacy of both CM1 and CP20 when the dose was reduced to 150 μmol/kg, CM1 
was found to be four times more effective than CP20 (2.6% compared with 0.6%, Table 4.6).  
 
Thus a second new orally active iron chelator CM1 was identified in this study. The results also 
suggested that a reduced dose could be applicable. The total recovery values in this study 
confirmed the reliability of the animal model (Table 4.6) 
       
 






























































Iron mobilisation % 
Mean ± SD 
Efficacy % 
Mean ± SD 
Total recovery % 
Mean ± SD 
No. 
CM1 75 20 2.2 ± 0.7 0.5 ± 0.6 75.2 ± 7.7 6 
CP20 75 10 1.6 ± 0.6 -0.7 ± 0.6 80.0 ± 10.5 6 
CM1 150 40 4.3 ± 1.5 2.6 ± 1.4 75.5 ± 11.2 6 
CP20 150 21 3.0 ± 1.7 0.6 ± 1.6 68.5 ± 10.4 6 
CM1 450 120 20.5 ± 13 18.6 ± 6.0 71.8 ± 12.0 6 
CP20 450 63 10.1 ± 2.8 7.5 ± 2.8 76.2 ± 12.4 6 




The effect of sex difference on the iron mobilisation efficacy has also been investigated. 
Interestingly, with CM1, a significant difference between male and female groups was observed 
at the dose of 450 μmol/kg; the male group displaying 2.5 times enhanced efficacy in iron 



































Mean ± SD 
Total Recovery % 
Mean ± SD 
No. 
Male 75 20 0.5 ± 0.6 75.2 ± 7.7 3 
Female 75 20 -0.7 ± 0.6 80.0 ± 10.5 3 
      Male 150 40 2.6 ± 1.4 75.5 ± 11.2 3 
Female 150 40 0.6 ± 1.6 68.5 ± 10.4 3 
Male 450 120 18.6 ± 6.0 71.8 ± 12.0 3 
Female 450 120 7.5 ± 2.8 76.2 ± 12.4 3 





The established in vivo rat 
59
Fe-ferritin model has provided a useful procedure to investigate the 
iron mobilisation efficacy of iron chelators, by specifically labeling the major iron overloaded site 
with radio iron, namely, the liver parenchymal cell (hepatocytes). Both CN128 and CM1 have 
displayed the efficient mobilisation of iron from the liver and excreted iron via the biliary route to 
faeces. Both CN128 and CM1 have demonstrated improved efficacy in iron mobilisation when 
compared with deferiprone/CP20. The iron mobilisation capacities were most enhanced at the 
lower doses of 150 μmol/kg for both compounds. Particularly, CN128 displayed superior efficacy 
at this low dosage, which was 15 times more efficacious compared with CP20. The efficient iron 
removal from the liver when chelators were introduced by oral gavage has also demonstrated 
that both compounds are orally active. The impact of sex difference on the iron mobilisation of 
CM1 has initiated additional considerations when using iron chelaters to treat patients of 
different gender. Both compounds were identified as potential candidates as alternatives of 
CP20/deferiprone for clinical use. The in vivo results indicate that they could be used for 
treatment of iron overload patients at a reduced dose to that adopted for CP20/deferiprone.  
 
The excellent efficacy that has been demonstrated in our in vivo model for CN128 was further 
investigated in Zhejiang University, China (Xin, 2016). It has been reported from China that 
CN128 is also efficient in iron chelation in the iron overloaded Cebus monkey model. The iron 
output was promoted by oral administration of CN128 and CP20 to Cebus monkeys. Enhanced 
iron output was observed when the dose of CN128 administered increased from 75 µmol/kg to 
600 µmol/kg. Optimal iron output was observed when CN128 was administered at a dose of 300  
µmol/kg, which was 2.5 times more than that of CP20 (Figure 4.11, Table 4.8). In addition, 
chronic toxicity tests have indicated that CN128 lacks the ability to trigger of agranulocytosis 
(Hoffbrand et al., 2003), which has been reported in deferiprone/CP20. Cytotoxicity studies 
using white cells, hepatocytes and cardiomyocytes have also been studied for CM1, which was 
reported to be effectively non-toxic (Pangjit et al., 2015).  
 





Figure 4.11 Iron output in urine and faeces of Cebus monkey after oral administration of CN128 and 







































































Urine iron output 
(mg/kg) 
Faeces iron output 
(mg/kg) 
No. 
CN128 75 22 0.017 0.100 6 
CN128 150 44 0.024 0.180 6 
CN128 300 89 0.080 0.340 6 
CN128 600 177 0.170 0.140 6 
CP20 300 42 0.120 0.050 6 

























Chapter 5 Conclusion and Remarks 
5.1 Systemic iron overload 
Several inherited diseases are associated with iron overload from the hyperabsorption of iron 
from the diet, for instance, hereditary haemochromatosis, which is common in Northern Europe 
and North America. These patients develop the symptoms of iron overload typically in the fourth 
or fifth decade of life. Because the patients are not anaemic, hereditary haemochromatosis can 
be successfully treated by phlebotomy (Pietrangelo, 2006). β-Thalassemia major is fatal in the 
absence of regular blood transfusion, which in turn is associated with systemic iron overload. 
With non-chelated transfused patients, death generally occurs in the second decade of life as a 
result of infection or heart disease (Rund and Rachmilewitz, 2005). More recently transfusion 
has also been introduced for the treatment of sickle cell anemia, owing to its beneficial effects in 
the treatment of crises and in the reduction of the incidence of stroke. However, as with β-
thalassemia major, regular transfusion induces iron overload (Lucania et al., 2011). Thalassemia 
and sickle cell genes are widely dispersed in tropical and subtropical regions of the world 
(Weatherall, 2008). Iron absorption may also be enhanced secondary to anemia in patients with 
β-thalassaemia intermedia, which is also a common disease in South East Asia (Rund and 
Rachmilewitz, 2005). In contrast to hereditary haemochromatosis, patients suffering from the 
various haemoglobinopathies outlined above are anaemic and so are not treatable by 
phlebotomy. Unless these disorders of iron overload can be prevented by chelation therapy, 
toxic and potentially lethal levels of iron are deposited in the liver, heart and endocrine organs.  
 
5.2 Clinically useful chelators 
There are currently three iron chelators available for clinical use, Desferrioxamine (DFO), 
CP20/deferiprone (DFP) and Deferasirox (DFS).  
 
Desferrioxamine (DFO), a natural siderophore, binds iron(III) extremely tightly, leading to the 
formation of a stable iron(III) complex (Dhungana et al., 2001), which promotes RE and 




hepatocellular iron excretion via both urinary and biliary routes in rats (Hershko, 1978). DFO is 
effective in preventing complications associated with iron overload in patients with thalassemia 
major (Brittenham et al., 1994). Unfortunately DFO is not orally active and has to be 
administered parenterally over prolonged time periods because of its rapid renal clearance. 
Patient compliance with this regimen is frequently poor (Pippard et al., 1978). Furthermore, 
even in well-chelated patients, NTBI is still present for a large percentage of the treatment 
period and therefore gradually loads the heart and endocrine tissues. A large proportion of 
patients treated with DFO suffer from serious cardiovascular adverse effects (Borgna-Pignatti et 
al., 2006).  
 
Deferasirox (DFS), a lead compound developed by Novartis, can penetrate membranes easily 
and possesses good oral availability due to its extreme hydrophobicity (Zhou et al., 2012). DFS 
has been demonstrated to be efficient at removing liver iron from regularly transfused patients 
(Cappellini et al., 2010) but is apparently less effective at removing cardiac iron (Wood et al., 
2010). By virtue of a high proportion of both the free ligand and the iron complex binding to 
albumin (greater than 98%), the ligand possesses low toxicity despite its strong lipophilic 
character (Weiss et al., 2006). Kidney toxicity is the prevalent side effect of this chelator (Rafat 
et al., 2009), although there is also a high incidence of rashes (Sharma et al., 2015).  
 
CP20/deferiprone (DFP) was the first orally active iron chelator extensively investigated for iron 
overload chelation therapy. It is a small molecule facilitating good oral absorption by the 
gastrointestinal tract. DFP is less effective in mobilising iron from hepatocellular iron stores as 
compared with DFS. However, it is efficient in readily removing iron from cardiac tissue (Pepe et 
al., 2011). Roughly 60% of DFP is bound to albumin, so there is free DFP available to enter 
cells and scavenge iron (Seyed Dorraji et al., 2014). Agranulocytosis and neutropenia are the 
most serious side effects of CP20/deferiprone. Fortunately, both symptoms are reversible on 








5.3 Chelators under development 
Clearly, at the present time, there is no ideal iron chelator available that is relatively free of toxic 
side effects. Consequently there is a requirement for the identification of new iron chelating 
agents with superior iron chelating efficacy / toxicity ratios. Desferrithiocin (DFT) (Figure 5.1 a) 
is a siderophore isolated from Streptomyces antibioticus. It binds iron(III)  with a high affinity 
(pFe
3+
 = 20.4) and forms a  2:1 complex using a phenolate oxygen, a carboxylate oxygen, and a 
nitrogen atom as ligands at physiological pH (Bergeron et al., 2014). The compound was shown 
to be an excellent iron chelating agent when administered orally to rodents (Bergeron et al., 
1991) and Cebus apella primates (Bergeron et al., 1993). However, the predominant side effect 
associated with DFT is nephrotoxicity (Bergeron et al., 1993). Nevertheless, the remarkable oral 
bioavailability and iron-chelating efficacy initiated a successful structure−activity investigation 





Figure 5.1 Chemical structures of Desferrithiocin (DFT) and analogues 
a. Desferrithiocin, b. Deferitrin, c. Deferitazole 
 
 
A range of such DFT analogues has been investigated and one of these compounds, Deferitrin 
(Figure 5.1 b) was identified with ameliorated nephrotoxicity. This led to a Phase I human 
clinical trial by Genzyme. The Initial results were promising when the drug was given s.i.d. 
(Donovan et al., 2005). However, when the ligand was given b.i.d.,
 
unacceptable renal toxicity 
was observed and the trials were terminated (Galanello et al., 2007). In a further attempt to 




develop a chelator lacking such side effects, a series of polyether analogs of desferrithiocin was 
prepared (Bergeron et al., 2006). A polyether derivative, deferitazole (formerly FBS0701, Figure 
5.1 c), was identified as a lead chelator. Deferitazole forms a stable complex with iron(III) with 
high selectivity under biological conditions. The affinity constant and pFe
3+
 values of deferitazole 
(log β2 33.1, pFe
3+
 22.3) are similar to those of deferasirox (Exjade)  (log β2 36.9, pFe
3+
 22.5) 
(Hider et al., 2015). It has been demonstrated to possess 4-fold higher iron chelation efficacy 
with no observable renal toxicity when compared with deferasirox in preclinical studies 
(Bergeron et al., 2008). It was subsequently entered into phase I and II clinical trials sponsored 
by Ferrokin Biosciences and initially promising iron chelating and scavenging was reported 
(Rienhoff et al., 2011, Neufeld et al., 2012). However, the compound has not been moved to 
Phase III trial due to neurotoxicity experienced by some of phase II patients (Hider R.C., 2016, 
pers. comm.)  
 
As discussed in the introduction, we have investigated a range of novel HPOs, but in particular 
an enantiomer pairs (Chapter 1, Section 1.8), CN128 and CN126 (Figure 5.2). Usually the 
development of chiral compounds as iron chelating agents is avoided because of the necessity 
of obtaining a single stereoisomer product rather than a racemic mixture. With most synthetic 
routes, racemic mixtures are produced, which must be resolved into the two enantiomeric 
components. However, the synthesis involved in the preparation of the chiral HPOs discussed in 
this thesis is relatively simple and yields chirally homogenous samples. The synthetic method is 
characterised by the following steps: Compound I is reacted with compound II to give 3-benzyl-
protected maltol (Compound III), and then reacted with different chiral amino alcohols 
(Compound IV) to get chiral 3-benzyloxypyridin-4-ones (Compound V), finally compound V is 
deprotected under palladium catalysed carbon as hydrogenation catalyst to form the compound 
VI (Scheme 5.1, (Hider R. C., 2014). The chiral amino alcohols are prepared from the 



















Scheme 5.1 Synthesis of chiral HPOs 
 




As mentioned in the introduction, CGP65015 is the high pFe3+ bidentate hydroxypyridinone 
developed by Novartis. It is interesting to note the similarities in the structures of CN128 and 
CGP65015 (Figure 5.2), they have very similar physical parameters, however whereas CN128 
is prepared directly from a chiral intermediate (the amino alcohol [IV]) and is over 99% chirally 
pure, CGP65015 is prepared as a racemic mixture (Lowther et al., 1999, Zbinden, 1997) and 
has never been resolved into the two pure enantiomeric forms. It was for this reason that Ciba 
(Basel, Switzerland) did not continue to develop this molecule.  
 
5.4 New lead HPO iron chelators 
In this thesis, I have demonstrated the high efficacy of CN128 in iron mobilisation studies over a 
wide range of doses in an in vivo rat 
59
Fe-ferritin model. Markedly enhanced efficacy was 
achieved at lower doses than those typically adopted clinically with CP20/deferiprone.  
 
In order for an international pharmaceutical company to take a novel drug into man, there must 
be a strong “composition of matter”, patent. Unfortunately, CM1, the pegylated HPOs and the 
closely related CP20/deferiprone analogues are all covered by earlier patents. In contrast, the 
concept of using enantiomeric pairs has enabled us to obtain Chinese (Yu Y.P., 2011) and 
European (Hider R. C., 2014) patents.  
 
Further chronic toxicity tests in mice and primates have demonstrated that the in vivo toxicity of 
CN128 is relatively low, in many tests, CN128 was found to be much less toxic than 
CP20/deferiprone. Significantly no influence on the white cell count in primates was observed 
with CN128 (Xin, 2016). This data has been submitted to the Chinese FDA. It is planned to 
initiate a combined Phase I/ Phase II clinical trial early in 2017.  
 
5.5 Development of new system for monitoring HPO metabolism 
In order to efficiently monitor the hepatic metabolic profiles of HPOs, we have established an in 
vitro metabolic model using human hepatic microsomes. A sensitive and selective bio-analytical 
method with high throughput has been developed and validated for the quantification of the 




hepatic metabolic depletion of HPOs in the human microsomal incubates. This method includes 
a solid phase extraction sample clean-up procedure, a UPLC system collaborated into a tandem 
quadrupole mass spectrometer (TQ-MS) operated in the multiple reaction monitoring (MRM) 
acquisition mode. This method enabled us to select a promising candidate compound 
demonstrating markedly reduced glucuronidation compared with CP20/deferiprone, which was 
subjected to an in vivo rat 
59
Fe-ferritin model for its efficacy study. However, it would have been 
ideal if we had obtained the metabolic data from rat microsomal incubations. However, we 
decided to adopt human mirosomes for the major study as this clearly will relate better to further 
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Figure I-1 Chromatography of CP94 rat liver microsomal incubates (NADPH+UDPGA included, 
alamethicin/microsomal protein ratio: 25 μg/mg). 
 



















Figure I-2 Chromatography of blank rat liver microsomal incubates (NADPH+UDPGA excluded, 



























Figure I-3 Chromatography of CP94 rat liver microsomal incubates (NADPH+UDPGA included, 

















Figure I-4 Chromatography of CP102 rat liver microsomal incubates (NADPH+UDPGA included, 
































Figure I-5 Chromatography of blank rat liver microsomal incubates (NADPH+UDPGA excluded, 

















Figure I-6 Chromatography of CP102 rat liver microsomal incubates (NADPH+UDPGA included, 


































Figure I-7 Chromatography of CP20 human liver microsomal incubates (NADPH+UDPGA included, 


















Figure I-8 Chromatography of blank human liver microsomal incubates (NADPH+UDPGA excluded, 
















Figure I-9 Chromatography of CP20 human liver microsomal incubates (NADPH+UDPGA included, 
















Figure I-10 Chromatography of CP94 human liver microsomal incubates (NADPH+UDPGA included, 













































Figure I-11 Chromatography of blank human liver microsomal incubates (NADPH+UDPGA 

















Figure I-12 Chromatography of CP94 human liver microsomal incubates (NADPH+UDPGA included, 





















Figure I-13 Chromatography of CP102 human liver microsomal incubates (NADPH+UDPGA 






















Figure I-14 Chromatography of blank human liver microsomal incubates (NADPH+UDPGA 





























Figure I-15 Chromatography of CP102 human liver microsomal incubates (NADPH+UDPGA 






























































Figure II-1. Percentage of CP20 metabolism by Phase I+II pathway in human liver microsomal 






























Figure II-2. Percentage of CP94 metabolism by Phase I+II pathway in rat liver microsomal 












































Figure II-3. Percentage of CP94 metabolism by Phase I+II pathway in human liver microsomal 
































Figure II-4. Percentage of CP102 metabolism by Phase I+II pathway in rat liver microsomal 










































Figure II-5. Percentage of CP102 metabolism by Phase I+II pathway in human liver microsomal 








































































Figure III-1. Percentage of CP20 metabolism by Phase I+II pathway in human liver microsomal 






























Figure III-2. Percentage of CP94 metabolism by Phase I+II pathway in rat liver microsomal 











































Figure III-3. Percentage of CP94 metabolism by Phase I+II pathway in human liver microsomal 





























Figure III-4. Percentage of CP102 metabolism by Phase I+II pathway in rat liver microsomal 














































Figure III-5. Percentage of CP102 metabolism by Phase I+II pathway in human liver microsomal 








































































Figure IV-1. Percentage of CP20 metabolism by Phase I+II pathway in human liver microsomal 
































Figure IV-2. Percentage of CP94 metabolism by Phase I+II pathway in rat liver microsomal 














































Figure IV-3. Percentage of CP94 metabolism by Phase I+II pathway in human liver microsomal 
































Figure IV-4. Percentage of CP102 metabolism by Phase I+II pathway in rat liver microsomal 















































Figure IV-5. Percentage of CP102 metabolism by Phase I+II pathway in human liver microsomal 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































             


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Scheme V-I Metabolic pathways of CN126 
 
(a) CN126; 
(b) 3-O-glucuronide conjugate of CN126; 
(c) CN126-1-(1-O-glucuronide) conjugate; 
(d) N-dealkylated metabolite of CN126; 











Scheme VI-II-1 Metabolic pathways of CP679 
 
(a) CP679; 
(b) 3-O-glucuronide conjugate of CP679; 
(c) CP679-5-hydroxymethyl metabolite; 
(d) Glucuronide of 5-hydroxymethyl conjugate of CP679; 












Scheme VI-II-2 Metabolic pathways of CP669 
 
(a) CP669; 
(b) 3-O-glucuronide conjugate of CP669; 
(c) CP669-5-hydroxymethyl metabolite; 
(d) Glucuronide of 5-hydroxymethyl conjugate of CP669; 












Scheme VI-II-3 Metabolic pathways of CP69 
 
(a) CP69; 
(b) 3-O-glucuronide conjugate of CP69; 
(c) CP69-6-hydroxymethyl metabolite; 
(d) Glucuronide of 6-hydroxymethyl conjugate of CP69; 











Scheme VI-II-4 Metabolic pathways of CP616 
 
(a) CP616; 
(b) 3-O-glucuronide conjugate of CP616; 
(c) CP616-5-hydroxymethyl metabolite; 
(d) Glucuronide of 5-hydroxymethyl conjugate of CP616; 
                                             (e) 3-O-glucuronide conjugate of CP616-5-hydroxymethyl metabolite; 
                                             (f) CP616-2-hydroxymethyl metabolite;   










Scheme VI-II-5 Metabolic pathways of CP617 
 
(a) CP617; 
(b) 3-O-glucuronide conjugate of CP617; 
(c) CP617-5-hydroxymethyl metabolite; 
(d) Glucuronide of 5-hydroxymethyl conjugate of CP617; 
                                             (e) 3-O-glucuronide conjugate of CP617-5-hydroxymethyl metabolite; 
                                             (f) CP617-2-hydroxymethyl metabolite;   












Scheme VIII-1 Metabolic pathways of C21 
  
(a) C21; 
(b) C21-2-hydroxymethyl metabolite; 
(c) Glucuronide of 2-hydroxymethyl conjugate of C21; 
(d) 3-O-Glucuronide conjugate of C21-2-hydroxymethyl metabolite; 
(e) N-dealkylated metabolite of C21; 
(f) 3-O-glucuronide conjugate of N-dealkylated metabolite of C21 















Scheme VIII-2 Metabolic pathways of 6d 
  
(a) 6d; 
(b) -2-hydroxymethyl metabolite; 
(c) Glucuronide of 2-hydroxymethyl conjugate of C11; 
(d) 3-O-Glucuronide conjugate of C11-2-hydroxymethyl metabolite; 
(e) N-dealkylated metabolite of C11; 





























Scheme VIII-3 Metabolic pathways of C31 
  
(a) C31; 
(b) C31-2-hydroxymethyl metabolite; 
(c) Glucuronide of 2-hydroxymethyl conjugate of C31; 
(d) 3-O-Glucuronide conjugate of C31-2-hydroxymethyl metabolite; 
(e) N-dealkylated metabolite of C31; 
(f) 3-O-glucuronide conjugate of N-dealkylated metabolite of C31 















Scheme VIII-4 Metabolic pathways of K31 
  
(a) K31; 
(b) K31-2-hydroxymethyl metabolite; 
(c) Glucuronide of 2-hydroxymethyl conjugate of K31; 
(d) 3-O-Glucuronide conjugate of K31-2-hydroxymethyl metabolite; 
(e) N-dealkylated metabolite of K31; 
(f) 3-O-glucuronide conjugate of N-dealkylated metabolite of K31 


















Scheme VIII-5 Metabolic pathways of K8 
  
(a) K8; 
(b) K8-6-hydroxymethyl metabolite; 
(c) 3-O-Glucuronide conjugate of K8-6-hydroxymethyl metabolite; 
(d) Glucuronide of 6-hydroxymethyl conjugate of K8; 



















Scheme VIII-6 Metabolic pathways of K5 
  
(a) K5; 
(b) K5-6-hydroxymethyl metabolite; 
(c) 3-O-Glucuronide conjugate of K5-6-hydroxymethyl metabolite; 
(d) Glucuronide of 6-hydroxymethyl conjugate of K5; 
































Scheme VIII-7 Metabolic pathways of K7 
  
(a) K7 


































Scheme VIII-8 Metabolic pathways of K6 
  
(a) K6 



































Table VII-1: Iron mobilisation efficacy study group 1 (11 male SD rats).  
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 230 5.6 2.0 65.3 
150 236 7.6 3.9 85.7 
300 239 24.4 20.8 49.7 
600 241 35.0 31.3 46.3 
1200 243 46.0 42.3 66.5 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 244 1.9 -0.6 59.0 
150 244 2.0 -0.4 80.7 
300 251 5.0 2.8 57.6 
600 253 10.5 8.1 64.5 
1200 255 29.5 27.1 71.7 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 




Table VII-2: Iron mobilisation efficacy study group 2 (11 female SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 229 4.6 0.8 80.6 
150 227 13.7 9.9 95.1 
300 222 14.1 10.3 87.8 
600 221 35.5 31.7 97.4 
1200 219 50.9 47.1 90.6 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 217 2.4 0.0 70.2 
150 216 2.5 0.1 66.1 
300 215 7.9 6.3 78.3 
600 214 20.6 18.2 57.9 
1200 213 33.2 30.8 59.5 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 






















Table VII-3: Iron mobilisation efficacy study group 3 (11 male SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 254 6.1 4.5 71.1 
150 262 10.6 9 73.6 
300 268 22.7 21.1 44.4 
600 268 56.6 54.9 82.6 
1200 284 65.1 63.4 92.6 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 289 0.9 -1.5 57.8 
150 292 2.2 -0.2 59.6 
300 300 5.7 2.4 85.6 
600 302 20.8 18.4 60.5 
1200 308 35.5 33.0 58.6 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 




Table VII-4: Iron mobilisation efficacy study group 4 (11 female SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 225 7.0 4.4 77.7 
150 224 9.7 7.1 91.9 
300 224 17.0 14.4 97.2 
600 218 27.0 24.4 91.0 
1200 214 55.5 52.9 84.5 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 214 1.1 -1.3 58.4 
150 213 2.7 0.3 68.0 
300 212 6.0 2.7 82.6 
600 211 24.7 22.3 71.6 
1200 210 28.3 25.9 60.5 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 





















Table VII-5: Iron mobilisation efficacy study group 5 (11 male SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 250 7.7 3.9 80.0 
150 270 11.9 8.2 91.5 
300 272 27.7 24.0 97.8 
600 273 29.1 25.4 92.1 
1200 274 36.5 32.8 83.1 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 279 1.6 -0.8 30.7 
150 279 3.0 0.6 65.5 
300 281 9.9 8.4 50.2 
600 282 20.6 18.2 57.9 
1200 289 33.2 30.8 59.5 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 




Table VII-6: Iron mobilisation efficacy study group 6 (11 female SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 309 3.0 1.2 68.8 
150 293 11.3 9.5 46.6 
300 292 28.2 26.4 49.6 
600 289 40.1 38.3 52.5 
1200 286 54.1 52.3 50.0 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 284 1.7 -0.1 65.7 
150 277 4.1 2.3 48.9 
300 277 5.8 4.6 59.5 
600 269 25.2 23.4 48.8 
1200 268 31.7 29.9 52.0 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 

















Table VII-7: Iron mobilisation efficacy study group 7 (11 male SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 285 7.6 5.1 75.5 
150 290 21.0 18.5 58.4 
300 299 25.5 23.1 88.0 
600 304 41.3 38.9 58.8 
1200 307 49.0 46.6 63.1 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 311 3.2 0.7 76.1 
150 317 3.6 1.1 70.0 
300 323 4.2 1.7 72.3 
600 327 32.3 29.9 65.9 
1200 344 36.9 34.5 97.8 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 




Table VII-8: Iron mobilisation efficacy study Group 8 (11 female SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 306 8.7 5.2 66.2 
150 305 8.9 5.5 55.9 
300 305 20.8 17.3 71.4 
600 291 27.1 23.6 59.4 
1200 288 51.7 48.2 56.7 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 281 2.5 -1.0 73.7 
150 280 5.9 2.4 64.9 
300 271 13.1 9.6 74.5 
600 269 20.2 16.7 81.3 
1200 260 21.4 17.6 73.0 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 





















Table VII-9: Iron mobilisation efficacy study group 9 (11 male SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 227 7.3 5.5 81.2 
150 236 9.6 7.8 58.9 
300 246 16.9 15.1 43.8 
600 248 46.6 44.8 48.0 
1200 252 61.3 59.5 47.8 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 270 1.5 -0.3 65.5 
150 279 2.7 0.9 67.4 
300 289 5.0 3.2 68.7 
600 290 27.4 25.6 53.8 
1200 291 36.0 34.2 61.8 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 




Table VII-10: Iron mobilisation efficacy study group 10 (11 female SD rats) 
 
CN128 B.W. % Iron mobilisation % Efficacy % Recovery 
75 270 6.0 3.3 64.1 
150 269 10.1 7.5 57.5 
300 269 12.8 10.1 76.4 
600 267 28.8 26.1 66.2 
1200 264 42.1 39.4 92.8 
CP20 B.W. % Iron mobilisation % Efficacy % Recovery 
75 263 0.9 -1.8 82.4 
150 262 1.2 -1.5 96.9 
300 262 4.5 1.9 96.9 
600 262 10.5 7.8 83.3 
1200 261 31.0 28.3 65.4 
Water B.W. % Iron mobilisation % Efficacy % Recovery 
 































































CN128 75 22 6.4 ± 1.7 3.6 ± 1.7 73.1 ± 6.7 
10 
 
CP20 75 10 1.8 ± 0.7 −0.7 ± 0.8 64.0 ± 14.2 
10 
 
CN128 150 44 11.4 ± 3.6 8.7 ± 3.9 71.5 ± 18.2 
10 
 
CP20 150 21 3.0 ± 1.3 0.6 ± 1.2 68.8 ± 12.7 
10 
 
CN128 300 89 21.0 ± 5.3 18.3 ± 5.7 70.6 ± 22.0 
10 
 
CP20 300 42 6.7 ± 2.7 4.4 ± 2.8 72.6 ± 14.2 
10 
 
CN128 600 177 36.7 ± 9.2 33.9±10.2 69.4 ± 19.6 
10 
 
CP20 600 83 21.3 ± 6.5 18.9 ± 7.0 64.6 ± 11.3 
10 
 
CN128 1200 354 51.2 ± 8.1 48.5 ± 9.1 72.8 ± 17.9 
10 
 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure VII-11: Iron mobilisation and efficacy of CN128 (N=10) 
 
     
 
